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Abstract 
Circulating osteoprotegerin (OPG) promotes bone formation in vivo and correlates with the 
presence of type 2 diabetes, severity of vascular calcification and coronary artery disease. 
Obesity is a risk factor for diabetes and cardiovascular disease but little is known about the 
impact of body weight on circulating OPG. The purpose of these experiments was to evaluate 
the impact of body mass index, vascular dysfunction and insulin sensitivity on circulating 
concentrations of OPG. This thesis investigated; (i) The effect of obesity and insulin sensitivity 
on circulating OPG levels; (ii) The effect of type 2 diabetes and vascular dysfunction on OPG 
levels; (iii) The influence of glycaemic status on circulating OPG concentrations. Briefly, our 
findings were as follows (i) obese subjects who have normal glucose tolerance and are free 
from cardiovascular disease have lower circulating levels of OPG than their lean age matched 
counterparts. (ii) Osteoprotegerin is inversely correlated with insulin sensitivity, adiponectin and 
indicators of total body and visceral adiposity and positively correlated with aerobic fitness. (iii) 
TNF receptor apoptosis inducing ligand (TRAIL) is positively correlated with both fat mass and 
waist circumference, independent of age, gender and BMI. (iv) OPG is significantly higher as is 
IL-6 and hsCRP and adiponectin significantly lower in type 2 diabetics than in age and gender 
matched normoglycemic controls, while there is no difference in TNF-α, TRAIL or sRANKL 
concentrations. (v) Osteoprotegerin is higher in type 2 diabetics after excluding patients with 
previously diagnosed vascular disease, a distinction which could not be made using traditional 
inflammatory markers such as IL-6, hsCRP or TNF-α. (vi). There is no difference in OPG 
concentrations between those with prediabetes and overt type 2 diabetes, however both 
conditions appear to have significantly higher levels than age and BMI matched obese 
normoglycemic controls. (Sipos et al., 2008) Lean subjects have OPG concentrations which are 
similar to that of both prediabetic and type 2 diabetic patients but significantly higher than their 
matched lean counterparts. Circulating OPG is lower in obese, but otherwise healthy subjects, 
and correlates with indices of insulin sensitivity. OPG (but not RANKL or TRAIL) was found to 
be elevated in type 2 diabetes. OPG may have a protective effect on vascular cells and the 
observed decrease in circulating concentrations with increasing BMI could be an early 
biomarker of vascular dysfunction. It remains to be determined whether an increase in insulin 
secretion, insulin resistance, adiposity or systemic inflammation is the main regulatory factor. 
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Chapter I Introduction 
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Obesity poses a major threat to the health of the developed world. The latest figures from the 
World Health Organisation estimate that globally 1.6 billion adults are overweight and as many 
as 400 million are obese, furthermore it is predicted that this will rise to 2.3 billion and 700 
million respectively by 2015 (World Health Organisation, 2000). One of the most devastating 
and insidious conditions associated with obesity is type 2 diabetes. At the turn of the century it 
was estimated that 171 million people worldwide had type 2 diabetes and this is expected to 
rise to 366 million by 2030 (Wild et al., 2004).  
 
Type 2 diabetes mellitus occurs when there is a concordance of insufficient secretion of the 
hormone insulin from the pancreatic β-cells superimposed upon a background of a reduced 
effectiveness of insulin to stimulate cellular glucose uptake (insulin resistance). In addition to its 
role in glucose disposal in a variety of tissue types, insulin is an important vasoactive hormone 
that has pleiotropic actions in skeletal muscle, adipose tissue and vascular endothelium 
(Cavaghan & Polonsky, 2005). The exponential increase in the prevalence of obesity and type 2 
diabetes mellitus is largely due to behavioural and lifestyle changes, with an increased intake of 
high fat foods and lower levels of physical exercise being the main causes (Zimmet & Thomas, 
2003). In addition to these lifestyle factors our genetic heritage has likely influenced the 
progression of these conditions. The mammalian genome has evolved to cope with a constant 
flux of nutrient availability and has allowed for the development of a highly efficient mechanism 
that permits the long-term storage of energy during times of nutritional oversupply. Humans and 
other mammals achieve this by sequestering excess calories to the adipose tissue. A number of 
clinical studies have demonstrated the importance of the distribution of this adipose tissue, in 
particular the contribution of visceral fat accumulation to the development of cardiovascular co-
morbidities such as congestive heart failure, myocardial infarction and stroke (Lakka et al., 
2002), (Kenchaiah et al., 2002). Many cross sectional studies have shown a strong association 
between obesity and type 2 diabetes. This relationship is in part due to increased insulin 
resistance, which is a clear predisposing factor in the development of type 2 diabetes (Olefsky & 
Kolterman, 1981). Insulin resistance is the result of a progressive decrease in receptor and 
post-receptor biological processes in a number of tissue types. These include decreased 
insulin-mediated glucose disposal in skeletal muscle, impaired glucose disposal, increased 
hepatic glucose production and increased lipolytic turnover with reduced fat oxidation in adipose 
tissues (Miller, 2003), (Shuldiner et al., 2001). In obesity there is an increased volume of 
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subcutaneous adipose tissue and a greater accumulation of fatty tissue around the organs in 
the visceral cavity. It has been repeatedly shown that greater total body adiposity and a 
preferential accumulation of visceral adiposity are independently associated with insulin 
resistance (Frayn, 2000), (Kissebah et al., 1982), (Bjorntorp, 1997). It is now well established 
that increased visceral fat is associated with increased morbidity independent of age, ethnicity 
and gender (Okosun et al., 2000), (Nicklas et al., 2004). Up until recently scientists and 
physicians have considered the adipose tissue to be a simple energy storage depot. However 
the alarming rise in obesity and type 2 diabetes towards the end of the last century has resulted 
in a wave of intense scientific study of this tissue type. The adipose tissue secretes a number of 
proteins and cytokines with autocrine, paracrine and endocrine functions. These cytokines 
exercise profuse metabolic influence. In addition to regulating fat mass and nutrient 
homeostasis, these “adipocytokines” are involved in the regulation of glucose and lipid 
metabolism. They exert anti- and pro-inflammatory effects, are involved in blood pressure 
control, haemostasis, bone mass turnover, and thyroid and reproductive regulation (Trayhurn, 
2005), (Rosen & Spiegelman, 2006), (Ahima & Flier, 2000). Increasing evidence suggests that 
these adipocytokines are intrinsically involved in the pathophysiology of obesity-related insulin 
resistance, inflammation and atherosclerosis. In the early 1990s Hotamisligil et al. (1993), 
observed that increased production of tumour necrosis factor– α (TNF-α) was present in several 
models of animal obesity. Two years later the same group found that TNF-α was also present in 
human adipose and muscle tissue and was positively related to insulin resistance and obesity 
(Hotamisligil et al., 1995). Adiponectin is another important adipocytokine that was discovered in 
the mid 1990s by three different research groups (Scherer et al., 1995), (Shapiro & Scherer, 
1998),  (Hu et al., 1996),  (Maeda et al., 1996). Circulating adiponectin is inversely related to 
body mass index (Zhao et al., 2007) and its expression is increased in response to weight loss 
(Reinehr et al., 2004), (Brichard et al., 2003). Interestingly, the globular head of adiponectin is 
structurally homologous to TNF-α and its mRNA expression in 3T3L1 adipocytes is substantially 
decreased in response to incubation with TNF-α (Ruan et al., 2002). A reduction in adiponectin 
and an increase in TNF-α synthesis have been shown to reduce insulin sensitivity (Yamauchi et 
al., 2001), (Valverde et al., 1998), (Feinstein et al., 1993), (Halse et al., 2001) and increase 
vascular dysfunction (Wang et al., 1994).  
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Significant epidemiological data has now accrued suggesting that cardiovascular disease and 
osteoporosis often coexist, implying that there may be a potential a link between bone and 
vascular tissue (Burnett & Vasikaran, 2002), (Koshiyama et al., 2006). Interestingly, several 
proteins such as osteocalcin, osteopontin and bone morphogenic protein, which were once 
thought to be bone-specific in their biological action, have been identified in atherosclerotic 
lesions (Abedin et al., 2004). Such observations have given rise to the suggestion of the 
existence of an interdependent set of connections between cytokines which interact on multiple 
levels and in multiple tissue types, an “Osteo-adipose-vascular” network as it were (Koshiyama 
et al., 2006). One such protein that has garnered considerable interest in recent years is the 
novel molecule osteoprotegerin (OPG). OPG shares an interesting connection with TNF-α, not 
only is it a member of the TNF receptor superfamily (Simonet et al., 1997) but it also appears to 
be upregulated in vitro by TNF-α (Olesen et al., 2005) and downregulated both in vivo 
(Jorgensen et al., 2009) and in vitro (Olesen et al., 2005) by insulin. It is released into the 
circulation as a soluble glycoprotein (Yun et al., 1998) and binds to receptor activator of nuclear 
factor қβ Ligand (RANKL) where it reduces bone resorption by blocking osteoclastogenesis. It 
also binds to another TNF-associated molecule, namely (TNF)-related apoptosis inducing ligand 
(TRAIL) (Corallini et al., 2008), (Emery et al., 1998), the binding of which may lead to the 
preservation of the integrity of the vascular wall by reducing vascular endothelial cell (VEC) 
apoptosis. However, the precise mechanism by which this is accomplished is poorly 
understood. Circulating OPG is significantly higher in patients with type 2 diabetes (Yaturu et 
al., 2008), (Secchiero et al., 2006), (Olesen et al., 2005), (Rasmussen et al., 2006) and 
coronary artery disease (CAD) (Jono et al., 2002), (Schoppet et al., 2003). It is also an 
independent predictor of silent CAD in type 2 diabetes (Avignon et al., 2005) and cardiovascular 
mortality (Browner et al., 2001), (Kiechl et al., 2004), (Ueland et al., 2004), (Omland et al., 
2008). OPG-deficient mice exhibit severe aortic and renal calcification in addition to profound 
osteoporosis (Bucay et al., 1998) suggesting an important link between OPG, vascular 
dysfunction and bone metabolism. All of these novel cytokines and circulating factors signify a 
thorough integration of what were once considered to be insular tissue types with isolated 
physiological pathways contributing independently to preserve metabolic homeostasis. 
 
The overall goal of this thesis is to investigate and evaluate the impact of body mass index 
(Zhao et al., 2007) and insulin sensitivity on circulating concentrations of OPG, TRAIL and 
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RANKL and to investigate how they relate to an established adipose tissue-derived indicator of 
insulin sensitivity; adiponectin, in a healthy cohort free from cardiovascular disease. We shall 
also attempt to examine the impact of diabetes and vascular disease on their circulating 
concentrations while probing how these novel markers relate to other traditional inflammatory 
adipocytokines. Finally we hope to consider the influence of glycaemic status and adiposity 
together on serum levels of OPG and to interrogate if a worsening glycaemic status can 
influence its relationship with adiponectin and systemic inflammation.  
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Experiment I 
An investigation of serum OPG, TRAIL and sRANKL levels and their relationship with indicators 
of adiposity and insulin sensitivity in a healthy, representative Irish cohort. 
Aims 
i. The purpose of this study will be to determine if BMI and insulin sensitivity influence the 
concentrations of serum OPG and TRAIL in subjects who do not have cardiovascular or 
metabolic disease. 
Hypotheses 
i. In a healthy cohort, in the absence of an inflammatory process, OPG may be 
differentially regulated in obesity and. 
ii. OPG will be related to fasting insulin and Oral Glucose Insulin Sensitivity (OGIS). 
 
Experiment II 
The relationship between osteoprotegerin, TRAIL, sRANKL and markers of inflammation in type 
2 diabetes and vascular disease. 
Aims 
i. To measure serum OPG/RANKL/TRAIL in a cohort of well controlled type 2 diabetic 
patients with no evidence of underlying metabolic bone disease and compare them to a 
healthy age and BMI control group. 
ii. To determine whether any differences that may arise can be attributed to the presence 
of underlying vascular disease or inflammation. 
Hypotheses 
i. OPG, along with other traditional inflammatory markers will be higher in type 2 diabetic 
patients.  
ii. OPG will be a sensitive marker of inflammation that can distinguish between diabetics 
and normoglycemic controls irrespective of prior history of vascular disease in these 
patients. 
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Experiment III 
The effect of glycaemic status and the underlying inflammatory state on circulating levels of 
OPG and adiponectin. 
Aims 
i. To examine changes in OPG levels across the typical pattern of the pathogenesis of 
type 2 diabetes, examining how OPG relates to insulin resistance and 
hyperinsulinaemia in the obese, pre-diabetic, and type 2 diabetic state 
ii. To investigate the influence of adiposity in combination with the developing 
inflammatory state of associated with the progression from lean – obese – prediabetes 
– type 2 diabetes states. 
Hypotheses 
i. The deteriorating inflammatory state coupled with the sharp rise in hyperinsulinaemia 
observed over the spectrum of glycaemic dysfunction will induce a break in continuity in 
the relationship between OPG, markers of inflammation and indicators of insulin 
sensitivity that have been observed in previous experiments.  
ii. Acute hyperinsulinaemia associated with an oral glucose load may act to suppress 
OPG secretion and that this will be differentially regulated depending of glycaemic 
status.  
 
 8
 
 
 
 
Chapter II Literature Review 
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Insulin has emerged as an important regulator of OPG production both in vivo and in vitro 
(Xiang et al., 2007), (Jorgensen et al., 2009), (Olesen et al., 2005). Insulin resistance has also 
been demonstrated to correlate with circulating OPG (Gannage-Yared et al., 2006), (Ugur-Altun 
et al., 2005). Therefore this review will consider in detail, the role of insulin in metabolic control 
and glucose homeostasis, furthermore its perturbations in obesity and type 2 diabetes will be 
interrogated.  Since there is evidence that TNF-α is an important player in OPG regulation and 
as a result of the structural homology of OPG and TRAIL to the TNF-receptor superfamily 
(Simonet et al., 1997), TNF-α and its role in insulin resistance will be discussed in greater detail. 
Additionally, as adiponectin has been shown to correlate with OPG in healthy cohorts 
(Gannage-Yared et al., 2006);(Gannage-Yared et al., 2008) and has been demonstrated to 
stimulate RANKL and inhibit OPG production it will be subject to further consideration in this 
chapter. Finally, the literature exploring the interaction of OPG, RANK, RANKL and TRAIL will 
be subject to a detailed examination. 
 
2.1 Insulin 
Insulin is the primary endocrine regulator of glucose metabolism. It was originally identified and 
extracted by Banting and Best from pancreatic islet cells in 1921 (Banting & Best, 1922c). Its 
biological activity began to be unravelled when it was used to maintain pancreatectomized dogs 
(Banting & Best, 1922a) and treat human patients with type 2 diabetes (Banting & Best, 1922b). 
Islet cells are made of four principal cell types, the glucagon-producing α-cell, the somatostatin-
producing δ-cell and the polypeptide-producing PP-cell. Insulin is released by the β-cells which 
make up 60-80% of all cells of the islets of Langerhans (Figure 2.1), the most important purpose 
of which is the synthesis, storage, and controlled secretion of insulin. When functioning correctly 
the β-cell ensures that there is an immediately available reservoir of insulin that can be quickly 
released in response to increased blood glucose levels. An increase in insulin secretion is 
compensated by augmented insulin biosynthesis, ensuring that insulin levels within the β-cell 
are continually preserved. Thus the biosynthesis and processing of the insulin molecule along 
the secretory pathway of the β-cell is a highly regulated and dynamic process (Rhode et al., 
2005). Insulin is a 6 kDa peptide formed by the C chain cleaved from proinsulin, the precursor of 
which is preproinsulin. Insulin is made up of two polypeptide chains, an “α” chain 21 amino 
acids in length, and a 30 amino acid “β” chain. The quaternary structure of insulin is primarily 
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enabled by two disulphide bonds, its secondary structure is mostly alpha helical (Rhodes, 
2000). It has a half-life of 5 – 8 min and is degraded primarily in the liver and kidneys. Insulin 
secretion is stimulated during nutrient absorption, particularly in response to carbohydrate, by 
release of the neurotransmitter acetylcholine from the vagus nerve. Insulin secretion can also 
be stimulated by gastrin, secretin and specific amino acids such as arginine and leucine and 
lycine, free fatty acids, many pituitary hormones and some steroid hormones. Epinephrine and 
norepinephrine and the neuropeptide galanin also inhibit its secretion (Ferrannini & Mari, 1998). 
 
 
Figure 2.1 Structure  of the  Pancreas  showing  different  types  of  cells  present (Freudenrich et al., 
2009) 
 
 
2.1.1 Regulation of Insulin secretion by Glucose 
Glucose is the most significant physiological molecule involved in the regulation of insulin 
secretion (Porte, Jr. & Pupo, 1969), (Chen & Porte, Jr., 1976), (Ward et al., 1984a). The first 
phase of this process involves glucose entering the β-cells by means of the GLUT-2 transporter. 
The first enzyme in the glycolytic pathway, glucokinase acts as an efficient sensor of ambient 
glucose concentrations. The subsequent metabolism of glucose and an increase in the 
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ATP:ADP ratio depolarises the cell membrane and triggers exocytosis of insulin secretory 
vesicles Insulin release under these circumstances occurs in a biphasic manner, with the first 
phase representing the release of stored insulin in granules primed at the plasma membrane 
and the second phase occurring as a result of further nutrient stimulus (Mayer et al., 2007). 
Glucose stimulated insulin production from the β-cell is dose-dependent with as littlie as 1.4 
units (~50 μg) being secreted in response to an oral glucose load of only 12 g (Waldhausl et al., 
1979), (Eaton et al., 1983), (Nauck et al., 1986). Ordinarily in response to glucose, insulin 
release from the β-cell does not appear to have a linear relationship with glucose concentration, 
instead the relationship appears to be best represented by a sigmoidal curve (Cavaghan & 
Polonsky, 2005), with a threshold corresponding to normal fasting blood glucose concentrations 
and with a rapid increase in the slope for that portion of the dose-response curve corresponding 
to the glucose levels normally found during the postprandial period (Pagliara et al., 1974), 
(Gerich et al., 1974), (Cavaghan & Polonsky, 2005). This sigmoidal pattern of the insulin 
secretory response to glucose has been attributed to a Gaussian distribution of thresholds for 
activation of insulin production among individual β-cells (Salomon & Meda, 1986), (Schmitz et 
al., 1997). A constant rate infusion of intravenous glucose triggers a biphasic release of insulin 
from the β-cell characterised by a rapid initial peak (0-10 min) followed by a second phase in 
which the slope is much less steep and continues to a second peak (180-mins) (Porte, Jr. & 
Pupo, 1969), (Cerasi & Luft, 1967). The importance of first phase insulin kinetics are still 
uncertain but it could be representative of the rapid secretion of the reservoir of immediately 
available insulin stored within the β-cell as previously discussed or may be indicative of a 
temporary increase and subsequent reduction of some metabolic signal for insulin secretion 
(Grodsky, 1972). 
 
2.1.2 Effect of Amino Acids on Insulin Secretion  
Several essential amino acids have been shown to increase insulin secretion without the 
presence of glucose. The most effective secretagogues are leucine, arginine and lysine (Levin 
et al., 1971) with the latter two being the most potent stimulators of β-cell insulin secretion. Even 
though the effects of these amino acids on insulin release are not related to concomitant 
fluctuations in glucose concentrations, the effects are enhanced by glucose (Ward et al., 
1984b), (Kadowaki et al., 1984). β-cell-insulin production has also been assessed in response 
 12
to a number of amino acid metabolites. α-ketoisocarporate, α-keto-β-methylvalerate, 
Phenylpyruvate and α-ketocaproate appear to increase insulin output from islet cells, and are 
effective without the presence of glucose (Pagliara et al., 1974). 
 
 
2.1.3 Effect of Lipids and Lipid Metabolites on Insulin secretion 
Several studies have demonstrated that the infusion of lipids, fatty acids and their metabolites 
do not acutely raise insulin secretion in the presence of low glucose in vivo (Campillo et al., 
1979), (Conget et al., 1994), (Warnotte et al., 1994). This has been explained by the fact that 
although β-cells are quite capable of oxidizing fatty acids (Berne, 1975), (Tamarit-Rodriguez et 
al., 1984), this does not lead to an increase in the ATP:ADP ratio and as a result does not 
polarize the plasma membrane and increase [Ca2+] (Warnotte et al., 1994). When there is a 
significant concentration of glucose present, it is possible for fatty acids to increase Ca2+ influx 
by opening Ca2+ ion channels. This amplification in the trigger signal can add to the insulin 
secretory potency of fatty acids under such conditions of elevated glucose (Henquin, 2005).  
However other studies have shown a direct stimulatory effect of free fatty acids on insulin 
secretion. Crespin et al., (1973) who infused long-chain fatty acids into the pancreatic arteries of 
dogs and found an acute increase in insulin in pancreatic venous blood (Crespin et al., 1973). 
Moreover, Hennes et al., (1973) demonstrated in healthy, young women that raising plasma 
free fatty acid concentrations from 0.5 to 1.1 mmol.l-1 led to a 17% increase in insulin secretion 
under euglycaemic conditions with no change in insulin clearance. Interestingly, when blood 
glucose concentrations were increased to 7 mmol.l-1 and plasma and free fatty acids to 1.1 
mmol.l-1, the resultant increase in insulin levels was as a result of an increase in insulin 
secretion but also to a decrease in metabolic clearance of insulin. When glucose was raised to 
11 mmol.l-1, the rise in insulin was almost entirely due to a decrease in the clearance of insulin 
clearance (Hennes et al., 1997). Although meals high in carbohydrate potently stimulate insulin 
release, carbohydrate-free fatty meals have little immediate effect on β-cell function (Muller et 
al., 1971). However, interestingly ketone bodies and short and long-chain fatty acids have been 
shown to stimulate insulin secretion from islet cells in vitro and in vivo in humans (Goberna et 
al., 1974), (Crespin et al., 1973), (Boden & Chen, 1999), (Paolisso et al., 1995). The influence of 
elevated free fatty acids on glucose-stimulated-insulin secretion is related to the length of the 
 13
treatment. Zhou et al., (1994) examined the effects of long-term exposure of pancreatic islets to 
free fatty acids and found that after 48 hours of co-culture with basal glucose (3.3 mmol.l-1), 
insulin secretion had increased several fold. However, during stimulation with a 
supraphysiological glucose concentration of 27 mmol.l-1, secretion was reduced by 30-50% and 
proinsulin synthesis was also decreased by 30-40%  (Zhou & Grill, 1994). Carpentier et al., 
(1999) demonstrated that the insulin resistance as a result of a 90 min increase in free fatty 
acids was met by a suitable rise in insulin secretion. However the compensatory insulin 
secretion-response of the β-cell was not sufficient to cope with the insulin resistance 
accompanying 48 hours of elevated fatty acids (Carpentier et al., 1999). Additional studies have 
demonstrated that the adverse effects of prolonged elevations in free fatty acids on glucose 
induced insulin secretion are not seen in individuals with type 2 diabetes. On the basis of these 
results, it appears that elevated free fatty acids may contribute to the failure of β-cell 
compensation in insulin-resistance (Cavaghan & Polonsky, 2005).  
 
2.1.5 Gut Hormones and the Regulation of Insulin Secretion 
Interestingly, the insulin secretory response is higher after oral than intravenous glucose 
infusion (Tillil et al., 1988), (Faber et al., 1979), (Madsbad et al., 1983), (Shapiro et al., 1987). 
This phenomenon has been known as the incretin effect (Nauck et al., 1986), (Creutzfeldt & 
Ebert, 1985) as the amplified reaction to oral glucose indicated that absorbance of glucose by 
the gut causes (i) an endocrine response or (ii) promotes other intermediary mechanisms that 
lead to improved sensitivity of the β-cell to an equivalent glucose load. Shapiro et al., (1987) 
studied nine healthy volunteers who received a glucose bolus intravenously at a rate designed 
to elicit glucose concentrations which had been previously achieved by an oral glucose load. 
The authors found that the insulin release after an intravenous load was 26% lower than that 
released in response to an oral glucose load (Shapiro et al., 1987). Glucose dependant 
insulinotrophic polypeptide (GIP) and glucagon-like peptide (GLP-1) are two such intestinal 
hormones that increase the release of insulin following glucose ingestion. These hormones are 
released from the intestinal endocrine cells postprandially and travel through the bloodstream to 
reach the β-cells where they act through secondary messengers to increase the sensitivity of 
the islet cells to glucose (Cavaghan & Polonsky, 2005). GLP-1 also inhibits glucagon secretion, 
slows the release of nutrients from the intestine and regulates post-meal satiety. However, 
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although GLP-1 effectively lowers blood glucose, it is rapidly degraded in the circulation by 
dipeptidyl peptidase 4 (Ranganath et al., 1996), (Vilsboll et al., 2002). A decrease in GLP-1 
expression has been implicated in the development of weight gain and obesity. The principle 
reason for this is because of its effect on appetite (Verdich et al., 2001). It has been shown that 
obese subjects have decreased GLP-1 after a meal when compared to lean healthy controls but 
this is reversed after weight loss (Verdich et al., 2001). The mechanism that leads to reduced 
GLP-1 production upon weight gain is not fully understood, but may be related to the insulin 
resistance that accompanies weight gain (Rask et al., 2001). Type 2 diabetes is also 
characterized by impaired gut hormone production which may contribute to the altered rates of 
insulin release evident in the disease (Nauck et al., 1986). A large part of this incretin defect is 
due to the loss of the insulin stimulating effect of GIP (Nauck et al., 1993) even though the 
secretion of GIP is normal in type 2 diabetes, there is a substantial reduction in GLP-1 release 
after a meal but the insulin stimulating effect is retained (Nauck et al., 1993). 
 
2.1.6 Insulin Secretion in Obesity 
Obesity is characterized by compensatory hyperinsulinaemia  (Kissebah et al., 1982) resulting 
from increased insulin production (Meistas et al., 1982), (DeFronzo, 1982) and reduced insulin 
clearance (Meistas et al., 1982), (Faber et al., 1981), (Savage et al., 1979), (DeFronzo, 1982), 
(Rossell et al., 1983). Despite a reduction in clearance rates it appears that hypersecretion is 
the predominant contributor to elevated levels of basal insulin (Polonsky et al., 1988a), (Jones 
et al., 1997).  It also appears that 24 hour insulin secretion rates are 3 or 4 times higher in the 
obese and are strongly correlated with BMI (Polonsky et al., 1988b). Polonsky et al. (1988) 
reported that the temporal pattern of insulin secretion was similar in lean and obese subjects. 
They also found that obese subjects do not have significantly elevated postprandial plasma 
glucose levels and that basal insulin secretion accounted for 50% of total 24 hr insulin secretion, 
interestingly, when the postprandial insulin release was expressed relative to basal insulin 
release, the insulin response was identical between obese and lean subjects, suggesting that 
the elevated secretion of insulin observed in the obese population may be due to an enlarged β-
cell mass rather than hypersensitivity (Cavaghan & Polonsky, 2005). This conclusion is in line 
with the much earlier findings of Ogilvie et al. (1933), who described a pathology of increased 
numbers of islet cells in obese subjects (Oglivie, 1933). This is also in a agreement with finding 
 15
of a compensatory mechanism of increased β-cell mass by Pick et al. (1998) to maintain 
glucose tolerance in insulin resistant Zucker fatty rats (Pick et al., 1998). Evidence to date would 
therefore suggest that obese subjects exhibit moderate insulin resistance and  tend to be 
hyperinsulineamic but have normal regulatory mechanisms controlling insulin secretion 
(Cavaghan & Polonsky, 2005). 
 
2.1.6 Insulin Secretion in Type 2 Diabetes 
Type 2 diabetes is characterized by hyperinsulinaemia, nevertheless even these elevated levels 
of insulin are too low to compensate for the levels of ambient circulating glucose (Cavaghan & 
Polonsky, 2005). Despite this, many patients in the early stages of type 2 diabetes have enough 
β-cell-insulin-secretory capacity to maintain glucose control with appropriate diet and exercise, 
with or without the use of oral therapeutic agents. The traditional aetiology of overt type 2 
diabetes has been the development of defective β-cell function against a background of 
deteriorating insulin resistance (Weir, 1982), (Reaven, 1984), (Cahill, Jr., 1988), (Polonsky et 
al., 1996), (Kahn, 1998). Pathological investigations of deceased diabetics give further weight to 
this observation (Kloppel et al., 1985), (Clark et al., 1988), (Stefan et al., 1982) underlining that 
inadequate growth of β-cell mass is a mitigating factor in the development of the condition (Pick 
et al., 1998). However, this viewpoint has been questioned and evidence to support a 
simultaneous decrease in secretion and resistance has also been proposed (Weyer et al., 
2001b). The acute insulin and C-peptide response to glucose is blunted or absent and the 
second phase response is significantly impaired (Pfeifer et al., 1981), (Garvey et al., 1985), 
(Ferner et al., 1986), (Nesher et al., 1987). The blunted acute insulin response to glucose 
remains even following improvements in glucose control (Pfeifer et al., 1981), (Garvey, 2006) 
These results suggest the presence of an inherent flaw in the β-cell in type 2 diabetes. Several 
studies have reported that circulating proinsulin is significantly elevated and that this increase 
occurs in tandem with an increased ratio of proinsulin to insulin in circulation (Duckworth & 
Kitabchi, 1972), (Mako et al., 1977), (Ward et al., 1987) supporting the theory that the 
propensity of the β-cell to release a surplus of immature insulin (proinsulin) is an important 
defect in type 2 diabetes. The concentration of proinsulin produced in these patients is related 
to their glycaemic control rather that to the duration of diabetes (Saad et al., 1990). In support of 
this, insulin specific assays report lower insulin concentrations in lean compared with obese 
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subjects with or without diabetes. However, when using a non-specific assay with cross-
reactivity for proinsulin the differences are not apparent (Temple et al., 1989), (Saad et al., 
1990), (Reaven et al., 1993b). Abnormalities in the temporal pattern of insulin secretion in 
patients with type 2 diabetes mellitus have also been demonstrated. Patients with type 2 
diabetes secrete a greater proportion of their daily insulin under basal conditions compared to 
obese, insulin resistant but non diabetic subjects (Cavaghan & Polonsky, 2005), This reduction 
in the proportion of postprandial insulin secretion appears to be related in part to a reduction in 
the amplitude of the secretory pulses of insulin that occur after meals rather than a reduction in 
the number of pulses (Cavaghan & Polonsky, 2005). The rapid oscillatory pattern of insulin 
production by the β-cells is also altered in patients with type 2 diabetes mellitus, who exhibit 
cycles that are shorter and more irregular than the persistent, regular, rapid oscillations present 
in healthy subjects (Lang et al., 1979).. Various therapeutic strategies that improve glycaemic 
control in type 2 diabetics also appear to improve the β-cell secretory response (Garvey et al., 
1985), (Turner & Holman, 1978), (Kosaka et al., 1980), (Hidaka et al., 1982), (Shapiro et al., 
1989). However, even with enhanced glycaemic control, the kinetics of β-cell insulin secretion in 
type 2 diabetics do not become normalized with therapeutic intervention (Garvey et al., 1985), 
(Hidaka et al., 1982), (Shapiro et al., 1989), (Cavaghan & Polonsky, 2005) implying that there is 
likely to be a continued inherent defect in the β-cell.  
 
2.1.7 Insulin Regulation of Glucose Metabolism 
The physiological significance of insulin is mediated through its effect on glucose metabolism in 
the liver, skeletal muscle and adipose tissue. These tissues are largely responsible for the 
control of whole body glucose homeostasis under physiological conditions. Brain cells and 
erythrocytes depend on glucose as their predominant fuel source and metabolise it at the same 
rate during overnight fasting as they do during the postprandial state. Consequently maintaining 
normoglycaemia despite oscillations in endogenous glucose production requires a careful and 
synchronized equilibrium between the regulation of glucose disposal and endogenous glucose 
production (DeFronzo, 1988). The liver, and to a lesser extent the kidneys, release glucose to 
compensate for whole body glucose disposal during rest or overnight fast. Under these 
conditions glucose utilisation by skeletal muscle and adipose tissue is relatively low and lipids 
are oxidised as the primary fuel source. After a meal, glucose and insulin levels are elevated 
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and glucose is transported from the circulation into the skeletal muscle, adipose tissue and liver 
(DeFronzo, 1988), (Konrad et al., 2006). In addition to promoting glucose uptake in muscle and 
adipose tissue, insulin promotes glycogen synthesis in muscle and the liver and the conversion 
of excess carbohydrate to lipid. Insulin concurrently inhibits the breakdown of these molecules 
through glycogenolysis and lipolysis. In a similar fashion, endogenous glucose production is 
curbed by insulin in the liver and kidney through the inhibition of glycogenolysis and 
gluconeogenesis (Gerich et al., 2001), (Moller et al., 2001). More recent studies using gene-
specific knockout animals have confirmed the direct effects of insulin on glucose metabolism. 
Liver insulin receptor knockout mice exhibit decreased endogenous glucose production during a 
hyperinsulinaemic clamp (Michael et al., 2000). Similarly a decrease in insulin-stimulated 
glucose transport and glycogen synthesis in skeletal muscle is evident in mice that have 
undergone ablation of the gene encoding the muscle insulin receptor. Surprisingly glucose 
uptake in adipose tissue is elevated in this model implying perhaps that the hormone’s target 
tissues are coordinated and can adapt in order to maintain whole body glucose homeostasis 
(Kim et al., 2000). 
 
2.2 Insulin Action 
 
2.2.1 Skeletal Muscle 
Ingested glucose has a number of potential fates. It can be oxidized, stored as glycogen in the 
muscle and liver, converted to gluconeogenic precursors or converted to fat by de novo 
lipogenesis. Early studies using indirect calorimetry during a euglycaemic-insulin clamp showed 
the primary role of  nonoxidative glucose disposal in normoglycaemic healthy humans 
(DeFronzo et al., 1981), (DeFronzo, 1992). Ex vivo glycogen concentrations, measured during 
muscle biopsy studies in the presence of high plasma glucose demonstrated that more than half 
of an intravenously administered glucose load was stored as glycogen (Bergstrom & Hultman, 
1967), (Nilsson & Hultman, 1974). Shulman et al. (1990) used 13C magnetic resonance 
spectroscopy (MRS) to directly measure changes in muscle glycogen during hyperglycaemic-
hyperinsulinaemic clamps in conjunction with indirect calorimetry to assess non oxidative 
glucose disposal (Shulman et al., 1990). They demonstrated for the first time that skeletal 
muscle accounted for the majority of insulin-mediated glucose disposal and that greater than 
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80% was subsequently stored as glycogen. 13C MRS has also been used to measure glycogen 
synthesis in normoglycemic individuals following a meal where it was found that skeletal muscle 
was responsible for the disposal of approximately 30% of ingested glucose (Woerle et al., 
2003). Several other studies which measured similar characteristics in type 2 diabetic and 
insulin resistant offspring of diabetics have found that muscle glycogen levels were reduced by 
30% in type 2 diabetics when compared to matched healthy controls (Carey et al., 2003), 
(Shulman et al., 1990). It was also noted that the rate at which glycogen was synthesised in 
skeletal muscle was 50 % lower in diabetics than in matched controls during hyperglycaemic-
hyperinsulinaemic clamps. In addition it was found that postprandial increases in skeletal 
muscle glycogen concentrations were also significantly lower than those found in controls 
(Carey et al., 2003). 
 
Facilitated by insulin, glucose is transported into the myocyte by glucose transporter 4 (GLUT4) 
where it is phosphorylated by hexokinase to Glucose-6-phosphate (G-6-P). G-6-P can then 
undergo anaerobic glycolysis or be converted to glycogen by glycogen synthase.  
Extracellular glucose → intracellular glucose → G-6-P → Glycogen (Savage et al., 2007) 
 
In order to assess the rate limiting steps in glucose transport Rothman et al., (1992) used 13C 
and 31P MRS to monitor intracellular G-6-P concentrations and intramuscular glycogen 
synthesis simultaneously during a hyperinsulinaemic-hyperglycaemic clamp in type 2 diabetics 
(Rothman et al., 1992). The lower concentration of G-6-P in the diabetic subjects despite a 
decreased rate of nonoxidative glucose metabolism suggested that glucose transport or 
phosphorylation, and not glycogen synthesis, were the rate-controlling step in skeletal muscle 
insulin-stimulated glucose (Shulman, 2000). This suggests that a defect in the glucose transport 
mechanism manifests itself before the development of type 2 diabetes in both offspring of 
diabetics and nondiabetic obese females, who together are at increased risk of developing type 
2 diabetes (Savage et al., 2007). Glucose transport into the myocyte is predominantly facilitated 
by the insulin responsive GLUT-4. Glucose phosphorylation however is enabled by hexokinase. 
If hexokinase were the rate controlling step in diabetes then intracellular glucose levels would 
be expected to rise significantly. To investigate this mechanism further and to determine 
whether glucose transport or phosphorylation was the rate controlling step, 13C MRS was used 
to assess intracellular free glucose in muscle (Cline et al., 1999). The authors concluded that 
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intracellular glucose was 1/25 what they might have expected had hexokinase been the primary 
rate controlling enzyme (Cline et al., 1999), These findings give further support to the contention 
that insulin stimulated GLUT-4 translocation to the plasma membrane is the crucial rate limiting 
step in regulating insulin stimulated muscle glycogen synthesis in type 2 diabetes 
 
2.2.2 The Liver 
The liver plays an important role in preserving glucose homeostasis during the constant 
switching between the fed and fasted state. Although peripheral tissues such as the skeletal 
muscle are responsible for the majority of postprandial insulin stimulated glucose disposal, the 
liver also plays an important balancing role by reducing hepatic glucose output and increasing 
the retention of glucose by hepatic glycogenesis (DeFronzo, 1992). While fasting, liver glycogen 
stores are readily used to maintain blood glucose levels. The breakdown of glycogen in the liver  
contributes approximately half of the endogenous glucose production in the initial hours of 
fasting (Petersen et al., 1998), while gluconeogenesis accounts for the other half.  
 
Net Glycogen synthesis is determined by the enzymes, glycogen synthase and glycogen 
phosphorylase. The production and breakdown of hepatic glycogen (glycogen cycling) occurs 
simultaneously (David et al., 1990), (Magnusson et al., 1994), (Petersen et al., 1998). The effect 
of glucose and insulin signalling on glycogen turnover under hypeglucagonaemic conditions 
was investigated using 13C MRS. It was demonstrated that hyperglycaemia decreases net 
hepatic glycogenolysis by inhibiting glycogen phosphorylase. In contrast hyperinsulinaemia 
inhibits net hepatic glycogenolysis primarily by upregulating glycogen synthase (Petersen et al., 
1998). The net rate of glycogen synthesis is dependant on portal vein insulin concentrations. 
Insulin levels in the region of 130 – 170 pmol.l-1 are required for half maximal stimulation of 
glycogen synthesis. Under basal insulin concentrations glucagon was shown to strongly 
regulate net hepatic glycogen synthesis (Roden et al., 1996a).  
 
2.2.3 Adipose Tissue 
Intravenous infusion of insulin results in an immediate and substantial reduction in circulating 
concentrations of non-esterified fatty acids (NEFAs). The effect on NEFAs can be more 
prominent than insulin’s ability to lower blood glucose (Frayn & Karpe, 2006). NEFAs are 
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secreted into the circulation mostly from the breakdown of triglycerides within adipocytes. 
Glycerol is a by-product of this process and its release from adipose tissue is considered to be a 
good indicator of total body lipolysis, particularly because adipocytes express little or no glycerol 
kinase activity (Frayn & Karpe, 2006). The insulin-mediated decrease in circulating NEFA levels 
is an essential part of the synchronization of metabolic processes that occur in the postprandial 
period. After a typical meal, glucose becomes the preferred fuel source for skeletal muscle and 
therefore it is advantageous for substrate competition from fatty acids to be reduced as much as 
possible. In addition, NEFAs provide a very effective stimulus for hepatic gluconeogenesis 
(Boden et al., 1994), (Chen et al., 1999). However, this stimulus would not be helpful in the 
period following a meal when hepatic glucose production must be reduced in order to maintain 
blood glucose at appropriate concentrations. As a result NEFA levels have significant diurnal 
variation. They tend to follow a pattern which is the opposite of insulin secretion with reduced 
postprandial concentrations and an obvious peak prior to the next meal (Frayn & Karpe, 2006). 
Insulin plays an important role in almost all aspects of adipocyte biology. In fact, adipocytes are 
among the most insulin-responsive cells (Kahn & Flier, 2000). Triglyceride storage in adipocytes 
is promoted by insulin in several ways, such as the initiation of the differentiation of 
preadipocytes to adipocytes, upregulation of glucose transport and lipogenesis in more mature 
adipocytes and the inhibition of lipolysis (Kahn & Flier, 2000). Insulin also increases the uptake 
of fatty acids from lipoproteins by enhancing the action of lipoprotein lipase in the adipocyte 
(Fielding & Frayn, 1998). The physiological effects of insulin on adipose tissue are brought 
about by a wide variety of tissue-specific actions, involving both changes in protein 
phosphorylation and function, as well as sudden changes in gene expression (Collins et al., 
2005). Insulin can also affect gene transcription in the adipocyte. The transcription factors 
adipocyte determination and differentiation factor-1 and sterol regulatory element–binding 
protein-1c (ADD-1 / SREBP-1C) also have an important function regulating insulin-mediated 
adipocyte gene expression (Kim et al., 1998), (Shimomura et al., 1999a), (Foretz et al., 1999) 
by activating genes that promote lipogenesis and suppressing those implicated in fatty acid 
oxidation. Other transcription factors, such as those belonging to the forkhead group have also 
been show to play an important role in translating insulin actions to the nucleus (Kops & 
Burgering, 1999).  
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2.2.4 Non-Classical Tissues 
Although the liver, skeletal muscle and adipose tissue account for the majority of insulin-
mediated glucose metabolism, almost all tissue types have insulin receptors. Tissue specific 
knockout models of the insulin receptor have provided further insight into the action of insulin in 
non-classical target tissues such as pancreatic β-cells, the central nervous system and vascular 
endothelial cells.  These tissues may also have a crucial role in controlling whole body insulin 
sensitivity. It has been demonstrated that β-cell-insulin receptor deficient mice have impaired 
glucose tolerance and decreased insulin secretion (Kulkarni et al., 1999). Mice lacking the 
insulin receptor in neural cells demonstrate increased nutrient intake and become obese as a 
result, suggesting that the binding of insulin in the central nervous system may produce an 
anorexogenic effect (Bruning et al., 2000). The counter-regulation of hypoglycaemia involves a 
myriad of hormones and neurotransmitters that are released to provide glucose for the brain, 
while decreasing glucose need in peripheral tissues (Hileman & Bjorbaek, 2006). Increases in 
counter-regulatory hormones such as glucagon, epinephrine, norepinephrine and cortisol take 
place when glucose levels reach ~ <3.6 mM. Symptoms of hypoglycaemia that are neural in 
origin such as sweating, hunger, tingling, weakness, dizziness and cognitive dysfunction begin 
to appear at glucose levels ~ < 3 mM (Mitrakou et al., 1991), (Schwartz et al., 1987). 
Decreasing glucose concentrations also lead to the release of epinephrine from the adrenal 
medulla which stimulates glucose production and limits glucose utilisation through a β2-
adrenergic-receptor-mediated mechanism. Epinephrine can also stimulate the mobilization of 
free fatty acids and inhibit pancreatic β-cell insulin production and secretion (Woods & Porte, 
Jr., 1974). In addition vascular endothelial cells insulin regulates vasodilation and capillary 
recruitment which in turn increase glucose uptake to the muscle bed (Clark et al., 2003). As 
these non classical tissues only make a small contribution to whole body glucose disposal, it 
has been suggested that they play a secondary role in the control of whole body glucose 
metabolism. (Konrad et al., 2006) 
2.3 Insulin Resistance 
Insulin resistance is an important precursor in the pathogenesis of the metabolic syndrome and 
type 2 diabetes mellitus. It can be defined as a state of diminished responsiveness to normal 
circulating concentrations of insulin. In the initial stages pancreatic β-cells secrete an adequate 
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amount of insulin to compensate for insulin resistance and preserve euglycaemia. Eventually, 
however, relative or absolute insulin deficiency ensues leading to hyperglycaemia and type 2 
diabetes (McGarry, 2002). Healthy humans respond to excess energy intake by storing the net 
energy surplus as triglyceride in adipose tissue, predisposing them to weight gain and ultimately 
obesity. This also results in ectopic lipid accumulation in sites such as the liver and skeletal 
muscle, and possibly in pancreatic β-cells and the kidney (Shulman, 2000), (Unger, 2003). One 
explanation for the deposition of intracellular lipid in these tissues is that excess energy 
availability exceeds the storage capacity of the adipose tissue leading to energy overflow 
(Unger, 2003), (Danforth E Jr, 2000). This is further evidenced by the occurrence of ectopic lipid 
accumulation in mice and humans with generalised lipodystrophy (Adams et al., 2004), a severe 
example of insufficient adipose tissue storage capability with excess calorie ingestion. One 
method by which ectopic lipid deposits in lipodystrophic mice can be reduced is to transplant 
adipose tissue from wild type mice. This technique considerably improves insulin sensitivity 
(Gavrilova et al., 2000). Ectopic lipid deposits can also be reduced in lipodystrophic mice and 
humans through the administration of the anorexogenic adipocytokine, leptin (Oral et al., 2002), 
(Shimomura et al., 1999b) leading to a reduction in energy intake and significantly improved 
insulin-stimulated liver and muscle carbohydrate metabolism (Petersen et al., 2002). The 
concept of energy overflow is further supported by the finding that significant weight loss as a 
consequence of liposuction does not improve the metabolic characteristics of obese individuals 
(Klein et al., 2004). The procedure simply reduces adipose tissue storage capability in the face 
of unchanged caloric intake (Savage et al., 2007). However even relatively small reductions in 
weight through diet and exercise can substantially improve insulin sensitivity (Petersen et al., 
2005), (Tamura et al., 2005). 
 
Metabolic derangements of type 2 diabetes have traditionally been viewed as glucocentric, 
however in recent years a more lipocentric approach to the problem has become accepted 
(McGarry, 2002). As well as hyperglycaemia most type 2 diabetics have abnormal lipid storage, 
secretion or metabolism, resulting in elevated circulating free fatty acids and triglycerides as well 
as increased ectopic fat deposits in a variety of tissues including the muscle bed (Reaven, 
1995), (Schalch & Kipnis, 1965). It is less clear if the change in lipid homeostasis is a cause or 
consequence of diabetes (Figure 2.2). There is growing evidence to suggest that excessive fat 
accumulation in muscle and other tissues contributes to the development of insulin resistance 
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and pancreatic β-cell dysfunction in type 2 diabetes (McGarry, 2002). Intravenous lipid infusion 
designed to increase the concentration of plasma fatty acids have been shown to impair both 
oral glucose tolerance (Felber & Golay, 2002) and insulin stimulated glucose disposal (Roden et 
al., 1996b), (Roden et al., 1996a), (Boden, 1997). Interestingly the reduction in insulin sensitivity 
observed during such infusions only seems to manifest itself between 3-5 hours after circulating 
levels of fatty acids begin to increase (Boden, 2001). 
 
Figure 2.2 Pathophysiology of hyperglycaemia and increased circulating fatty acids in type 2 diabetes 
Insulin secretion from the pancreas normally reduces glucose output by the liver, enhances glucose 
uptake by skeletal muscle, and suppresses fatty acid release from fat tissue. The various factors shown 
that contribute to the pathogenesis of type 2 diabetes affect both insulin secretion and insulin action. 
Decreased insulin secretion will reduce insulin signalling in its target tissues. Insulin resistance pathways 
affect the action of insulin in each of the major target tissues, leading to increased circulating fatty acids 
and the hyperglycaemia of diabetes. In turn, the raised concentrations of glucose and fatty acids in the 
bloodstream will feed back to worsen both insulin secretion and insulin resistance (Stumvoll et al., 2005). 
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2.3.1 The Glucose Free Fatty Acid Cycle – Randle / Reverse Randle Hypothesis 
Randle et al. (1963) demonstrated that fatty acids compete with glucose for substrate selection 
in rodent heart muscle (RANDLE et al., 1963). They hypothesized than an increase in lipid 
oxidation might be responsible for insulin resistance by increasing mitochondrial acetyl CoA: 
CoA and NADH: NAD ratios. These biochemical changes would inactivate pyruvate 
dehydrogenase, increase citrate concentrations and inhibit phosphofructokinase and G-6-P 
accumulation. As G-6-P inhibits hexokinase activity there would be an accumulation of 
intracellular glucose and decreased glucose uptake. However this hypothesis has been 
challenged recently (Roden et al., 1996a), (Boden et al., 1994), (Dresner et al., 1999), (Griffin et 
al., 1999). When free fatty acid concentrations were maintained at high concentrations for 5 h 
during a euglycaemic-hyperinsulinaemic clamp the decrease in glucose disposal was 
accompanied by a decrease in G-6-P concentrations (Roden et al., 1996) and not an increase 
as would have been predicted by the Randle Cycle These findings were consistent with those 
observed in type 2 diabetic patients (Rothman et al., 1992). Furthermore, Sidossis et al., (1996) 
challenged the traditional view by proposing a “reverse Randle cycle”. They found that,, contrary  
to the predictions of Randle’s glucose-fatty acid cycle, that the intracellular availability of  
glucose and not fatty acids was the primary determinant of substrate selection (Sidossis & 
Wolfe, 1996).  
 
2.3.2 Influence of Circulating Free Fatty Acids on Glucose Uptake and Glycogen 
Synthesis 
The cellular mechanism responsible for free fatty acid mediated insulin resistance may be an 
inhibition of insulin signalling to GLUT-4 containing vesicles or a decrease GLUT4 trafficking 
between the intracellular compartment and the cell surface (Savage et al., 2007). To investigate 
this mechanism in more detail Dresner et al. (1999), examined various elements of the insulin 
signalling pathway in skeletal muscle biopsies obtained from subjects infused with high levels of 
free fatty acids for 5 h before and during a hyperinsulinaemic-euglycaemic clamp (Dresner et 
al., 1999). Glucose oxidation and glycogen synthesis were 50 - 60% lower after free fatty acid 
infusion when compared to a glycerol control trial. The lipid infusion trial was associated with a 
decrease in intramuscular G-6-P of approximately 90%, suggesting that there had been a 
significant decrease in glucose transport or phosphorylation. Intracellular glucose was 
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decreased in the lipid infusion trial, suggesting that glucose transport is the rate controlling step 
(Savage et al., 2007). Insulin receptor substrate 1 (IRS-1) associated phosphatidylinositol-3 
kinase activity was also decreased under these conditions. Later studies carried out in rodent 
models have suggested that this might be as a result of increased serine phosphorylation of 
IRS-1 (Dresner et al., 1999), (Griffin et al., 1999), (Morino et al., 2005), (Yu et al., 2002). The 
specific nature of the lipid product responsible for fatty acid induced insulin resistance has been 
the subject of some debate but long-chain acyl-coenzyme A (LCCoAs) and diacylglyceride 
(DAG) are thought to be important players. Neschen et al., (2005) found that mitochondrial acyl-
CoA:glycerol-3-phosphate acyltransferase 1 (mtGPAT1) knockout mice have increased hepatic 
insulin sensitivity and LCCoAs but decreased DAG and TG. Their results suggest that DAG may 
mediate fatty acid-induced hepatic insulin resistance (Neschen et al., 2005). Protein Kinase C 
(PKC) is a serine/threonine kinase, activated by DAG and may offer a potential link between 
lipid accumulation and serine phosphorylation of IRS-1 (Griffin et al., 1999), (Schmitz-Peiffer et 
al., 1997). Itani et al., (2002) noted that an accumulation of DAG in skeletal muscle during lipid 
infusions was correlated with an increase in PKC-β11 and PKC-δ expression and activity (Itani 
et al., 2002). Therefore the breakdown in lipid dynamics in type 2 diabetes that lead to an 
increase in LCCoAs and DAG in hepatic and muscle tissue would lead to lipid induced insulin 
resistance (Shulman, 2000).  
 
2.3.3 Skeletal Muscle Insulin Resistance – Defects in Signalling Pathways 
Skeletal muscle metabolic dysfunction occurs early on in pathogenesis of insulin resistance as 
healthy first degree relatives of type 2 diabetics exhibit decreased insulin-stimulated glucose 
uptake (Eriksson et al., 1989), (Vaag et al., 1992). GLUT4 protein content is similar in diabetic 
and non-diabetic skeletal muscle (Eriksson et al., 1989), (Kahn et al., 1992) but the 
translocation of GLUT-4 containing vesicles is impaired (Dohm et al., 1988); (Zierath et al., 
1996). Therefore much of the research has focused on characterising the insulin signalling 
cascade and identifying loci with impaired kinase activity. Tyrosine phosphorylation of the 
insulin receptor has been shown to be decreased (Goodyear et al., 1995) or unchanged in 
diabetic skeletal muscle (Arner et al., 1987), (Krook et al., 2000). Research has consistently 
demonstrated a decrease in IRS-1 tyrosine phosphorylation and IRS-1 associated PI3-K activity 
(Bjornholm et al., 1997), (Kim et al., 1999), (Krook et al., 2000). As well as tyrosine 
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phosphorylation IRS-1 can be phoshorylated at multiple serine theronine residues , which serve 
to either reduce or improve insulin signalling (Gual et al., 2005). Many circulating factors related 
to the insulin resistant state such as free fatty acids and TNF-α, appear to augment IRS-1 serine 
phosphorylation therefore inhibiting its function (Gual et al., 2005), (Hotamisligil et al., 1994b). 
As previously mentioned, accumulation of DAG may impair insulin action by PKC-mediated 
serine phosphorylation of IRS-1. 
 
2.3.4 Hepatic Insulin Resistance 
In insulin resistant type 2 diabetes, elevated fasting blood glucose concentrations are heavily 
influenced by the presence of increased rates of endogenous glucose production (Bogardus et 
al., 1984), (DeFronzo, 1992), (Fery, 1994). This is likely to result from increased 
gluconeogenesis and decreased glycogenolysis. Magnussen et al. (1992) examined net hepatic 
glycogenolysis in poorly controlled type 2 diabetic patients and found that fasting hepatic 
glycogen concentrations were sharply decreased in the diabetics when compared to matched 
controls. Therefore, as well as reduced insulin stimulated muscle glycogen synthesis (Shulman 
et al., 1990), it appears type 2 diabetics also have a reduced capacity to store and/or synthesise 
liver glycogen leading to an increased incidence of elevated postprandial hyperglycaemia. 
These reductions in hepatic glycogen synthesis were linked to a decrease in hepatic 
glycogenolysis and a further 60 % upregulation in the rate of gluconeogenesis (Shulman et al., 
1990). 
 
2.3.5 Insulin Resistance in Adipose Tissue 
Insulin resistance in adipose tissue leads to an increased rate of lipolysis which is accompanied 
by a rise in plasma free fatty acids. The increased circulating free fatty acids impair hepatic and 
skeletal muscle insulin action and β-cell insulin release, leading to the development of type 2 
diabetes mellitus (Reaven, 1988). A degree of mitochondrial dysfunction also contributes to 
insulin resistance (Richardson et al., 2004) by limiting lipid oxidation and promoting intracellular 
accumulation of fatty acyl-CoA and other lipid by-products. Fatty acid oxidation is also impaired 
by the accumulation of intracellular malonyl-CoA, and the downregulation of carnitine 
palmitoyltransferase activity. This accumulation of acyl-CoA impairs insulin action in skeletal 
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muscle which results in even greater insulin resistance (Ferrannini & DeFronzo, 2004), (Schling 
& Loffler, 2002). 
 
2.4 Insulin Resistance and Atherosclerosis 
Haffner et al. (1998) found that the 10-year risk of myocardial infarction (MI) in a normoglycemic 
cohort with no prior history of infarction was less than 4% and increased to 19% for those with a 
previous MI. However, in diabetic subjects who had never had an MI the relative risk was 20% 
and the risk of a second MI was 45% in this cohort (Haffner et al., 1998). Several 
epidemiological studies have also demonstrated that insulin resistance measured using both the 
euglycaemic-hyperinsulinaemic clamp (Bokemark et al., 2001) and the frequently sampled 
intravenous glucose tolerance test (Howard et al., 1996) is an independent risk factor for CVD 
using carotid intima-media thickness as a surrogate measures of atherosclerosis. The European 
Group for the Study of Insulin Resistance is currently conducting a large, multi centre study to 
investigate insulin resistance as an independent risk factor for cardiovascular event rate 
(Cleland & Connell, 2006).  
 
2.5 Hemodynamic Action of Insulin 
In order for insulin to dock with its target receptor on the plasma membrane it must first cross 
the endothelial monolayer (Figure 2.3). Before it can reach the perivascular space, insulin is 
internalized by the vascular endothelial cells (Wiernsperger, 1994) in a poorly understood 
receptor-mediated process (Cersosimo & DeFronzo, 2006). This process can delay insulin-
stimulated glucose uptake in insulin resistance (Bonadonna et al., 1998), (Laakso et al., 1990), 
(Olefsky et al., 1973), (Sjostrand et al., 2002). Studies assessing insulin-mediated glucose 
disposal have demonstrated a substantial delay in obese (Laakso et al., 1990), and type 2 
diabetic patients (Olefsky et al., 1973), (Cersosimo & DeFronzo, 2006) healthy lean controls 
(Bonadonna et al., 1998). Baron et al. (1995) and others (Steinberg et al., 2000) (Baron & 
Brechtel, 1993) have shown that there is a significant increase in leg blood flow during a 
euglycaemic-hyperinsulinaemic clamp at physiological levels in lean,, obese and diabetic 
individuals. When insulin was administered at a rate of 40 or 120 μU.ml-1, leg blood flow 
increased after 240 min by 100% at both infusion rates. The physiological importance of the 
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insulin-mediated vasodilatory response is still unclear (Cersosimo & DeFronzo, 2006), (Yki-
Jarvinen & Utriainen, 1998), as a significant vasodilatory response only begins to happen after 
40-50 min of insulin infusion at supraphysiological concentrations (Ueda et al., 1998). However, 
in patients with coronary artery disease, insulin stimulated glucose uptake in the myocardium is 
significantly impaired (Paternostro et al., 1996). One theory that may be teleologicaly attractive 
is that insulin is a chronic regulator of blood flow in the vascular beds of metabolically active 
tissues (Cleland & Connell, 2006). Such a mechanism would be advantageous as insulin would 
potentially direct fuel substrates such as glucose and fatty acids to important tissues before 
stimulating their cellular uptake. This link is supported by Cleland et al., (1999) who showed a 
positive correlation between insulin sensitivity and insulin-mediated vasodilation in healthy 
normotensive men (Cleland et al., 1999). The mechanism by which this insulin-induced 
vasodilation occurs has become clearer in recent years. It is now recognized that the integrity of 
vascular endothelium must be intact and that the endothelial-derived vasodilator, nitric oxide 
(NO) is an important facilitator of the vascular actions of insulin (Scherrer et al., 1994), (Zeng & 
Quon, 1996), (Landry & Oliver, 2001). In the intact vascular endothelium, arginine is converted 
enzymaticaly to NO by endothelial nitric oxide synthase (eNOS). The activity of NOS is 
increased several fold by insulin responsive cytokines such as IL-1β, IL-6, TNF-α, interferon-γ 
and adenosine (Landry & Oliver, 2001) There is also evidence that nitric oxide synthase is 
directly upregulated in response to a pharmacological dose of insulin in cultured endothelial 
cells (Zeng & Quon, 1996). As previously stated, insulin increases eNOS activity in the vascular 
endothelial cells (VEC) (Zeng & Quon, 1996), (Aljada & Dandona, 2000), (Kuboki et al., 2000), 
In fact all of the components of the insulin signalling cascade are present in endothelial cell 
culture and higher concentrations of insulin will increase the activation of IRS-1, PI3 kinase and 
PKB/AKT (Cleland & Connell, 2006). Adding insulin to VEC cultures leads to an immediate 
increase in NO release and the uptake of L-arginine by it’s specific receptor transporter 
(Sobrevia et al., 1996). Insulin stimulated NO production can be achieved at physiological 
concentrations (Cleland & Connell, 2006), (Cleland et al., 1999).  
 
The insulin-mediated pathway that regulates eNOS activity/synthesis may be similar in adipose 
tissue and skeletal muscle. The similar regulation of the insulin signalling cascade in the 
vascular endothelium and adipocytes suggests that insulin resistance and endothelial 
dysfunction may be linked. A direct association between insulin resistance and eNOS 
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availability in healthy males (Petrie et al., 1996), type 2 diabetic or hypertensive subjects 
(Cleland et al., 2000) has been observed. There is also evidence from animal studies for a 
direct vasoactive function of insulin. Defective endothelium-dependent vasodilation has been 
shown in IRS-1 knockout mice (Abe et al., 1998) and insulin signalling is impaired in the 
vascular endothelium of the Zucker fatty rat (Jiang et al., 1999). The fact that insulin signalling is 
essential for the normal function of most metabolically active tissues, such as skeletal muscle, 
adipose tissue and the vascular endothelium means it is reasonable to assume that there is 
significant insulin-mediated crosstalk between these tissues that may influence the development 
of endothelial dysfunction. In addition, insulin resistance and endothelial function can improve in 
response to a variety of interventions and treatments, such as exercise, weight loss and 
pharmacotherapy. The adipose tissue secretes a multitude of adipocytokines that can act to 
regulate insulin sensitivity and endothelial function. TNF-α is one such adipocytokine that can 
induce insulin resistance by disruption of the insulin signalling cascade (Valverde et al., 1998), 
(Feinstein et al., 1993), (Halse et al., 2001), while simultaneously promoting endothelial 
dysfunction (Wang et al., 1994). This TNF-α-mediated effect on endothelial function may be the 
result of nuclear factor-κβ (NF-κβ) activation (Ruan et al., 2002). Cytokines such as  IL-1β and 
TNF-α, that stimulate NF-κβ, can also be directly activated by the NF-κβ pathway, 
demonstrating some auto-regulation in this signalling cascade (Yamamoto & Gaynor, 2001). 
Insulin has been shown to have a potent anti-inflammatory effect in vitro by inhibition of the NF-
κβ pathway and up-regulation of the inhibitor of nuclear factor κβ (Iκβ) (Dandona et al., 2001) 
Thiazolidinediones (TZDs) which reduce NF-κβ production, block TNF-α induced insulin 
resistance (Peraldi et al., 1997). Additionally aspirin, which is known to up regulate Iκβ, reduces 
insulin resistance and supports the belief that it is an important molecule, linking insulin 
signalling, endothelial dysfunction and the inflammatory process  (Hundal et al., 2002), 
(Brandstrom et al., 1998). 
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Figure 2.3 Hemodynamic actions of insulin. The time-course of insulin’s hemodynamic action is closely 
integrated with its metabolic effects. Following its passage through the endothelial barrier, insulin promotes 
precapillary sphincter tone relaxation with capillary dilatation. As a result, more microvessels are recruited, 
the capillary network is expanded, and peripheral microvascular perfusion increases. Insulin then diffuses 
into the interstitial fluid more readily, and the exposure of the target tissues to insulin is magnified, resulting 
in an increase in insulin-mediated glucose metabolism, (reproduced from (Cersosimo & DeFronzo, 2006). 
 
2.6 Adipocytokines 
The discovery of adipose tissue-derived cytokines (adipocytokines), which regulate skeletal 
muscle and hepatic glucose metabolism and insulin sensitivity (Figure 2.4) (Fruhbeck et al., 
2001), (Havel, 2004) has given new insight into the important endocrine function of adipose 
tissue. Adiponectin increases insulin sensitivity by suppressing hepatic glucose production as 
well as increasing glucose uptake by skeletal muscle (Combs et al., 2001), (Tomas et al., 2002). 
Adiponectin also acts on the vascular endothelium and shows significant promise as a mediator 
of both vascular and metabolic function (Yamauchi et al., 2001). Leptin, signals through its 
receptors in the arcuate nucleus of the hypothalamus to decrease food intake and increase 
energy expenditure (Leibel, 2002). It has been suggested that leptin may also have a role in 
regulating peripheral insulin sensitivity (Ceddia et al., 2002). Insulin positively regulates the 
gene expression and secretion of leptin from adipose tissue (Fasshauer et al., 2002), (Stefan & 
Stumvoll, 2002). Changes in the plasma concentrations of these adipocytokines provide 
evidence of a secondary regulator of glucose metabolism that complements insulin action. In 
addition, several other adipocytokines have been implicated in metabolic and endothelial 
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dysfunction (Stears & Byrne, 2001), (Saltiel & Kahn, 2001), (Shulman, 2000), IL-6, a powerful 
inducer of hepatic CRP production, has been associated with diabetes and CVD in many 
longitudinal and cross-sectional epidemiological studies (Bermudez et al., 2002), (Han et al., 
2002), (Festa et al., 2002) and there is also good support for a connection between IL-6 
synthesis and insulin resistance (Bastard et al., 2002). It has also been demonstrated that leptin 
is an active regulator of insulin sensitivity and acts directly on the vascular endothelium 
(Mantzoros, 1999), (Shimomura et al., 1999b) (Steppan et al., 2001).  
 
 
 
Figure 2.4 Adipocytes secrete proteins with varied effects on glucose homeostasis.  Adipocyte-derived 
proteins with anti-diabetic action (green arrows) include leptin, adiponectin, omentin and visfatin. Other 
factors tend to raise blood glucose (Lincz et al., 2001), including resistin, TNF-α and RBP4. TNF-α and 
human resistin are probably secreted by non-adipocytes within the fat pad. IL, interleukin. (adapted from 
(Rosen & Spiegelman, 2006) 
 
2.6.1 TNF-α Structure and Function 
TNF-α was initially depicted as an endotoxin-induced serum factor that promoted necrosis in 
tumours (Carswell et al., 1975). It has more recently been perceived as an important regulatory 
cytokine of inflammatory processes, cell survival and apoptosis, production of secondary 
cytokines, such as IL-1 and IL-6, and induction of insulin resistance in a variety of clinical 
settings. TNF-α is synthesized as a monomeric 26 kDa molecule which is bound to the plasma 
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membrane (Kriegler et al., 1988). Proteolytic cleavage by the TNF-α converting enzyme (TACE) 
of the membrane-bound precursor protein leads to the release of the TNF-α molecule into the 
circulation as a biologically active 17 kDa protein (Collins et al., 2005), where it multimerizes to 
form a 51 kDa homotrimer (Kriegler et al., 1988), (Beutler, 1995), (Xu et al., 1999), (Clarke & 
Mohamed-Ali, 2006). (Maskos et al., 1998) (Black et al., 1997). Even before the molecule was 
specifically named, TNF-α had long been associated with insulin resistance (Pekala et al., 
1983). Many studies have demonstrated both an epidemiological and mechanistic link between 
adipose tissue-TNF-α secretion, obesity and insulin resistance in human and animal models. 
(Hotamisligil et al., 1995), (Hotamisligil et al., 1994a). 
 
2.6.2 The role of TNF-α in Insulin Resistance 
A negative role for TNF-α in insulin resistance is evidenced by the fact that knockout of TNF-α 
functionality leads to an improvement in insulin sensitivity and maintenance of glucose 
homeostasis in obese mice (Uysal et al., 1997). In addition, TNF-α infusion in healthy humans 
leads to skeletal muscle insulin resistance, impaired insulin signalling and decreased glucose 
uptake (Plomgaard et al., 2005). The biological activity of TNF-α is mediated by two specific 
receptors, TNF receptor-1 (Chen & Goeddel, 2002) and TNF receptor-2 (TNF-R2) that are 
present on the membranes of almost all cell types. Both TNF-α and its membrane receptors are 
significantly elevated in obesity and insulin resistance (Hofmann et al., 1994). There is 
substantial data demonstrating its capacity to negatively regulate components of the insulin 
signalling pathway (Clarke & Mohamed-Ali, 2006). TNF-α reduces adipocyte mRNA expression 
and secretion of GLUT-4 (Stephens & Pekala, 1991), (Ohsumi et al., 1994), (Hauner et al., 
1995) and reduces insulin-mediated glucose uptake by the adipocyte. Feinstein et al. (1993) 
demonstrated one mechanism by which TNF-α reduces insulin sensitivity. Incubating insulin-
sensitive rat hepatoma cells with TNF-α for 1 hour led to a 65% decrease in insulin-induced 
tyrosine phosphorylation of the insulin receptor beta-subunit and IRS-1, and an upregulation in 
serine phosphorylation, thus preventing the tyrosine phosphorylation cascade (Feinstein et al., 
1993). In vitro, TZDs lead to a considerable reduction in TNF-α expression in adipocytes 
(Okuno et al., 1998). In this model TZD administration also inhibits TNF-α-induced decreases in 
GLUT-4 expression, (Ohsumi et al., 1994) and can augment IRS-1 tyrosine phosphorylation. 
(Peraldi et al., 1997), (Iwata et al., 2001), (Solomon et al., 1997), (Shibasaki et al., 2003). This 
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mechanism seems to be mediated by downstream actions on PPARγ (Clarke & Mohamed-Ali, 
2006). TZDs have also been demonstrated to have positive effects on secondary mechanisms 
of TNF-α induced-insulin resistance, such as reduced levels of systemic free fatty acids and an 
increase in lipoprotein lipase expression (Shibasaki et al., 2003), (Porat, 1989),  (Kroder et al., 
1996). TNF-α has also been shown to inhibit insulin signalling and reduce insulin action in 
skeletal muscle (Lang et al., 1992), (Nolte et al., 1998), (del Aguila et al., 1999), (Halse et al., 
2001), (Li & Reid, 2001). In a similar fashion TNF-α induces insulin resistance in hepatic tissues 
by reducing tyrosine phosphorylation (Solomon et al., 2001), (Lang et al., 1992). Hence the 
three most important tissues involved in insulin-stimulated glucose disposal are targets for TNF-
α induced insulin resistance. In addition, TNF-α considerably augments the expression of  IL-6, 
(Stephens et al., 1992), (Fasshauer et al., 2003) decreases the expression of adiponectin 
(Maeda et al., 2001) and resistin (Fasshauer et al., 2001), (Shojima et al., 2002), and is 
correlated with elevated leptin concentrations (Bullo et al., 2002). TNF-α can also reduce the 
sequestering of lipid in adipocytes because it upregulates premature adipocyte apoptosis, thus 
reducing space for excess lipid storage. This results in pre-existing adipocytes being burdened 
by the excess lipid and in turn diverting it to other tissues, such as skeletal muscle and the liver 
(Prins et al., 1997), (Niesler et al., 1998). TZDs also appear to ameliorate the TNF-α-induced 
adipocyte apoptosis. This leads to an increased number of smaller fat cells, without reducing 
the total mass of adipose tissue (Okuno et al., 1998).  
 
2.6.3 Downstream Signalling of TNF-α 
TNF-α binding to the TNF-R1 on the cell surface results in the activation of two important 
transcription factors (c-Jun and NF-κβ) that consequently activate several genes implicated in 
the inflammatory pathway, the stress response and cell growth and development. TNF-α 
binding causes structural alterations to the receptor, which result in the recruitment of the 
adaptor protein; TNF receptor-associated death domain (TRADD) (Chen & Goeddel, 2002). 
TRADD then promotes the ligation of other adaptor proteins, such as receptor-interacting 
protein (RIP) and TNF receptor-associated factor 2 (Kanazawa & Kudo, 2005), leading to the 
eventual activation of c-Jun NH2-terminal kinase (JNK) and NF-κβ pathways (Chen & Goeddel, 
2002) (Figure 2.5). 
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Figure 2.5 TNF-α signal transduction pathway. Initiation of TNF-α signaling leads to activation of two major 
pathways; JNK and NF-κβ. Both of which have been implicated in the negative regulation of insulin 
signalling Engagement of TNF with its cognate receptor TNF-R1 results in the formation of a receptor-
proximal complex containing the important adaptor proteins TRADD, TRAF2, RIP. These adaptor proteins 
in turn recruit additional key pathway-specific enzymes. Activation of the IKK complex leads to 
phosphorylation of IKβ, which marks it for ubiquitination and proteasomal degradation. This sequence of 
events permits NF-κβ to enter the nucleus and regulate gene expression.  
 
2.6.4 Adiponectin Structure and Function 
Recent research indicates that the adipocytokine, adiponectin regulates insulin sensitivity and 
has a role in carbohydrate and lipid metabolism (Kralisch et al., 2005), (Jazet et al., 2003) as 
well as anti-atherogenic and anti-inflammatory processes (Havel, 2004), (Trujillo & Scherer, 
2005). Adiponectin was discovered almost simultaneously by four different laboratories in 1995. 
It was first identified as a protein synthesised and secreted by cultured 3T3-L1 adipocytes 
(Scherer et al., 1995) and was named adipocyte complement related protein 30kDa (ACRP30) 
because of it’s sequence homology to complement C1q and structural homology to TNF-α 
(Shapiro & Scherer, 1998). It was also named adipoQ (Hu et al., 1996), adipose most abundant 
gene transcript 1: APM1 (Maeda et al., 1996) and gelatine-binding protein 28 kDa: GBP28 
(Nakano et al., 1996). It is 247 amino acids long and is secreted by adipocytes (Scherer et al., 
1995). Structurally adiponectin consists of 3 distinct domains; a globular domain at the C 
terminus, a signal sequence near the N terminus, and a collagenous domain. Three of these 
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collagen like domains bind together to form a trimer and four to six of these trimers bind 
together to form a multimer. In circulation adiponectin exists in three forms (i) as a hexamer (two 
bound trimers) called low molecular weight (LMW), (ii) as an oligomer of high molecular weight 
(HMW, and (iii) in the globular form. Although all of these are present in plasma, HMW 
adiponectin is considered to have the most potent biological activity (Pajvani et al., 2003), (Tsao 
et al., 2003). Adiponectin is the most abundant protein secreted by the adipose tissue. Plasma 
concentrations range from 5 – 30 µg/ml in humans. Unusually by comparison to most other 
adipocytokines, adiponectin decreases concurrently with obesity and increases in response to 
weight loss (Reinehr et al., 2004), (Brichard et al., 2003). 
 
2.6.5 Adiponectin in Obesity, Type 2 Diabetes and Cardiovascular Disease 
Plasma concentrations of adiponectin are negatively correlated with body mass index (Hu et al., 
1996), (Kern et al., 2003), (Matsubara et al., 2003), (Milan et al., 2002), (Yang et al., 2002). 
Concentrations are also lower in type 2 diabetes mellitus patients than in age and BMI matched 
controls (Hotta et al., 2000) and have been shown to correlate strongly with insulin sensitivity, 
implying that low levels of adiponectin are linked to insulin resistance (Stefan et al., 2002). As 
adiponectin expression is specific to the adipocyte a changes in adipose tissue mass can alter 
serum adiponectin levels. Weight loss significantly increases the expression of adiponectin 
(Lazzer et al., 2005) but weight gain has the opposite effect (Weyer et al., 2001a). Plasma 
adiponectin levels are approximately 40% higher in women than in men. This is thought to be a 
result of androgenic suppression (Combs et al., 2003), (Nishizawa et al., 2002). Additionally 
women have higher ratios of HMW adiponectin than men (Pajvani et al., 2003). Adiponectin is 
reduced in cardiovascular disease (Ouchi et al., 1999) and in type 2 diabetes mellitus (Hotta et 
al., 2000). Evidence from longitudinal studies suggest that low levels of adiponectin are 
predictive of later development of type 2 diabetes (Spranger et al., 2003), (Lindsay et al., 2002) 
and myocardial infarction (Pischon et al., 2004) 
 
2.6.6 Adiponectin Signalling 
Adiponectin signals through two recently cloned receptors, AdipoR1 and AdipoR2 which are 
predominantly expressed in skeletal muscle and hepatic tissue respectively (Yamauchi et al., 
2003) but have also been found in the brain, macrophages and atherosclerotic lesions. AdipoR1 
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has a high affinity for the globular form of adiponectin, which acts on skeletal muscles to 
increase glucose uptake and oxidation as well as lipid oxidation (Lihn et al., 2005), (Lara-Castro 
et al., 2006). The activation of these receptors leads to the phosphorylation and activation of 
AMP-activated protein kinases (AMPK) and peroxisome proliferator-activated receptor-gamma 
(PPARγ) (Yamauchi et al., 2003). This results in an upregulation of proteins involved in fatty 
acid transport and oxidation such as CD36, acetyl-coenzyme A oxidase, uncoupling protein-2, 
and PPARα, leading to an increase in β-oxidation (Kadowaki & Yamauchi, 2005). Consequently 
there is a reduced concentration of intramuscular triglycerides and a decrease in plasma free 
fatty acids and FA influx in the liver.  
 
Elevated intramuscular triglyceride concentrations or decreased IMTG turnover impede insulin 
signalling and GLUT-4 translocation by increasing serine phosphorylation of the insulin receptor 
and IRS-1. Therefore reductions in fatty acid concentrations improvement insulin signalling and 
insulin sensitivity (Jequier, 1998), (Frayn, 2003). In the liver, AdipoR2 has a greater affinity for 
full-length adiponectin. Adiponectin activated AMPK reduces the expression of enzymes 
involved in gluconeogenesis such as glucose-6-phosphase. This in turn reduces hepatic 
glucose production and output, which contributes to whole body glucose homeostasis and thus 
enhances insulin sensitivity (Kralisch et al., 2005), (Jazet et al., 2003), (Havel, 2004), 
(Yamauchi et al., 2003) (Figure 2.6). 
 
 
 37
Adipo R2
Adipo R1
 
Figure 2.6 Adiponectin can activate AMPK and PPARα in the liver and skeletal muscle. In skeletal muscle, 
both globular and full-length adiponectin activate AMPK, thereby stimulating phosphorylation of ACC, fatty-
acid oxidation, and glucose uptake. Adiponectin activates PPARα, thereby also stimulating fatty-acid 
oxidation and decreasing tissue TG content in muscle. In the liver, only full-length adiponectin activates 
AMPK, thereby reducing molecules involved in gluconeogenesis and increasing phosphorylation of ACC 
and fatty-acid oxidation. Adiponectin activates PPARα, thereby stimulating fatty-acid oxidation and 
decreasing tissue TG content in the liver (Kadowaki & Yamauchi, 2005). 
 
Emerging evidence suggests that weight loss not only increases total adiponectin but possibly, 
also influences the ratio of the different adiponectin isoforms. A recent study has reported that 
obese subjects who participated 6 month dietary restriction weight loss programme had 
significantly greater HMW adiponectin (0.37 ± 0.07 vs. 0.49 ± 0.08 µ.ml-1), MMW (2.3 ± 0.2 vs. 
2.9 ± 0.3 µ.ml-1) but not LMW adiponectin (Bobbert et al., 2005). Several other studies have 
demonstrated a similar increase in HMW adiponectin after biliopancreatic bypass in obese 
subjects (Salani et al., 2006) and after hypocaloric diet-induced weight loss in obese and 
overweight postmenopausal women (Polak et al., 2007). The expression of HMW isoforms is 
also increased in murine adipocytes following treatment with the PPARγ agonist, pioglitazone 
(Bodles et al., 2006). Indeed many of the inverse relationships identified between total 
adiponectin and measures of insulin resistance (Hara et al., 2006), (Katsuki et al., 2006) obesity 
(Araki et al., 2006) and other markers of metabolic dysregulation (Aso et al., 2006) are stronger 
with the HMW isoform. Studies have consistently demonstrated an inverse relationship between 
adiponectin and insulin resistance (Cnop et al., 2003), (Matsubara et al., 2003). Hotta et al., 
(2001) generated a genetically modified model of type 2 diabetes in rhesus monkeys, and found 
that plasma adiponectin decreased with the onset and development of insulin resistance. Lihn 
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et al., (2003) found that first degree relatives of subjects with type 2 diabetes were 
characterised by reduced adiponectin mRNA expression in the adipose tissue (Lihn et al., 
2003a). 
 
Interestingly, insulin resistance is a feature of obesity but also lipodystrophy, a condition where 
adipose tissue is partially or totally depleted (Carr et al., 1998). Both lipodystrophy and HIV-
associated dystrophy syndrome is correlated with reduced plasma adiponectin and mRNA 
expression in adipose tissue (Lihn et al., 2003b), (Tong et al., 2003) This suggests that reduced 
adiponectin may play an important role in the pathogenesis of insulin resistance in 
lipodystrophy. Yamauchi et al., (2001) administered recombinant adiponectin to lipodystrophic, 
insulin resistant mice with no detectable plasma adiponectin. Adiponectin reduced blood 
glucose and insulin concentrations by suppressing hepatic glucose production and increased 
the expression of genes involved in lipid transport and fatty acid oxidation. The content of 
muscle and liver triglyceride was reduced and insulin resistance was almost completely 
reversed. These results suggest that insulin resistance in lipodystrophy may result from a lack of 
adiponectin production (Yamauchi et al., 2001). 
 
2.6.7 Adiponectin and Atherosclerosis 
The antiatherogenic properties of adiponectin have also been shown in animal models. 
Adiponectin knockout mice develop more severe intimal thickening in response to endothelial 
injury than wild-type mice (Okamoto et al., 2002). Additionally, increased expression of 
adiponectin by adenovirus transfection reduces the formation of atherosclerotic plaques in 
apolipoprotein E knock out mice (Matsuda et al., 2002). As adiponectin circulates in large 
quantities, it comes in contact with the vascular endothelium all over the body. 
Immunohistochemical staining of vascular cells with antibodies to adiponectin show no 
adiponectin protein in normal rabbits. However immunohistochemical staining with adiponectin 
antibodies revealed high levels of adiponectin in balloon injured vascular walls, indicating that 
adiponectin may play a restorative role in endothelial vascular injury (Okamoto et al., 2002). 
 
Investigations of its cellular actions have revealed that adiponectin exerts many important 
antiatherogenic effects. When the vascular endothelium is injured by aggravating factors such 
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as oxidised low density lipoprotein (LDL), chemical substances and mechanical stress, 
adiponectin accumulates in the subendothelial intima by binding to collagen in the extracellular 
matrix. Adiponectin suppresses monocyte binding by downregulating the production of 
endothelial adhesion molecules such as vascular cell adhesion molecule 1 (VCAM1), 
intracellular cell adhesion molecule 1 (ICAM1) and E-selectin through inhibition of Nuclear 
Factor ĸβ (Ouchi et al., 2000). It appears that adiponectin also attenuates the proliferation of 
smooth muscle cells into the intimal space (an important step in the development of 
atherosclerotic plaques) by inhibiting mitogen-activated protein kinase (Arita et al., 2002). 
Furthermore, adiponectin appears to directly stimulate nitric oxide in endothelial cells (Shimada 
et al., 2004) which is a vasodilator and facilitates normal endothelial function.  
 
2.6.8 Adiponectin and Exercise 
Exercise mediated weight loss significantly increases serum adiponectin, which is also 
accompanied by increases in insulin sensitivity (Yatagai et al., 2003). However it is not known if 
increased adiponectin is a cause or consequence of exercise-mediated insulin sensitivity. 
Yatagai et al., (2003) studied twelve non-obese sedentary men before and after a 6-week 
training programme that involved stationary cycling at lactate threshold for 60 minutes per day, 
5 days per week. Following the training programme VO2max and lactate threshold increased, BMI 
and body fat mass remained unchanged, fasting glucose and insulin decreased indicating 
increased insulin sensitivity, but adiponectin concentrations either remained the same or 
showed a slight decrease. These results suggest that increased insulin sensitivity following 
exercise training is not due to increased serum adiponectin and also implies that adiponectin 
concentrations may only increase following exercise training that induces weight loss (Yatagai 
et al., 2003), (Hulver et al., 2002).  
 
These results seem to contradict other studies examining the effect of exercise training on 
adiponectin levels. Fatouros et al., (2005) examined the effect of a 6-month resistance training 
programme on adiponectin in overweight inactive elderly adults. The subjects were randomly 
assigned to a control group, a low intensity group (45-50% 1RM), a moderate intensity group 
(60-65% 1 RM), or a high intensity group (80-85% 1 RM) group where they completed 3 sets of 
10 exercises, 3 days per week for 6 months. Strength, maximal oxygen consumption, and 
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insulin sensitivity increased following the intervention and this was accompanied by a decrease 
in BMI. Circulating adiponectin increased in the moderate and high intensity groups but not in 
the low intensity group, although this was associated with increased insulin sensitivity and 
decreased BMI (Fatouros et al., 2005). Monzillo et al. (2003) showed weight loss induced by 
exercise and caloric restriction increased adiponectin levels similarly in diabetic and non-
diabetic groups (Monzillo et al., 2003).   
  
Hara et al., (2005) investigated the effect of exercise training on young obese men who were 
divided into either an aerobic training group, an aerobic and resistance training group, or a 
control group. The aerobic exercise group underwent 8 weeks of training, 3 times per week, for 
more than 30 minutes at ventilatory threshold. The resistance and endurance exercise group 
underwent the same aerobic training in addition to 2 or 3 resistance training sessions consisting 
of 3 sets of 10 repetitions of 14 exercises at 80% of 1 RM. Adiponectin levels did increase but 
this increase was due to decreased body composition associated with exercise training (Hara et 
al., 2005). Current evidence suggests that increases in adiponectin, which occur with exercise 
training, are related to changes in adiposity rather than the exercise training itself. This is 
supported by the fact that serum adiponectin remained unchanged following a single bout of 
aerobic exercise despite increased insulin sensitivity that occurred immediately after exercise 
(Jamurtas et al., 2006).  
 
2.7 Osteoprotegerin, RANKL and TRAIL 
 
2.7.1 Structure and Function of OPG 
OPG is a soluble glycoprotein and member of the TNF-receptor superfamily that is 
characterized by its ability to bind to RANKL and TRAIL (Corallini et al., 2008), (Emery et al., 
1998). It exists as a 60-kd monomeric structure or as a disulfide linked 120-kd homodimer and 
is encoded on chromosome 8q (Yun et al., 1998). In contrast to other members of the TNF 
receptor superfamily, OPG does not have specific transmembrane or cytoplasmic domains. It is 
instead secreted into the circulation as a soluble receptor (Yun et al., 1998), (Corallini et al., 
2008). OPG consists of 401 amino acids, however the cleaving of a 21-amino acid signal 
peptide leads to the formation of a mature 380 amino acid form (Simonet et al., 1997). OPG 
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also distinguishes itself from other members of the TNF-receptor superfamily because it 
maintains biological activity in its soluble, circulating form. It was identified in 1997-1998 
simultaneously by two separate groups (Simonet et al., 1997), (Tsuda et al., 1997) and has had 
a number of synonyms including osteoclastogenesis inhibitory factor (OCIF), TNF receptor like 
molecule 1 (Kwon et al., 1998), and follicular dendritic cell-associated receptor 1 (FDCR-1). 
However, OPG is now the accepted term for this glycoprotein. At the time of discovery both 
groups demonstrated an important role for OPG in the regulation of bone turnover as a result of 
its direct inhibition of osteoclastogenesis (Simonet et al., 1997), (Tsuda et al., 1997), (Reid & 
Holen, 2009). It consists of 4 amino-terminal cysteine rich domains that are structurally similar to 
the extracellular portions of other associates in the TNF receptor superfamily. The carboxy-
terminal incorporates portions 5 and 6, that are death domain homologous regions (Baker & 
Reddy, 1998) (Figure 2.7) 
 
Figure 2.7 Schematic representation of the structure of OPG. Main domains and their biochemical and/or 
functional properties are indicated. NH2 indicates amino-terminus; COOH, carboxy-terminus (reproduced 
from (Corallini et al., 2008). 
 
2.7.2 Role of the OPG/RANK/RANKL axis in Bone Turnover: Evidence from mouse 
studies 
A physiological role for OPG in regulating bone formation and resorption was initially 
demonstrated when OPG deficient mice, produced by targeted disruption of the gene were 
viable and fertile but developed profound bone loss, marked destruction of growth plates and 
reduced trabecular femur bone mass (Bucay et al., 1998). In this study the authors further noted 
that the elevated mortality of these adolescent mice was related to an increased occurrence of 
vertebral or endochondral fractures. Interestingly the offspring of surviving, female double 
knockout mice gave birth to histologicaly normal double knockout offspring, suggesting that 
OPG is not essential for normal foetal development. Besides the effect on bone quality and 
elevated alkaline phosphatase, mice who survived to 6 months appeared to have no untypical 
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haematological or biochemical characteristics. In a similar study Mizuno et al., (1998) also 
created an OPG homozygous mouse: they found no histopathological abnormalities in the 
femurs of these mice at 5 weeks. However there was a marked increase in osteoclast size, 
number and proliferation, coupled with a progressive loss of trabecular femoral bone found 
between 8 and 13 weeks, suggesting that the early osteoporotic phenotype observed in these 
adolescent mice is likely due to an increase in osteoclastogenesis. (Mizuno et al., 1998). A 
putative role for OPG in this process was first elucidated in a classical study by Simonet et al. 
(1997) who created OPG-overexpressing mice. At 10 weeks, other than an enlarged spleen 
(~38%), these mice were phenotypically no different from their normal littermates; however they 
showed signs of profound osteopetrosis characterized by significant radio-opacity of the long 
bones, vertebrae, and pelvis when compared to their ordinary littermates. Mice that highly 
express the OPG transgene displayed obvious signs of osteopetrosis by x-ray at birth, the 
severity of which increased significantly into adolescence and adulthood. Despite this increase 
in radio-density, there was no irregularity in tooth eruption, a symptom commonly observed in 
ostepetrotic mice (Yoshida et al., 1990), (Soriano et al., 1991). In order to investigate the effect 
of OPG on healthy mice, Simonet et al. (1997) administered recombinant OPG to 4 week old 
wild-type mice and found that after 7 days they had a 3 fold increase (31.1% versus 12.0%) in 
trabecular bone of the proximal tibial metaphysis when compared to controls (Simonet et al., 
1997). The authors further clarified a role for OPG in the regulation of bone formation 
demonstrating that the administration of recombinant OPG blocks differentiation of precursor 
cells into osteoclasts in a dose dependant manner in vitro. Additionally the authors underlined a 
possible clinical application of recombinant OPG by illustrating the potential for OPG therapy to 
ameliorate the bone loss that one would expect in ovariectomized rats, where bone volume in 
the proximal tibial metaphysis was increased in OPG treated rats relative to controls (Simonet et 
al., 1997).  
 
2.7.3 The RANK/OPG/RANKL Axis 
The mechanism of action for OPG has been well described. Osteoblasts and their precursor 
cells, stromal cells express the homotrimeric, transmembrane protein; RANKL, particularly in 
regions where there is active bone remodelling or inflammatory osteolysis (Hofbauer & 
Schoppet, 2004). RANKL is a 316 amino acids sequence that is abundantly expressed in 
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osteoblastic / stromal cells, and T cells in lymph tissue (Figure 2.8). RANKL appears in 
circulation after being secreted by T cells or following proteolytic cleavage from cell surfaces 
(Hofbauer & Heufelder, 2001), (Walsh & Choi, 2003), (Schoppet et al., 2002). RANKL 
stimulates RANK, a transmembrane receptor, consisting of 616 amino acids that is found on the 
surface of cells with a monocyte/macrophage lineage, such as dendritic cells and osteoclasts 
and their precursors (Dougall et al., 1999). RANKL binds to RANK on osteoclast precursors and 
more mature osteoclasts, upregulating intracellular pathways that increase proliferation and 
survival of osteoclasts leading to activation of osteoclastogenic processes, increased bone 
resorption and bone loss. Generally an increase in RANKL is associated with a decrease in 
OPG, such that the ratio of RANKL to OPG changes in favour of osteoclastogenesis. Many 
papers have given credence to the claim that the RANKL to OPG ratio is an important 
determinant of bone density (Hofbauer & Schoppet, 2004). Both stromal cells and osteoblasts 
secrete OPG as a homodimer, which acts as a decoy receptor, binding to RANKL, thus blocking 
the resultant inhibition of osteoclastogenesis and bone loss (Corallini et al., 2008). In vitro 
investigations have demonstrated the importance of OPG dimerisation for this process. 
Homodimeric OPG binds strongly (KD  10nM) with homotrimeric RANKL to form stable dimer-
trimer compounds. 
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Figure 2.8 Crystal structure of RANKL. (a) Ribbon diagram of the RANKL trimer, shown with the β-strands 
(green) and connecting loops (orange) of one RANKL monomer. The other two RANKL monomers are 
cyan and magenta, respectively. (b) In this view, oriented identically to a, the RANKL transmembrane stalk 
projects to the top of the image, while the membrane-distal region is toward the bottom. The homotrimer 
exhibits the shape of a truncated pyramid, being slightly wider at the membrane proximal end. (c) Ribbon 
diagram of the RANKL trimer viewed down the axis of threefold symmetry, oriented with the membrane-
distal face forward. The secondary structure of monomer X is labelled as in a. (d) The RANKL trimer, 
shown with the molecular surfaces of monomers X, Y, and Z colored in green, cyan, and magenta, 
respectively. The orientation of the molecule is identical to that in c. from (Lam et al., 2001) 
 
Schneeweis et al., (2005) showed, using sedimentation velocity analysis that 1:2 OPG-RANKL 
complexes were not formed in mixtures containing a 2-fold molar excess of RANKL over OPG, 
implying that both of the OPG monomers in the homodimer cannot bind to a separate RANKL 
trimer simultaneously. However, 2:1 OPG-RANKL complexes did emerge when OPG was 
present at a 2-fold molar excess over RANKL. Moreover, the authors found that the second 
OPG dimer displayed a significant loss of affinity (KD – 3μM). The authors concluded that the 
most likely explanation based on these findings was that the high affinity OPG-RANKL binding 
is dependant on avidity. Two of the OPG monomers in each dimer bind to two out of three of the 
RANKL monomers in each trimeric structure. Only one monomer in the second OPG molecule 
is able to weakly interact with the third and only available RANKL monomer (Schneeweis et al., 
2005). 
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2.7.4 RANKL / RANK Molecular Pathway Inducing Osteoclastogenesis 
The regulatory role of RANKL in bone resorption and formation has also been shown in vivo, 
Baud'huin et al., (2007) demonstrated that administration of RANKL to adult mice induces bone 
resorption, whilst mice deficient in functional RANKL develop osteoporosis (Baud'huin et al., 
2007). A crucial mechanism in promoting the resorptive action of osteoclasts is the binding of 
RANK to RANKL. As an affiliate of the TNF receptor superfamily, RANK does not have any 
kinase activity, therefore it is necessary for RANK to enlist the help of associated factors to 
transduce the signals after binding to its ligand (Leibbrandt & Penninger, 2008). Binding of 
RANK to its ligand leads to the translocation of TNF receptor-associated factors (TRAFs) to the 
intracellular surface of RANK. RANK has been shown to associate with TRAFs 1 – 6 during in 
vitro experiments (Darnay et al., 1998), (Galibert et al., 1998), (Wong et al., 1998), (Leibbrandt 
& Penninger, 2008). The cytoplasmic domain of RANK has several TRAF binding sites that 
cluster in specific regions. The areas enclosed by the amino acids 235–358 and 359–531 bind 
the TRAF6 adaptor molecule and the 532–625 region contains several binding locations for 
TRAFs 2, 5, and 6 (Darnay et al., 1998), (Wong et al., 1998), (Wong et al., 1999). However, 
only TRAF6 interacts with the membrane-proximal region of the RANK cytoplasmic domain 
which is distinct from other TRAFs. The functional significance of these TRAF binding domains 
is to initiate RANK-induced NF-κβ and c-Jun NH2-terminal kinase (JNK) activation. Deletion of 
the TRAF6 binding site of RANK almost completely blocked the RANK-dependent activation of 
NF-κβ (Galibert et al., 1998). However, JNK activation was intact and demonstrating that 
interactions with TRAF6 are essential for NF-κβ but not JNK pathway activation (Darnay et al., 
1998), (Wong et al., 1998), (Galibert et al., 1998), (Lee et al., 2000). Armstrong et al. (2009) 
used genetically modified gene constructs of RANK that selectively inhibited TRAF protein 
binding, to show that TRAF6 was the only functional TRAF protein downstream of RANK 
affecting osteoclast differentiation. The interaction of RANK with TRAF6 however was extremely 
important for the formation of cytoskeletal structures and the resorptive activity of osteoclasts 
(Armstrong et al., 2002). Lomaga et al., (1999) found that viable TRAF6 double knockout mice 
appeared phenotypically normal at birth but did not mature and died soon after birth. The 
TRAF6−/− animals that lived longer than 14 days had a 20 - 30% reduction in body mass and 
length. In addition, they had modest enlargement of the heart and liver which was accompanied 
by significant splenomegaly, represented by an increase in organ size of 2 – 6 fold compared to 
wild type littermates. X-ray examination of these mice showed that their long bones and 
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vertebral bodies were radio-opaque. The long bones, especially the femur, were reduced in 
length and exhibited a distinct broadening at the ends attributable to a failure in bone modelling, 
indicative of osteopetrosis. Molars and incisors of the double knockout animals had failed to 
erupt which is, again, common in osteopetrotic mice (Popoff & Marks, Jr., 1995), as bone 
resorption allows for the opening of a channel through the jawbone for teeth to grow. Peripheral 
quantitative computed tomography analysis of the proximal tibial bone metaphyisis showed a 
significant increase in bone mass in double knockout compared to the transgenic mice (Lomaga 
et al., 1999). These findings were strengthened by Naito et al. (1999) who also found that in 
addition to premature mortality and runting, TRAF6 double knockout mice had limited bone 
marrow cavities consisting of mostly spongy bone. Further histological analysis highlighted 
abnormal bone formation and thickened epiphyseal growth plates. Like Lomaga et al., (1998), 
the authors attributed this profound osteopetrosis to a failure of osteoclast precursors to 
differentiate into mature osteoclasts in response to RANKL. (Lomaga et al., 1999), (Naito et al., 
1999). 
 
The contributions of TRAF2 and TRAF5 to osteoclastogenesis seem to be relatively small. 
TRAF2−/− liver derived progenitor cells have only marginally reduced multinuclear osteoclasts 
accumulation and the activation of NF-κβ and JNK by RANKL was comparable to normal 
controls. Similarly, TRAF5 deficient cells only had a mild defect in osteoclastogenesis, and NF-
κβ and JNK activation was not affected by RANK stimulation. (Kanazawa & Kudo, 2005), 
(Kanazawa et al., 2003). There are at least seven distinct pathways activated by RANK-induced 
protein kinase signalling; four of them directly induce osteoclastogenesis; inhibitor of NF-κβ 
kinase/NF-κβ, c-Jun amino-terminal kinase/activator protein-1, c-myc, calcineurin/nuclear factor 
of activated T cells (NFATc1). There are three others that directly mediate osteoclast activation 
(src and MKK6/p38/ MITF) and survival (src and extracellular signal-regulated kinase) (Boyce & 
Xing, 2007). These studies indicate that TRAF6 is the most important adaptor molecule linking 
RANK signalling to the NF−κβ osteoclastogenesis pathway and that other TRAFs may 
circumvent and compensate for TRAF6-deficiency (Leibbrandt & Penninger, 2008). In addition 
to TRAFs, there are other adapter molecules that bind to RANK to induce signalling in this 
pathway. This in turn results in the activation of the transcription factor NF-κβ. (Matsumoto et 
al., 2000), (Xing et al., 2002). Growth factor receptor-bound protein 2 (Grb-2) associated binder 
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2 (Wada et al., 2005) is one of a family of adapter proteins phosphorylated at tyrosine residues 
that leads to the recruitment of a variety of signalling molecules with steroid receptor coactivator 
2 (Src 2) homology domains. Loss of Gab2 results in reduced RANKL/RANK-induced osteoclast 
differentiation, decreased bone resorption, and mild osteopetrosis (Boyce & Xing, 2007), (Wada 
et al., 2005), suggesting that it is an important player in RANKL-induced osteoclastogenesis 
(Wada et al., 2005).   
 
The vital role of NF-κβ/activator protein-1/ (NFATc1) signalling for osteoclast formation was 
revealed after genetic disruption of the p50 and p52 subunits of NF-κβ and of the immediate 
early gene transcript, c-Fos (Karsenty & Wagner, 2002). A subsequent study that transferred 
NFATc1-/- stem cells to cFos-/- mice resulted in osteoclast formation (Takayanagi et al., 2002). 
Over expression of a constitutively active form of NFATc1 induces osteoclast formation by 
Macrophage-Colonly Stimulating Factor (M-CSF) treated Fos-/- or NF-κβ p50/p52-/- osteoclast 
precursors in the absence of RANKL (Yao et al., 2005) indicating that it is downstream from NF-
κβ and c-Fos (Figure 2.9). On the basis of all of these studies, NFATc1 has been described as 
a master regulator of osteoclastogenesis (Boyce & Xing, 2007), (Takayanagi et al., 2002). 
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Figure 2.9 The essential signaling pathway for normal osteoclastogenesis. Under physiologic conditions, 
RANKL produced by osteoblasts binds to RANK on the surface of osteoclast precursors and recruits the 
adaptor protein TRAF6, leading to NF-κβ activation and translocation to the nucleus. NF-κβ increases c-
Fos expression and c-Fos interacts with NFATc1 to trigger the transcription of osteoclastogenic genes. 
OPG inhibits the initiation of the process by binding to RANKL. NFAT, nuclear factor of activated T cells; 
NF-κβ, nuclear factor-κB; OPG, osteoprotegerin; RANKL, receptor activator of nuclear factor-κB ligand; 
TRAF, tumor necrosis factor receptor associated factor. (adapted from (Boyce & Xing, 2007) and 
(Hofbauer & Schoppet, 2004) 
 
2.7.5 Disorders of RANKL/OPG/RANK Signalling 
Disequilibrium in the RANKL/OPG fraction or signalling contributes to the clinical pathology of 
many disorders of the skeleton, where increased bone resorption/formation, or inappropriate 
bone remodelling are a factor (Hofbauer & Schoppet, 2004). This is supported by Whyte el al. 
(2002) who demonstrated a loss in osteoprotective function for homozygous deletions of 100 kb 
of OPG in patients with the autosomal-recessive disorder; Juvenile Paget’s Disease a condition 
in which increased resorption, severe osteopaenia, and persistent fractures are primary 
symptoms (Whyte et al., 2002). It is further supported by the identification of an inactivating 
deletion in exon 3 of OPG in which idiopathic hyperphosphatasia, which is an autosomal-
recessive disease typified by increased bone resorption, deformities of long bones, kyphosis, 
and acetabular protrusion (Cundy et al., 2002), (Daroszewska et al., 2004), (Boyce & Xing, 
2007). The central role of defective OPG signalling and secretion in Juvenile Paget’s Disease 
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was verified by Cundy et al., (2005) where the weekly subcutaneous administration of  
recombinant OPG to two adult siblings with Juvenile Paget’s Disease led to a decrease in the 
speed of bone resorption, a decrease in skeletal bisphosphonate retention by 37 and 55 % 
respectively and improved radio-density upon examination by x-ray (Cundy et al., 2005).  
 
In addition, in vivo models such as the T-cell-dependent model of rat adjuvant arthritis (Kong et 
al., 1999) and collagen induced arthritis (Schett et al., 2003) are both characterized by severe 
joint inflammation, bone and cartilage destruction and crippling. Blocking RANKL by 
osteoprotegerin treatment at the onset of disease prevents bone and cartilage destruction but 
interestingly not inflammation (Kong et al., 1999). In addition, blockade of this pathway has 
been shown to prevent bone and tooth loss in an animal model of periodontal disease, without 
having any significant effect on the immune process (Teng et al., 2000). More recent animal 
models have used combination therapy to block RANKL with the administration of OPG in 
conjunction with the blockade of various inflammatory agents, including; IL-1 and TNF-α and 
found that with the use of these two treatments in tandem significantly reduces bone loss and 
systemic inflammation (Zwerina et al., 2004). 
 
There have been several studies in postmenopausal women that have attempted to investigate 
the relationship between circulating OPG and Bone Mineral Density (BMD). However the 
findings from these studies are conflicting. Circulating OPG has been shown to increase 
(Rogers et al., 2002) or decrease with osteoporosis and be negatively correlated to BMD. 
Mezquita et al., (2005) studied a cohort of 206 postmenopausal women and found that lower 
concentrations of circulating OPG were positively related to low BMD as well as prevalence of 
vertebral fracture (Mezquita-Raya et al., 2005). However a study by Yano et al. (1999) 
comparing serum OPG in Japanese men and women found that serum OPG was significantly 
increased in postmenopausal women who were osteoporotic (Yano et al., 1999). A possible 
reason for the differences between these studies could be the difference in experimental design 
and different populations utilized. (Reid & Holen, 2009) 
 
In addition to the severe osteoporosis observed in OPG deficient mice (Mizuno et al., 1998), 
OPG knockout mice appear to exhibit significant renal and aortic calcification (Bucay et al., 
1998). Furthermore, administration of recombinant OPG to rodents appears to prevent the 
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onset of arterial calcification induced by warfarin treatment or high doses of vitamin D (Price et 
al., 2001). Arterial calcification usually complicates chronic atherosclerosis and it appears to be 
accelerated in these mice, suggesting that OPG may play an important role in protecting large 
blood vessels from medial calcification and other complications of atherosclerosis (Bucay et al., 
1998). The relationship between osteoporosis and vascular calcification in these animal models 
of OPG deficiency is somewhat reminiscent of the clinical setting where these conditions often 
occur congruently (Hofbauer et al., 2007). Longitudinal analysis of bone loss and vascular 
calcification over a 25-year period in the Framingham Heart Study showed that women with the 
greatest magnitude of bone loss had the most severe progression of abdominal aortic 
calcification (Kiel et al., 2001). Furthermore a cross sectional study in 2,348 postmenopausal 
women revealed that aortic calcification strongly predicts low bone mineral density and 
occurrence of fractures. A subgroup of 228 women within this cohort who were longitudinally 
observed showed that the percentage yearly increase in aortic calcification accounted for 
almost half of the variance in the percentage rate of bone loss. Additionally a strong graded 
association was observed between the progression of vascular calcification and bone loss for 
each quartile. Women in the highest aortic calcification-quartile had four times greater yearly 
bone loss than women in the lowest quartile (Schulz et al., 2004). 
 
2.7.6 OPG Expression and Function in the Vascular System  
Evidently the RANKL/RANK/OPG triad is an important player in the homeostatic control of the 
immune and skeletal systems. Research in recent years has also begun to shed light on an 
equally intriguing role for this axis in the homeostasis of the vascular environment. Many of the 
same signals that modulate RANKL and OPG, both immunomodulatory and osteogenic in 
origin, may also regulate their expression in the vascular endothelium. As well as the typical 
activity of OPG in boney tissues, OPG expression and secretion is also found at high 
concentrations in the arterial wall, where the content in aortic extracts is reported to be 500 – 
1000 times greater than those found in the circulation (Olesen et al., 2005), (Knudsen et al., 
2003), a similar concentration to that found in bone. It has also been demonstrated that both 
micro/macro vascular endothelial cells (VECs) and vascular smooth muscle cells (VSMCs) 
secrete OPG (Collin-Osdoby et al., 2001), (Secchiero et al., 2006), (Zhang et al., 2002). A 
number of potential growth factors and inflammatory cytokines which are thought to be key 
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players in the pathogenesis of atherosclerosis and coronary artery disease have also been 
implicated in the regulation of OPG in the vascular wall. VEC-expression of OPG can be 
induced by the addition of the inflammatory cytokines; TNF-α, IL-1α, IL-1β, activated integrin 
αvβ3 and additionally porphyromonas gingivalis, an initiating activator of periodontal disease. 
(Kobayashi-Sakamoto et al., 2004), (Secchiero et al., 2006), (Ben-Tal et al., 2007). Collin-
Osdoby et al. (2001) demonstrated that human microvascular ECs express mRNA transcripts 
for both RANKL and OPG. In addition they showed that RANKL and OPG mRNA are 
significantly and dose-dependently upregulated in response to TNF-α and IL-1 as measured by 
semi-quantitative real time PCR. Further analysis of the time course of OPG and RANKL mRNA 
expression revealed that the rise in RANKL expression was first observed at 10 hours after the 
addition of TNF-α and by 24 hours, had risen to a peak of 3–6-fold in comparison to untreated 
VECs. These levels of expression continued between 48 and 72 hours when continuously co-
cultured with TNF-α. Removal of the cytokine after 24 hours led to a sustained decline in 
RANKL expression, however levels were still elevated by as much as 2-fold after 48 hours. 
OPG mRNA levels in VEC rose more swiftly in response to TNF-α. Elevated OPG mRNA levels 
were apparent within 1 hour, reached their highest level by 10 hours, but declined to 
approximately half their maximum values at 24 hours, and thereafter fell more slowly up to 72 
hours. Despite this, OPG mRNA levels were ten times higher than the unconditioned VECs. 
OPG mRNA levels quickly returned to concentrations similar to that of untreated VECs after 
withdrawal of TNF-α treated media. (Collin-Osdoby et al., 2001).  
 
2.7.7 Expression of OPG in Vascular Endothelial Cells 
Zannettino et al., (2005) have identified the site of OPG endothelial intracellular localisation to 
compartments known as Weibel-Palade Bodies (WPBs). They also observed that OPG was 
physically associated with von Willebrand Factor both in WPBs and in serum  (Zannettino et al., 
2005). Following thrombogenic and inflammatory insult with cytokines such as TNF-α, and IL-
1β, the contents of WPBs quickly translocate to the plasma membrane and extracellular space, 
where they promote migration of leukocytes and platelets to inflammatory sites and areas of 
thrombus formation (Arnaout, 1993), (Wagner, 1993), strongly suggesting a vasoactive role for 
OPG in maintaining haemostasis and possibly in the prevention of vascular injury and 
inflammation. In VECs, activation of integrin αvβ3 and porphyromonas gingivalis appear to 
 52
augment OPG expression levels via initiation of the NF-κβ transcription pathway (Kobayashi-
Sakamoto et al., 2004); (Malyankar et al., 2000); TNF-α and IL-1α also activate signalling 
pathways that result in NF-κβ activation suggesting that activation of this transcription pathway 
may be an important step in modulating production of endothelial cell OPG (Baud & Karin, 
2001), (Wesche et al., 1997). 
 
2.7.8 Expression of OPG in Vascular Smooth Muscle Cells 
Within the general vasculature however, OPG is more highly expressed in VSMCs compared to 
ECs, with VSMCs secreting up to 20-30 times that of endothelial cells. (Zhang et al., 2002). 
Interestingly the specific area of OPG activity in the arterial architecture seems to be important 
as higher concentrations have been found in the tunica media of diabetics relative to 
normoglycaemic controls, however no difference in OPG concentration was observed in the 
same cohort when intimal tissue was compared (Golledge et al., 2004). In vascular smooth 
muscle cells, a number of cytokines have been shown to augment OPG expression, including 
TNF-α, IL-1β, insulin, basic fibroblast growth factor (bFGF), platelet-derived growth factor 
(PDGF), and angiotensin II (Collin-Osdoby et al., 2001), (Olesen et al., 2005), (Ben-Tal et al., 
2007), (Zhang et al., 2002) (Figure 2.10). 
 
Zhang et al. (2002) demonstrated that PDGF-induced OPG gene expression in VSMCs could 
be blocked by inhibition of the PI3-kinase/AKT and p38/MAPK signalling pathways but that 
inhibition of NF-κβ did not attenuate PDGF-mediated OPG increases in VSMCs (Zhang et al., 
2002). This contrast with the NF-κβ pathway that upregulates OPG in VECs and suggests that 
other pathways are important in OPG production in VSMCs. Olesen et al. (2005) also found that 
TNF-α increased the amount of OPG produced from the VSMCs (Olesen et al., 2005) but OPG 
secretion was attenuated by the addition of insulin to the media. Recent work by this group 
demonstrated that the addition sRANKL to VSMC cultures led to a decrease in the activation of 
the insulin signalling pathway by reducing the activity of 16 of the 52 genes that were 
upregulated in by insulin. Interestingly knock down of OPG production by the addition of siRNA 
did not affect the insulin signalling pathway (Olesen et al., 2009). OPG production in VSMCs 
has also been shown to be reduced by peroxisome proliferator-activated receptor gamma 
(PPARγ) antagonists (Fu et al., 2002). The authors found that OPG expression was inhibited by 
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PPARγ ligands in human VSMCs and that this effect was completely abolished by a PPARγ 
antagonist. Moreover overexpression of PPARγ in these cells by transfection of an adenovirus 
considerably decreased OPG expression (Fu et al., 2002).  
 
There is now accumulating evidence to suggest a role for OPG in the regulation of VEC survival 
(Malyankar et al., 2000), (Cross et al., 2006), (Pritzker et al., 2004). However the specific means 
by which, OPG reduces VEC apoptosis has not yet been fully elucidated. It is unlikely that this 
involves protection from apoptosis induced by OPGs second cognate ligand, TRAIL, as a 
number of studies have found that ECs are resistant to apoptosis induction by TRAIL, and are 
only sensitized to TRAIL-induced apoptosis under harsh conditions such as serum deprivation 
(Secchiero et al., 2003), (Scatena & Giachelli, 2002). Only one group have implicated TRAIL 
inhibition in the OPG-mediated reduction in EC apoptosis (Pritzker et al., 2004), TRAIL will be 
discussed in more detail later in this chapter. Other groups have not found TRAIL to be present 
in EC cultures at all (Cross et al., 2006), (Zauli et al., 2007). Malyankar et al. (2000) reported 
that ECs plated on osteopontin had increasing OPG mRNA and protein secretion and a 
resultant reduction in EC apoptosis (Malyankar et al., 2000). In addition Cross et al. (2006) 
found that OPG enhanced EC growth and differentiation in addition to promoting the growth of 
cord-like arrangements on a matrigel base (Cross et al., 2006) 
 
Several studies have demonstrated that in chronic exposure to inflammatory cytokines such as 
in rheumatoid arthritis, multiple myeloma, diabetes, or hyperlipidaemia, OPG synthesis and 
storage in ECs has been shown to be low, or  indeed, absent altogether (Browner et al., 2001), 
(Giuliani et al., 2001), (Wallin et al., 2001). One possibility is that this may be as a consequence 
of the continued secretion of OPG leading to a significant depletion of vascular endothelial 
intracellular content after an extended time. 
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Figure 2.10 OPG, RANKL and RANK Expresion in the Vascular Endothelium. In the vascular system, 
RANKL and RANK are expressed by endothelial cells. RANKL /RANK interactions regulate endothelial 
survival and apoptosis. RANKL may be blocked by OPG, which is secreted by endothelial and smooth 
muscle cells. The physiological role of the OPG/RANKL /RANK system in the vascular wall and 
interactions with other ligands are currently under investigation. Adapted from (Hofbauer & Schoppet, 
2004). 
 
 
The specific area of OPG activity in the arterial architecture is important, as higher 
concentrations have been found in the tunica media but not intimal tissue of diabetics relative to 
normoglycaemic controls (Golledge et al., 2004). This phenomenon of medial compared to 
intimal calcification was further studied by Schoppet et al. (2004) who found increased 
expression of OPG (but not RANKL) around areas of intimal and medial calcification in samples 
from patients with Monckeberg’s sclerosis which is characterized by medial calcification but not 
in patients with atherosclerosis where intimal calcification is more common (Schoppet et al., 
2004). These findings were similar to those of Dhore et al., (2001) and again suggest that OPG 
may be involved in the process of vascular calcification (Dhore et al., 2001).   
 
Subsequent to their earlier work (Olesen et al., 2005), Olesen et al. (2007) showed that the 
addition of β-glycerophosphate to VSMC cultures led to significant calcification and as assessed 
by the measurement of total cellular calcium content was increased still further by the addition 
of insulin at a concentration of 1000 μU.ml-1. Interestingly the authors showed that there was a 
concomitant reduction in OPG expression, suggesting that this down-regulation of OPG may 
 55
play some role in the increased calcification (Olesen et al., 2007). Unlike their previous study 
(Olesen et al., 2005), lower levels of insulin (200 μU.ml-1) did not effect OPG secretion and the 
authors proposed this may have been due to the fact that the latter study was performed in the 
presence of serum or that the effects of insulin on OPG may be different depending on the 
degree of hyperinsulinaemia.  
 
Induction of diabetes by streptozotocin led to an increase in detectable OPG levels and a fall in 
free RANKL concentration in apo-E null mice, and the addition of TNF-α (but not glucose or 
insulin) stimulated OPG release from human umbilical vein endothelial cells (Secchiero et al., 
2006). Using samples from human atherosclerotic plaque obtained at the site of rupture during 
an acute myocardial infarction and plaque from apoE knockout mice, Sandberg et al., (2006) 
showed increased activity of the OPG/RANKL/RANK system. In addition they showed that 
RANKL increased the release of chemoattractant peptide-1 in mononuclear cells of patients 
with unstable angina and also stimulated matrix metalloproteinase activity in VSMCs (Sandberg 
et al., 2006).  Other factors influencing the secretion and expression of OPG and RANKL 
include the bone morphogenetic proteins BMP-2 and BMP-7 as well as transforming growth 
factor β1 (TGFβ1). All of these reduce OPG secretion and mRNA expression but BMP-2 and 
BMP-7 increase RANKL mRNA while TGFβ1 reduced RANKL. To address the question of 
whether OPG is elevated in states of atherosclerosis and vascular calcification as a 
compensatory mechanism or if it is playing a negative role in the pathogenesis of these 
conditions, Zauli et al., (2007) examined the effect of OPG on adhesion of pro-inflammatory 
cytokines to endothelial cells (Zauli et al., 2007). They found that OPG promotes the adhesion 
of primary polymorphonuclear neutrophills and leukaemic HL60 cells to endothelial cells in vitro, 
and they confirmed these findings in vivo in rat mesentery. The authors concluded that OPG 
may play a deleterious role in endothelial pathophysiology by instigating leukocyte adhesion to 
the endothelium which is thought to be an early step in the causation of endothelial dysfunction. 
On the other hand, Bennett et al. (2006) found that OPG-deficient ApoE-/- mice developed larger 
atherosclerotic lesions in addition to more vascular calcification than their OPG+/+ littermates 
and that it acted as a survival factor for serum-deprived smooth muscle cells (Bennett et al., 
2006). The exact role of OPG in the process of atherosclerosis was further examined by 
Moroney et al., (2008). They fed atherogenic LDL receptor knockout mice a high-fat diet and 
treated them with recombinant OPG or vehicle. The vehicle-treated mice developed 
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atherosclerosis with associated calcification and their OPG levels rose in parallel.  The degree 
of calcification, but not atherosclerosis was significantly reduced in the mice given recombinant 
OPG. The authors concluded that these results supported the theory that OPG inhibits vascular 
calcification, and may act as a marker (rather than a mediator) of atherosclerosis progression 
(Morony et al., 2008).  It also appears that, in addition to slowing vascular calcification and 
possibly mediating atherosclerosis, OPG may be a pro-angiogenic factor (McGonigle et al., 
2009). When added in vitro to a rat aortic ring model of angiogenesis OPG increased neo-
angiogenesis, an effect that was abrogated by pre-incubation with RANKL or TRAIL. 
Additionally, RANKL induced apoptosis on the endothelial cells. Circulating OPG has been 
shown to be significantly higher in patients with type 2 diabetes (Yaturu et al., 2008), (Secchiero 
et al., 2006), (Olesen et al., 2005), (Rasmussen et al., 2006), and is higher in the tunica media 
of type 2 diabetics than matched normal controls (Olesen et al., 2005). Moreover, OPG is higher 
in individuals with severe Peripheral Artery Disease (PAD) than in those classified as having a 
mild to moderate PAD (Ziegler et al., 2005), additionally it has also been shown that OPG can 
independently predict silent coronary artery disease in type 2 diabetic patients (Avignon et al., 
2005). 
 
Many of the same signals that modulate RANKL and OPG in bone or immune cells may also 
regulate their expression in vascular cells. From an indirect perspective, it is likely that the 
RANKL/RANK/OPG axis exerts important effects on the vascular system through 
immunomodulatory and osteogenesis-related mechanisms. Despite the seemingly therapeutic 
effect, the exact mechanism by which OPG acts to protect the vascular wall remains elusive. 
However there is growing evidence to suggest that OPG may play a part in the regulation of EC 
survival/apoptosis in cell models (Pritzker et al., 2004), (Scatena & Giachelli, 2002). It has been 
suggested that the pro-survival action of OPG on ECs may in part be due to inhibition of TRAIL-
mediated apoptosis (Corallini et al., 2008), although several studies have suggested that ECs 
are resistant to TRAIL-induced apoptosis under normal physiological conditions (Scatena & 
Giachelli, 2002), (Secchiero et al., 2003). OPG can promote EC (Cross et al., 2006), (Malyankar 
et al., 2000) and VSMC survival by a mechanism which may involve the blocking of TRAIL-
induced apoptosis in these cells lines. Furthermore, in vitro evidence shows that OPG can 
increase matrix metalloproteinase-9 activity in macrophages and smooth muscle cells and act 
as a survival factor for serum-deprived smooth muscle cells (Bennett et al., 2006). A common 
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feature of atherosclerosis is the dysfunction and death of vascular cells (Littlewood & Bennett, 
2003), (Reid & Holen, 2009). Therefore, the capability of OPG to improve survival of vascular 
smooth muscle and endothelial cells implies that it may play some protective role in this 
progression.  
 
2.7.9 Serum OPG and Insulin Sensitivity / Resistance 
There have been a number of studies which have attempted to elucidate the relationship 
between serum OPG and insulin sensitivity/resistance.  In a study of 286 women with a mean 
age of 52 years, Oh et al. (2005) found that LDL, total cholesterol, follicle stimulating hormone 
as well as age and waist to hip ratio were positively correlated with OPG, but there was no 
relationship between OPG and fasting glucose, fasting insulin, or insulin sensitivity (Oh et al., 
2005). Ugur-Altun et al. (2004) also investigated the relationship between OPG and insulin 
resistance using the HOMA-IR model in 50 obese and 24 lean individuals who were not taking 
any medications. The authors found that OPG was lowest in the most insulin resistant obese 
group, and that OPG correlated negatively with insulin resistance, as measured by HOMA-IR 
(Ugur-Altun et al., 2004). Gannage-Yared et al. (2006) had similar findings in a study of 151 
older men where they found a weak positive correlation between OPG and insulin sensitivity 
using the Quantitative Insulin Sensitivity Index (QUICKI), in addition the authors found a, weak 
correlation with (positive) adiponectin and (negative) triglycerides (Gannage-Yared et al., 2006). 
The same group subsequently investigated  a relationship between OPG and insulin resistance 
in an obese cohort of patients undergoing bariatric surgery (Gannage-Yared et al., 2008). Unlike 
the matched non-obese group, OPG showed a correlation with HOMA-IR even with adjustment 
for age and presence of diabetes. Multiple linear regression revealed that the acute phase 
reactant and marker of vascular in inflammation, CRP in addition to HOMA-IR were 
independent predictors of OPG concentration, a relationship which had not been observed in 
previous studies (Ugur-Altun et al., 2004), (Browner et al., 2001). This contrasted with the 
negative correlation seen between OPG and HOMA-IR in an obese population in an earlier 
study (Ugur-Altun et al., 2004), and the positive correlation between OPG and QUICKI in the 
same group’s previous work (Gannage-Yared et al., 2006). The authors speculated that the 
small numbers in the HOMA paper (n=12 of obese with high HOMA) (Ugur-Altun et al., 2004), 
and the different population studied in their previous paper (ie elderly males) (Gannage-Yared 
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et al., 2006) might account for the differences (Gannage-Yared et al., 2008). Considering these 
somewhat contradictory results some caution should be exercised when comparing findings 
from different studies. Several studies have used commercially available assays that measure 
unbound and uncomplexed forms of both sRANKL or OPG (Xiang et al., 2006), (Knudsen et al., 
2003), (Rasmussen et al., 2006), (Jorgensen et al., 2009). The data which is the subject of this 
body of work refers to free soluble RANKL and total OPG. This OPG assay measures both 
monomeric and dimeric isoforms of OPG, including OPG bound to RANKL and TRAIL and has 
been used to measure total OPG in many cohorts (Gannage-Yared et al., 2006), (Gannage-
Yared et al., 2008), (Anand et al., 2006), (Schoppet et al., 2003). In addition because of the non 
standard units of measurements used in other commercial ELISA assays and the difficulty in 
ascribing an exact molecular weight to the OPG-isoforms which they measure i.e. bound or 
unbound, monomeric or dimeric, the process of converting these values to SI units is somewhat 
complicated. Therefore previous studies that have exclusively measured uncomplexed OPG 
may unintentionally have excluded a large portion of the biologically active total circulating OPG 
which has either bound to TRAIL or RANKL or indeed has undergone some other unspecific 
binding. Recombinant OPG with a molecular weight of 19.9kD was used to calibrate the ELISA 
plates in these studies. This is identical to the extra cellular domain of RANK (TNF-receptor 
family). This in turn is identical to OPG. The precoated monoclonal anti-OPG capture antibody 
bound to the microtiter plate, binds to circulating OPG. The detection antibody is a biotinylated 
polyclonal anti-Osteoprotegerin antibody. The ELISA used in these experiments measures free 
OPG and complexed OPG-RANKL, since the binding site of the capture antibody lies outside of 
the binding site to sRANKL. The OPG ELISA detects the monomeric as well as the dimeric form 
of OPG. In the literature there is some discrepancy on the molecular weight of OPG. Molecular 
weights from 120 kD down to 35 kD can be found. The reason for this discrepancy are due to 
how the MW was determined either using isolation, SDS Page or DNA determination. 
 
2.7.10 Tumour Necrosis Factor Receptor Apoptosis Inducing Ligand (TRAIL) 
In addition to the essential role governing RANK–RANKL ligation in bone, OPG can also 
promote cell survival by binding to TRAIL. As OPG also acts as a soluble receptor for TRAIL 
(Emery et al., 1998) and since TRAIL is able to preferentially induce tumour cell apoptosis over 
normal cells, there has been much interest in its potential as a cancer chemotherapeutic (Smyth 
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et al., 2003), (Takeda et al., 2002). The physiological importance of TRAIL-OPG connections is 
highlighted by the fact that OPG can bind to TRAIL with a similar affinity to that of RANKL under 
normal physiological conditions (Vitovski et al., 2007). TRAIL is expressed and secreted by 
immune cells such as T cells that can penetrate the tumourous cellular environment (Reid & 
Holen, 2009). TRAIL that has been secreted by these T cells can bind to the death receptor-
regions 4 and 5 expressed on the surface of tumour cells. These receptors enclose extracellular 
death domains that initiate apoptotic signalling cascades, leading to specific programmed 
tumour-cell apoptosis. Two other membrane-bound decoy receptors for TRAIL have been 
found, DcR1 and DcR2. However little is known about their biological activity and in this context 
they do not seem to play a major role. DcR1 does not have a cytoplasmic domain and the DcR2 
cytoplasmic apoptotic region appears to be truncated and inactivated (Marsters et al., 1999), 
(Sheridan et al., 1997), (Reid & Holen, 2009). In vitro evidence suggests OPG may also 
promote survival in malignant tumours and cancer cell lines. (Wiley et al., 1995). OPG may be 
involved in survival of a number of tumour cell types in this way (Holen et al., 2002). Neville-
Webbe et al., (2004) demonstrated that OPG production from bone marrow stromal cells 
isolated from breast cancer patients was sufficient to increase survival of breast cancer cells 
that reach the bone microenvironment as part of the metastatic process. The authors suggested 
that OPG production may protect breast cancer cells from undergoing TRAIL induced apoptosis 
(Neville-Webbe et al., 2004). Furthermore, Shipman et al., (2003) demonstrated that TRAIL-
induced apoptosis could be prevented in myeloma cells by the addition of recombinant OPG, an 
effect which seemed to be reversed by the addition of sRANKL (Shipman & Croucher, 2003). 
This may be important for tumour cells to escape apoptosis, since host immune cells present in 
the tumourous cellular environment produce TRAIL, and in vivo data suggests this to be 
important in promoting anti-tumour action (Almasan & Ashkenazi, 2003), (Griffith et al., 1999), 
(Takeda et al., 2002). Therefore, secretion of OPG by tumour cells may be a possible 
mechanism of defence by these cells to TRAIL-induced apoptosis (Holen et al., 2002). 
However, there is still some doubt about this mechanism and some authors consider it unlikely 
to be related to its binding and neutralization of TRAIL, as TRAIL quickly induces apoptosis in a 
number of such cell lines and primary tumours but interestingly, it appears to demonstrates little 
or no toxicity to normal healthy cell lines (Corallini et al., 2008), (Reid & Holen, 2009). However 
emerging evidence suggests that circulating TRAIL may be related to body composition and 
lipid status. Choi et al., (2004) found that TRAIL was higher in individuals who had greater total 
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body fat and that it was positively correlated with LDL cholesterol (Choi et al., 2004). TRAIL also 
exerts an effect at the level of the vascular wall with some studies suggesting it may contribute 
to plaque instability. Sato et al. (2006) found that the dominant plaque residing T cells, CD4 T’s 
induce rapid apoptosis in cultured VSMCs by TRAIL expression which activates death receptors 
on the surface of VSMCs (Sato et al., 2006). The addition of OPG appears to promote survival 
of cultured VEC (Cross et al., 2006), (Malyankar et al., 2000), (Pritzker et al., 2004), though the 
exact means by which this is accomplished is still unclear. It may be related to a reduction in 
TRAIL-induced apoptosis (Pritzker et al., 2004). However, other studies have not found TRAIL 
to be present in VEC cultures (Cross et al., 2006), (Zauli et al., 2007). These conflicting findings 
may suggest an alternative pathway by which OPG promotes survival of this cell type. 
Furthermore, healthy VECs seem to be resistant to TRAIL-induced apoptosis, which concur with 
the notion that non-malignant cells are unresponsive to TRAIL (Cross et al., 2006). It is probable 
that OPG has other binding partners as well as TRAIL and RANKL. In this regard, it appears 
that OPG can promote leukocyte adhesion to the endothelial cell surface and this could be 
induced via interaction between the endothelial cell monolayer and the OPG heparin-binding 
domain. At this point however a binding associate for OPG in this process has yet to be 
identified. A potential mechanism that may mediate this activity is the interaction between 
proteoglycans containing heparan sulphate, such as syndecan-1, which can undergo ligation 
with several heparin-binding proteins, one of which is OPG (Borset et al., 2000). 
 
2.7.11 The Bone – Vascular Calcification Paradox 
Vascular calcification is an active, cellularly controlled process in which mineral is ectopically 
deposited predominantly in the larger elastic and muscular arteries, such as the aorta, the 
coronary, carotid and iliofemoral arteries as well as in the cardiac valves more and more the 
advancement of this process has been recognised as a risk factor for cardiovascular disease 
(Arad et al., 2005) and mortality (Budoff et al., 2007). Interestingly, localized arterial 
mineralization is often observed in conjunction with a significant decrease in bone mineral 
density or increased bone turnover. This paradoxical inverse relationship, is best typified by the 
concomitant occurrence of osteoporosis and chronic kidney disease, and is often referred to as 
a “the calcification paradox” (Persy & D'Haese, 2009). Ectopic vessel mineralization can occur 
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in either in the tunica intima or in the tunica media of the artery. The idiosyncratic characteristics 
of both of these forms of vascular calcification are described in Figure 2.x 
Intima calcification  Media calcification
 
Atherosclerosis    Arteriosclerosis or Monckeberg’s sclerosis 
 
Calcification  Focal, in plaques    Generalized 
pattern  
 
 
 
 
 
 
 
 
Risk factors  Dyslipidemia, hypercholesterolemia  Aging, diabetes, renal failure, osteoporosis,  
hypertension 
 
Molecular  Lipid accumulation    Transdifferentiation of VSMCs into bone-like cells 
mechanisms Foam cell formation    (osteoblast-chondrocyte and osteoclast-like cells)  
Inflammation     Ca, P, vitamin D metabolism 
Oxidative stress    Loss of calcification inhibitors  
Apoptosis    (pyrophosphate, MGP, fetuin) 
      
Result   Plaque formation: stenosis   Arterial stiffening: increased pulse pressure, 
` Plaque calcification: controversial elevated pulse wave velocity  
effect on plaque stability, possibly 
relating to the localization of 
calcification 
 
Complication Ischemia, infarction    Systolic hypertension, left ventricular hypertrophy  
Figure 2.11 Ectopic vessel mineralization can be localized to either in the tunica intima or in the tunica 
media of the vessel. Intima calcification is associated with atherosclerosis and results in focal calcification 
of atherosclerotic plaques, whereas media calcification (arteriosclerosis or Monckeberg’s sclerosis) is more 
generalized and is found mainly in the elderly and in patients with CKD, osteoporosis, hypertension or 
diabetes mellitus. Monckeberg’s sclerosis leads to vessel stiffening, which is characterized by increases in 
pulse pressure and pulse wave velocity and is associated with increased cardiovascular risk. Adapted from 
(Persy & D'Haese, 2009) 
 
In General, however these two structurally distinct forms of vascular calcification are not 
differentiated in cross-sectional or longitudinal epidemiological studies, an important factor 
which must be considered when interpreting results from such studies. London et al. (2003) 
delineated the two forms of calcification morphologically using plain x-ray images and found that 
the increasing severity led to an elevated mortality risk in patients undergoing haemodialysis 
(London et al., 2003). As previously mentioned ectopic calcification in the vasculature is often 
occurs in conjunction with decreased bone mineral density or increased bone turnover. This 
conflicting association has been found in the general population (Hyder et al., 2007), in 
osteoporosis and CKD patients (Raggi et al., 2007;Toussaint et al., 2008) and in more rare 
conditions such as Paget’s disease (Laroche & Delmotte, 2005). An inverse correlation between 
BMD and vascular calcification has also been observed several cross-sectional and longitudinal 
studies using different techniques in postmenopausal osteoporosis, Additionally, several studies 
have reported that this calcification is in fact correlated with the occurrence of fragility fractures 
(Bagger et al., 2006;Schulz et al., 2004) 
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Moreover, in a large prospective study of over six thousand postmenopausal women Kado et al. 
(2000) using DEXA scanning found that for each decrease of one standard deviation in BMD, 
risk of cardiovascular mortality was amplified by 30% (Kado et al., 2000). It appears this 
relationship is not merely a phenomenon exclusive to osteoporosis, it was also observed by 
Farhat et al. (2006) in a cohort of healthy perimenopausal subjects with a low prevalence of 
osteoporosis (Farhat et al., 2006) as well as in a heterogeneous cohort of healthy men and 
women (Hyder et al., 2007). Vascular calcification is a feature of the increased cardiovascular 
morbidity and mortality observed in patients with CKD (Schiffrin et al., 2007). In addition to 
increased calcification of atherosclerotic plaques, patients on dialysis also show characteristic 
calcifications of the tunica, contributing to their elevated cardiovascular mortality (London et al., 
2003). Calcification quickly progresses in both dialysis (Goodman et al., 2000) and end stage 
renal disease (Sigrist et al., 2007). Increased circulating phosphate levels, elevated 
concentrations of calcium as well as high parathyroid hormone (PTH) concentrations have been 
acknowledged as risk factors for vascular calcification and mortality in patients with CKD, as 
well as the administration of calcium-containing phosphate binders and vitamin D metabolites 
(Ganesh et al., 2001;Kestenbaum et al., 2005) The decline in renal function associated with the 
progression of CKD often leads to the development of metabolic bone disease traditionally 
grouped under the name renal osteodystrophy. Monckeberg’s sclerosis was first described in 
the mid nineteenth century and is a cell-mediated process (Steitz et al., 2001) whereby VSMCs 
deposit hydroxyapatite in the tunica media (Wada et al., 1999). The subject of bone 
mineralization and localized mineralization of the vasculature, with the transformation of 
vascular cells to bone-like cells that express a number of bone related proteins, such as bone 
sialoprotein, osteocalcin and alkaline phosphatase. Interestingly though, in vivo evidence 
suggests that these simultaneous expression patterns appear to have accumulate to 
contradictory results, leading to vascular calcification, whereas bone formation is actually 
impaired or disturbed. 
 
Opposing regulation of the OPG–RANK–RANKL triad in bone and vasculature by transforming 
growth factor b fibrogenic hormone (TFG-β) might be one mechanism to explain this 
calcification paradox. TGF-β increases RANKL expression and reduces OPG expression in ECs 
but reduces RANKL in cells of an osteoblastic lineage (Hofbauer & Heufelder, 2001) leading to 
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an increase in the OPG/RANKL ratio in bone, inhibiting osteoclastic bone resorption, and 
decreases the OPG/RANKL ratio in blood vessels, decreasing the potential calcification 
inhibition possible with OPG.  
 
 
2.7.12 Therapeutic Role for OPG 
Simonet et al. (1997) first confirmed the role of OPG in the regulation of bone formation 
demonstrating that the administration of recombinant OPG blocks differentiation of precursor 
cells into osteoclasts in a dose dependant manner in vitro. The authors also outlined a possible 
clinical application of recombinant OPG by suggesting a potential for OPG therapy to ameliorate 
the bone loss that one would expect in ovariectomized rats, where bone volume in the proximal 
tibial metaphysis was increased in OPG treated rats relative to controls (Simonet et al., 1997). 
Since this discovery there has been much interest in the use of OPG and or manipulation of the 
RANKL/RANK/OPG axis to treat bone related disorders.  Evidence from both animal and in vivo 
studies have shown that RANKL expression can be reduced by 17β-estradiol (Eghbali-
Fatourechi et al., 2003) and that its biological activity can be ameliorated by introducing a 
barrier so it can not effectively bind to its receptor. This can be achieved by administration of 
peptides which mimic the function of OPG and include soluble RANK fusion proteins, (Hsu et 
al., 1999), (Oyajobi et al., 2001), OPG fusion proteins, (Simonet et al., 1997), (Kong et al., 
1999), (Teng et al., 2000), (Honore et al., 2000), or antibodies to RANKL. In addition post-
receptor signalling after RANK-RANKL binding to the c-Jun pathway can also be interrupted by 
the addition of estrogen to stromal cells (Shevde et al., 2000). What's more, in vitro OPG 
secretion can also be upregulated in response to 17β-estradiol (Hofbauer et al., 1999), the oral 
selective estrogen receptor modulator; raloxifene (Viereck et al., 2003) and bisphosphonates 
(Hofbauer & Schoppet, 2004). Therapeutic efficacy has focused on OPG-Fc and RANK-Fc 
fusion proteins. Synthetic OPG fusion proteins do not have a heparin-binding region and as a 
result they are less prone to sequestration than naturally circulating OPG (Standal et al., 2002). 
However, because OPG has the ability to bind RANKL and TRAIL, RANK-Fc fusion protein may 
be a more desirable modality for therapeutic inhibition of this pathway as it has no effect on 
TRAIL signalling (Oyajobi et al., 2001). However OPG-Fc and RANK-Fc fusion proteins seem to 
be successful and without adverse side effects in animal models of arthritis (Kong et al., 1999) 
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and osteoporosis (Simonet et al., 1997), bone disease caused by multiple myeloma (Sezer et 
al., 2003) and bone metastases (Honore et al., 2000). One randomized controlled trial has 
investigated the acute effects of OPG-Fc fusion protein on markers of bone turnover. Bekker et 
al., (2001) examined the effect of a single dose of OPG-Fc administered subcutaneously on 
biochemical markers of bone resorption in postmenopausal osteoporotic women. Participants 
were followed up after 85 days and it was found that OPG treatment led to a substantial and 
prolonged reduction of bone resorption as indicated by a reduction of 80% in urinary excretion 
of deoxypyridinoline concentrations and an increase in bone formation markers of 20% as 
indicated an increase in serum levels of osteocalcin (Bekker et al., 2001). Another study which 
compared the effects of an OPG bolus against the bisphosphonate, pamidronate in 28 patients 
with myeloma related bone disease and in 26 women with multiple bone metastases as a result 
of breast cancer, with a follow-up of 6 months. The authors found that that urinary N-telopeptide 
(a marker of bone resorption) was reduced in OPG treated breast cancer patients by 74% and 
by 47% in the other group. This was similar to the outcomes observed in the bisphosphonate 
treated group (Body et al., 2003). Administration of OPG-Fc fusion protein  in such trials has 
only a few side effects, such as hypocalcaemia, and in only a few exceptional cases it has led to 
the production of anti-OPG antibodies, none of these side effects have been observed in 
patients who have had RANK-Fc fusion proteins (Bekker et al., 2005) The potential for this 
mechanism as a therapeutic target has led to the development of a human monoclonal IgG2 
antibody to RANKL, AMG162 (Denosumab). Denosumab selectively binds to RANKL but does 
not cross react with TNF-α, TNFβ, CD40 ligand, or TRAIL (Dougall & Chaisson, 2006). After 
binding to RANKL, denosumab blocks the interaction between RANKL and RANK, a 
mechanism similar to that of endogenous OPG. Denosumab is currently in Phase II clinical trials 
for postmenopausal women with osteoporosis (Bone et al., 2008), breast cancer-related bone 
metastases (Lipton et al., 2007) and structural damage in patients with rheumatoid arthritis 
(Cohen et al., 2008). McClung et al., (2006) showed that subcutaneous administration of 
denosumab at either 12 or 26 week intervals to more than four hundred postmenopausal 
women with low bone mineral density led to a continued reduction in bone resorption and a swift 
and significant increase in BMD. (McClung et al., 2006). In a two year study conducted by Bone 
et al., (2008) over three hundred postmenopausal patients with osteoporosis receiving 6-
monthly subcutaneous administration of Denosumab showed significantly increased BMD and 
reduction in indicators of bone resorption both in early and late postmenopausal osteoporotic 
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females (Bone et al., 2008). Similar positive results have been obtained in a study in patients 
with breast cancer and multiple myeloma who have radiographicly verified bone lesions. A one 
time dose of Denosumab led to an immediate and continued reduction in bone resorption (Body 
et al., 2006). No data are currently available on whether this new therapeutic compound can 
also regress vascular calcifications, an issue that is worth investigating in view of the potential 
role of the OPG–RANK–RANKL triad in the development of vascular calcification.The possibility 
of using OPG or manipulating this axis for the treatment of vascular disease or calcification is 
somewhat more complex. OPG has been shown to act in an autocrine manner to reduce 
apoptosis and increase survival of endothelial cells (Malyankar et al., 2000). However, it 
appears that RANK and RANKL are absent in tissue from arterial walls of wild-type mice and 
only appear to be present in calcified atherosclerotic plaques of OPG-deficient mice (Min et al., 
2000). There has been little evidence to date that RANK and its ligand play an important role in 
the biology of human vascular diseases. Furthermore, the molecular mechanisms involved and 
the mode of action by which OPG is engaged in the process of vascular disease and 
dysfunctions are still unclear.  
 
2.8 General Summary 
There has been a dramatic increase in the prevalence of obesity during the past two decades. 
Increased adiposity is associated with the development of insulin resistance and type 2 
diabetes. Type 2 diabetes occurs when there is inadequate insulin secretion from the β-cells in 
tandem with increased insulin resistance in multiple tissues. In addition to its role in glucose 
disposal, insulin is an important vasoactive hormone that exerts pleiotropic actions in skeletal 
muscle, adipose tissue and vascular endothelium. In recent years there has been intense study 
of the biological activity of the adipose tissue, as a result of which it is now recognised that the 
adipose tissue is an active metabolic organ, releasing adipocytokines into the circulation, which 
influence insulin action and contribute to vascular dysfunction. Adiponectin and TNF-α are two 
such adipocytokines that which in addition to insulin also appear to regulate OPG production 
and secretion. Insulin resistance has also been demonstrated to correlate with circulating OPG. 
The role played by OPG, RANK and RANKL in bone turnover and bone-related disease has 
been the subject of extensive research. Most of these studies show that OPG exerts a 
protective effect on bone via inhibition of bone resorption. OPG also appears to be an important 
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player in the vasculature and may prevent processes involved in the pathogenesis of 
atherosclerosis. There is some evidence, albeit controversial to suggest that this may be 
achieved via its ability to promote VEC survival by acting as a decoy receptor for TRAIL. The 
interaction between these families of molecules and the evidence demonstrating significant 
cross-talk between their metabolic pathways provides support for the premise that they form a 
complex array of interconnected cytokines involved in physiological regulation in multiple tissue 
types. 
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Chapter III An investigation of 
serum OPG, TRAIL and sRANKL 
levels and their relationship with 
adiposity and indicators of insulin 
sensitivity in a healthy Irish 
cohort. 
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3.1 Introduction 
Rationale 
Circulating OPG has been shown to be significantly higher in patients with type 2 diabetes 
(Yaturu et al., 2008), (Secchiero et al., 2006), (Olesen et al., 2005), (Rasmussen et al., 2006), 
and is higher in the tunica media of type 2 diabetics than matched normal controls (Olesen et 
al., 2005). In addition, OPG is higher in individuals with severe Peripheral Artery Disease (PAD) 
than those classified as mild to moderate PAD (Ziegler et al., 2005). Indeed it has also been 
shown that OPG can independently predict silent coronary artery disease (Griffin et al., 1999) in 
type 2 diabetic patients (Avignon et al., 2005). Despite the higher circulating and tissue 
concentrations of OPG in metabolic and cardiovascular disease patients there has been little 
research on high risk obese subjects. Gannage-Yared et al. (2006) examined the relationship 
between OPG and components of the metabolic syndrome in 151 healthy ageing men. Contrary 
to many previous studies, they found that OPG was inversely correlated with fasting plasma 
glucose and insulin sensitivity and positively correlated with adiponectin. Despite their 
classification of this population as healthy, over 60% of this cohort had the metabolic syndrome, 
28% had hypertension and 15% had previously diagnosed coronary artery disease (Gannage-
Yared et al., 2006). There has been significant research in diseased populations demonstrating 
that OPG is associated with the presence and severity of CAD and cardiovascular mortality 
(Browner et al., 2001), (Jono et al., 2002), (Kiechl et al., 2004), (Omland et al., 2008), (Schoppet 
et al., 2003), (Ueland et al., 2004). There have, however been few published papers that have 
examined the relationship between insulin sensitivity, adiposity and OPG in a normal population 
free from overt cardio-metabolic disease.  
 
Aims 
The purpose of this study was to determine if BMI and insulin sensitivity influence the 
concentrations of serum OPG and TRAIL in subjects who do not have cardiovascular or 
metabolic disease. 
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Hypothesis 
We tested the hypothesis that in a healthy cohort circulating OPG would be lower in obese 
subjects and inversely related to insulin resistance. 
 
3.2 Materials and Methods 
3.2.1 Experimental Design Overview 
One hundred and thirty six subjects volunteered to participate in the study. Of these thirty six 
were excluded because of undiagnosed hypertension, impaired glucose tolerance, and 
abnormal ECG. Subjects visited the laboratory on two separate occasions, separated by at least 
4 days. On the first occasion they reported to the laboratory in the morning following an 
overnight fast. Subjects were interviewed by a physician, had anthropometric measurements 
and a 2 hr oral glucose tolerance test. On the second visit, subjects reported to the laboratory 
approximately 3 hr following a meal. They had a resting 12-lead ECG followed by an ECG 
stress test with oxygen consumption (Figure 3.1). 
 
12 hr overnight fast
No Smoking
or caffeine
No strenuous exercise
= 4 days between visits
Initial Briefing 
Meeting
VISIT 1
Anthropometrics
OGTT 2 hr
Fasting Blood Samples
Resting Blood Pressure
Medical Screening
Resting ECG
Risk Assessment
VISIT 2
Exercise Test
 
Figure 3.1 Schematic of experimental design for experiment I 
 
3.2.2 Participant Recruitment  
Participants were recruited by means of an open call for volunteers who were free from 
cardiovascular and metabolic disease. A plain language statement was given to those 
expressing an interest in the study, after which a briefing meeting was scheduled to allow for 
questions to be asked in relation to the study and written informed consent was provided by 
individuals wishing to participate. In total 136 subjects volunteered to participate in the study. Of 
these 36 were excluded because of undiagnosed hypertension, impaired glucose tolerance, and 
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abnormal ECG. The final cohort that met the inclusion criteria consisted of 100 subjects, aged 
22-74 yrs. This group comprised a similar number of males (n=51) and females (n=49) and the 
distribution of normal weight (n=36), overweight (n=41) and obese (n=23) subjects is similar to 
the Irish adult population (Morgan et al., 2008). The study was approved by the Dublin City 
University Research Ethics Committee and conformed to the Declaration of Helsinki. Finally, 
each participant completed a health history questionnaire and underwent medical screening 
examination see (Appendix 2, 3, 4). 
 
3.2.3 Exercise Stress Test and Maximal Oxygen uptake 
Following the medical examination all subjects underwent a multistage exercise treadmill test 
using a modified Bruce protocol. All exercise tests took place under standard laboratory 
conditions (19-21°C, 40-55% relative humidity). Expired oxygen, carbon dioxide, ventilatory 
volume, respiratory exchange ratios and VO2max were determined by indirect calorimetry 
(Sensormedics Vmax 229, Sensormedics Corp., Yorba Linda CA). Systolic and diastolic blood 
pressure was measured using a sphygmomanometer and recorded when the subject was 
standing immediately before testing and during the last minute of each exercise stage. Electrical 
activity of the heart was also recorded at rest and at the end of each stage. Subjects exercised 
until reaching volitional fatigue. The test was deemed to be maximal if two or more of the 
following criteria were satisfied (i) plateau of oxygen consumption (increase of less than 2 ml.kg-
1.min-1), (ii) heart rate within 10 beats of the subjects’ age predicted maximum heart rate (220 
bpm – age in years) and (iii) respiratory exchange ratio > 1.10. VO2 max was determined to be 
the highest minute average recorded for oxygen uptake during the test. 
 
3.2.4 Anthropometric and body composition measurements 
Height and body mass were measured to the nearest 0.1 cm and 0.1 kg respectively (SECA, 
Hamburg, Germany). Subjects were weighed barefoot and with minimal clothing. Harpenden 
Skinfold Callipers (British Indicators, 15 9LB. England) were used to measure double thickness 
subcutaneous adipose tissue on the right side of the body at seven sites. Waist and Hip 
circumferences were measured to the nearest 0.1 cm. Waist circumference was taken midway 
between the lowest rib (laterally) and the iliocristale landmark. Hip circumference was measured 
at the greatest protrubence of the gluteals. Body density was calculated by the method of 
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Jackson & Pollock (1985) (Jackson & Pollock, 1978) based on the sum of seven skinfolds 
(tricep, subscapular, mid-axillary, pectoral, suprailiac, abdominal, thigh). Percentage body fat 
was calculated from the equation of Siri (Suzuki et al., 2004). 
 
3.2.5 Glucose Tolerance and Insulin Sensitivity 
In order to rule out previously undiagnosed type 2 diabetes, impaired fasting glucose or 
impaired glucose tolerance, subjects underwent a standard 2 hr Oral Glucose Tolerance Test. 
(OGTT) (Reinauer et al., 2002). The 75 g (113 ml) anhydrous glucose equivalent (Polycal; 
Nutricia Clinical, Trowbridge, United Kingdom) was consumed in 300 ml of water within 5 min. 
Blood samples were taken prior to and at 30, 60, 90 and 120 min after the glucose load. Total 
area under curve (AUC) for glucose and insulin was determined by the trapezoidal method (Tai, 
1994) and HOMA-IR was used as an indicator of insulin resistance (Matthews et al., 1985). 
Insulin Sensitivity was estimated using the validated Oral Glucose Insulin Sensitivity (OGIS) 
predictive model (Mari et al., 2001) 
 
3.2.6 Collection of Blood Samples 
Prior to the OGTT subjects had a 20 or 22 GA indwelling cannula (BD VialonTM, Biomaterial, 
Spain) introduced into a prominent forearm vein for blood sampling. Samples for glucose 
analysis were collected in grey top plasma tubes (BD Vacutainer®, 10 mg sodium fluoride, 8 mg 
potassium oxalate). Samples for insulin determination and other analytes were collected in red 
top serum tubes (BD Vacutainer®). Blood samples were collected 10 min before the oral 
glucose load and, 30, 60, 90 and 120 min after. Lines were flushed with saline solution after 
each blood draw and approximately 2.5 ml of blood was evacuated as waste at each time point 
before collection of analytical samples. Serum was allowed to stand for 30 min before 
centrifugation at 3000 r.p.m-1 (Dovio et al., 2007) for 15 min at 4ºC at which point aliquots were 
stored at -80○C for further analysis.  
 
3.2.7 Biochemical Analysis and Assays 
Plasma glucose was measured using the glucose oxidase method (YSI 2300 Stat Plus, Yellow 
Springs, Ohio). Serum insulin was measured with a commercially available fluoroimmunoassay 
 72
(Delphia; Perkin Elmer, Wallac, Turku, Finland).  Serum OPG, total sRANKL (Biomedica, 
Vienna, Austria), TRAIL and adiponectin (R&D Systems Inc., Minneapolis, MN), were measured 
using commercially available ELISA kits. The minimal detectable limit for OPG was 0.014 pmol.l-
1, 0.02 pmol.l-1 for total sRANKL, 0.246 ng.ml-1 for adiponectin and 2.86 ng.ml-1 for TRAIL. The 
intra and inter assay coefficients of variance were <6 % for OPG and total sRANKL and <5 % 
for Adiponectin and TRAIL. High sensitivity C-Reactive Protein (hsCRP), triglycerides, High 
Density Lipoprotein (HDL), Low Density Lipoprotein (LDL) and total cholesterol were measured 
with Randox reagents on the Randox-Daytona automated analyser using a spectro-photometric 
method (Randox, Antrim, Northern Ireland). 
 
3.2.8 Statistical Procedures  
SPSS 15.0 for Windows (SPSS Inc., USA) was used for statistical analysis. Data are reported 
as means ± SEM. Normally distributed variables were explored using simple bivariate or partial 
regression. Non-normally distributed variables including fasting glucose, insulin, 2 hr insulin, 
AUC glucose, AUC insulin, HOMA IR, adiponectin, sRANKL, low density lipoprotein and high 
density lipoprotein were log-transformed. The degree of relationship was calculated using 
Pearson’s product moment (r). Participants were classified as normal weight, overweight or 
obese based on their BMI. A one-way analysis of covariance (ANCOVA) was used to examine 
differences between BMI categories with age and gender as covariates. Bonferroni’s post hoc 
test was applied to determine differences among means. Statistical significance was set at 
p<0.05. 
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3.2.9 Subject Characteristics 
Physical and metabolic characteristics for male and female subjects are presented in Table 3.1 
and for the normal weight, overweight and obese subjects are presented in Table 3.2. 
 
Table 3.1 Selected Characteristics of Subjects broken down by gender. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BMI (Body mass index), BP (blood pressure), VO2 max, (maximal oxygen consumption).Values 
are mean ± SEM. * p < 0.05 vs. Normal weight. † p < 0.05 vs. Overweight. 
 
Table 3.2 Selected Anthropometric and Cardiovascular Characteristics of Subjects 
BMI (Body mass index), BP (blood pressure), VO2 max, (maximal oxygen consumption).Values 
are mean ± SEM. * p < 0.05 vs. Normal weight. † p < 0.05 vs. Overweight. 
 Male Female 
 (53) (57) 
Age (years) 44.5 ± 1.5 47.7 ± 1.8 
BMI (kg.m-2) 27.0 ± 0.4 25.7 ± 0.5  
Waist Circumference (cm) 92.4 ± 1.3 84.2 ± 1.9 * 
Waist to Hip Ratio 0.90 ± 0.01 0.83 ± 0.01 * 
Body fat (%) 21.6 ± 0.9 29 ± 1.2 * 
VO2 max (ml.kg.min-1) 41.6 ± 1.5 32.0 ± 1.2 * 
Systolic BP (mmHg) 123.2 ± 1.6 119.5 ± 1.9 
Diastolic BP (mmHg) 77.8 ± 1.2 75.2 ± 1.5 
 Normal weight Overweight Obese 
 (36) (41) (23) 
Gender (male/female) 19/17 19/22 11/12 
Age (years) 44.4 ± 1.5 46.7 ± 2.0 47.2 ± 2.8 
BMI (kg.m-2) 22.8 ± 0.2 26.7 ± 0.2 * 31.4 ± 0.3 * † 
Waist Circumference (cm) 78.5 ± 1.2 89.8 ± 1.2 * 102.2 ± 2.0 * † 
Waist to Hip Ratio 0.82 ± 0.01 0.87 ± 0.01 * 0.93 ± 0.02 * † 
Body fat (%) 19.6 ± 1.15 27 ± 1.16 * 31.9 ± 1.5 * † 
VO2 max (ml.kg.min-1) 41.5 ± 1.9 37.5 ± 1.5 29.6 ± 1.7 * † 
Systolic BP (mmHg) 117.1 ± 2.2 120.4 ± 1.6 130.3 ± 2.2 * † 
Diastolic BP (mmHg) 74.0 ± 1.5 76.5 ± 1.4 80.6  ± 2.1 * 
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3.3 Results 
3.3.1 Physical Characteristics 
Age and gender distribution was similar for the three groups but there were significant 
differences in BMI, % body fat, waist circumference and waist-to-hip ratio. In addition, the obese 
group had significantly higher systolic and diastolic blood pressure and lower aerobic capacity 
compared with the other two groups Table 3.2. Glucose and Insulin kinetics during the OGTT 
are presented in Figure 3.1. 
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Figure 3.1 Insulin (A) and Glucose (B) kinetics in response to a 75 g Oral Glucose Tolerance Test in age 
and gender matched; Obese ♦, overweight ▲ and lean subjects ■. 
 
3.3.2 Metabolic Phenotype 
All subjects had normal glucose tolerance but the obese group had significantly higher fasting 
glucose, insulin and triglycerides compared to the other groups. They also had a greater 
glucose and insulin response to the OGTT and had lower insulin sensitivity, as determined by 
OGIS and HOMA-IR. Circulating adiponectin was significantly lower in males compared to 
females (4.99 ± 0.35 vs. 10.06 ± 0.71 μg.ml-1, p < 0.001) and in overweight and obese subjects 
compared to controls (Table 3.3). 
 
Table 3.3 Metabolic Markers and Indicators of Insulin Sensitivity.  
  Normal weight Overweight Obese 
Fasting Glucose (mmol.l-1) 4.8 ± 0.1 5.0 ± 0.1 5.3 ± 0.1 * † 
Fasting Insulin (ρmol.l-1) 26.4 ± 3.5 38.2 ± 4.2 * 51.3 ± 5.6 * 
Triglycerides (mmol.l-1) 0.97 ± 0.05 1.32 ± 0.10 * 1.55 ± 0.15 * 
HOMA-IR 0.83 ± 0.12 1.25 ± 0.14 * 1.8 ± 0.2 * † 
OGIS (ml.min.m-2) 533 ± 11 512 ± 9 451 ± 11 * † 
AUC Glucose (mmol.l.min) 671 ± 18 738 ± 19 * 831 ± 36 * † 
AUC Insulin (pmol.l.min) 20487 ± 2444 29585 ± 4285 42336 ± 4979 * † 
hs-CRP (mg.L-1) 0.92 ± 0.18 0.92 ± 0.08 1.16 ± 0.15 
Adiponectin (μg.ml-1) 9.9 ± 0.9 6.6 ± 0.5 * 4.8 ± 0.5 * 
TRAIL (ρg.ml-1) 72.2 ± 5.4 81.6 ± 3.9 82.4 ± 6.9 
sRANKL (ρg.ml-1) 3.4 ± 0.6 3.0 ± 0.4 2.9 ± 0.7 
HOMA-IR (Matthews et al., 1985), OGIS (Mari et al., 2001), AUC Glucose (area under the 
glucose curve after 2 hr), AUC Insulin (area under the insulin curve after 2 hr), hs-CRP (high 
sensitivity C-Reactive Protein), TRAIL (TNF-related apoptosis inducing ligand), sRANKL 
(soluble receptor activator of NF-κβ ligand). Values are mean ± SEM. *p < 0.05 vs. Normal 
weight. †p < 0.05 vs. Overweight. 
 
3.3.3 Osteoprotegerin  
Circulating OPG was lower in males than in females (5.13 ± 0.20 vs. 6.07 ± 0.23 ρmol.l-1, p = 
0.003). There was a significant decrease in OPG in the obese compared with normal weight 
and overweight groups (Figure 3.2). Neither TRAIL nor sRANKL were significantly different 
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between BMI categories (Table 3.3). There was no significant relationship between OPG and 
age, however as previous studies have consistently shown a correlation between age and OPG 
(Khosla et al., 2002), (Szulc et al., 2001), (Kudlacek et al., 2003), we controlled for age in 
addition to gender in all subsequent analysis. For correlation analysis, this was achieved in 
SPSS using the partial correlation function, which, in addition to examining the relationships 
between variables of interest, allows the user to control for the potential bias that may be 
caused by confounding variables such as gender, age, ethnicity etc. A similar method whereby 
potential covariates are adjusted for in SPSS is used when comparing between three or more 
groups (ANCOVA) 
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Figure 3.2 Osteprotegerin for Normal weight, Overweight and Obese subjects. Values are mean ± SEM.*p 
<0.05 vs. Normal weight, †p < 0.05 vs. Overweight. 
 
3.3.4 Correlation Analysis  
OPG showed a significant inverse correlation with BMI and waist circumference (Figure 3.3) and 
a positive relationship with VO2max. There were also significant relationships between OPG and 
several other metabolic indices including a significant inverse correlation with fasting glucose, 
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fasting insulin, AUC glucose, AUC insulin, HOMA-IR and was positively correlated with OGIS 
and adiponectin (Table 3.4). The correlation between OPG and adiponectin persisted after 
additional adjustment for BMI. Controlling for age and gender, TRAIL was significantly related to 
fat mass (r = 0.255, p < 0.05) and waist circumference (r = 0.207, p < 0.05), these relationships 
were maintained after additional adjustment for BMI. (r = 0.373, p < 0.001), (r = 0.257, p < 0.05). 
 78
0
2
4
6
8
10
12
15 20 25 30 35 40
Body Mass Index (kg.m-2)
O
P
G
 (p
m
ol
. l-1
)
0
2
4
6
8
10
12
60 80 100 120
Waist Circumference (cm)
O
P
G
 (p
m
ol
. l-1
)
r = -0.348, p< 0.001, controlling for 
age and gender, r = -0.268, p =0.008
r = -0.348, p< 0.001, controlling for 
age and gender, r = -0.331, p =0.001
A
B
O
P
G
 (p
m
ol
. l-1
)
O
P
G
 (p
m
ol
. l-1
)
 
Figure 3.3 Relationship between A) OPG and BMI, B) OPG and waist circumference. 
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Table 3.4 Age and Gender Adjusted Correlations Between OPG and Anthropometric 
and Metabolic Indices. 
 r p  
BMI (kg.m-2) -0.331 ***   
Waist Circumference (cm) -0.268 **   
VO2 max (ml.kg.min-1)  0.237 *   
Fasting Glucose (mmol.l-1) -0.248 *   
Fasting Insulin (ρmol.l-1) -0.202 **   
AUC Glucose (mmol.l.min) -0.279 **   
AUC Insulin (pmol.l.min) -0.271 **   
HOMA-IR -0.222 *   
OGIS (ml.min.m-2)   0.221 *   
Adiponectin (μg.ml-1)   0.391 ***   
BMI (Body mass index), VO2 max, (maximal oxygen consumption), AUC Glucose (area under the 
glucose curve), AUC Insulin (area under the insulin curve), HOMA-IR (Matthews et al., 1985), 
OGIS (Mari et al., 2001). *p < 0.05, **p < 0.01, ***p < 0.001 
 
3.4 Summary 
The main findings of Experiment I are that obese subjects who are normal glucose tolerant and 
free from cardiovascular disease, have lower circulating osteoprotegerin when compared with 
normal weight and overweight individuals. In this cohort OPG is positively correlated with 
adiponectin and insulin sensitivity. 
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Chapter IV The relationship 
between OPG, TRAIL, sRANKL 
and markers of inflammation in 
Type 2 Diabetes and Vascular 
Disease. 
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4.1 Introduction 
Rationale 
Type 2 diabetes mellitus is associated with an accelerated pathogenesis of atherosclerosis and 
a more than threefold increased risk of cardiovascular disease (Kannel & McGee, 1979).  
Arterial calcification is a prominent feature of atherosclerosis and common in patients with type 
2 diabetes (Chen & Moe, 2003). It is an independent risk factor for cardiovascular mortality in 
both newly diagnosed (Niskanen et al., 1994) and established type 2 diabetes (Lehto et al., 
1996).  Arterial calcification of the tunica media was first identified almost a century ago, but our 
understanding that this may be an active, rather than a passive, carefully-regulated process has 
further developed in recent times with the identification of a possible role for the 
OPG/RANKL/TRAIL pathway in this process (Doherty et al., 2004). Studies of serum RANKL 
have been inconclusive, with both increased (Kiechl et al., 2007) and reduced (Schoppet et al., 
2003) risk of CVD disease being reported with elevated levels of RANKL concentration.  Only 
one paper has measured RANKL levels in individuals with type 2 diabetes, finding no difference 
from healthy individuals (Secchiero et al., 2006). TRAIL also appears to affect the vasculature 
and may contribute to plaque instability (Sato et al., 2006), though others have shown that 
administration of TRAIL to atherogenic Apo E-/- mice induced plaque regression and 
stabilisation of residual plaques (Secchiero et al., 2006). Whether serum OPG, RANKL and 
TRAIL are higher in patients with type 2 diabetes compared to non-diabetic individuals is still 
under investigation.  Studies to date suggest higher serum OPG levels in type 2 diabetes but 
these studies have often mixed groups of diabetic and non diabetic patients, examined OPG in 
patients with diabetes related microvascular complications, and have poorly defined control 
groups with no attempt to control for underlying metabolic bone disease, which could affect 
serum OPG and RANKL levels. It is well-accepted that inflammation plays an important role in 
the pathogenesis of diabetes and IL-6 and hsCRP are frequently used to gain a measure of the 
degree of underlying inflammation (Wellen & Hotamisligil, 2005).  Whether OPG/RANKL/TRAIL 
could be a reflection of low-grade vascular inflammation in individuals with diabetes is not 
known.  
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Aims 
The aim of this experiment was to measure serum OPG/RANKL/TRAIL in a cohort of well 
controlled type 2 diabetic patients with no evidence of underlying metabolic bone disease and 
compare them to a healthy age and BMI control group. We also determined if any differences 
could be attributed to the presence of underlying vascular disease or inflammation. 
 
Hypothesis 
We hypothesised that OPG, along with other traditional inflammatory markers would be higher 
in type 2 diabetic patients. We also tested the hypothesis that OPG would be a sensitive marker 
of inflammation that would distinguish between diabetics and normoglycemic controls 
irrespective of prior history of vascular disease in these patients.  
 
4.2 Materials and Methods 
4.2.1 Experimental Design Overview 
One Hundred and ten subjects volunteered to participate in this study. Fifty eight 
normoglycemic, healthy subjects free from CVD were recruited from Dublin City University and 
sixty two patients with type 2 diabetes were recruited from the diabetes clinic in Beaumont 
Hospital. A plain language statement was given to those expressing an interest in the study, 
after which a briefing meeting was scheduled to allow for questions to be asked about the study 
and written informed consent was provided by individuals wishing to participate. Subjects 
reported to the laboratory in the morning following an overnight fast at which point fasting blood 
samples were collected. Subjects were interviewed by a physician and had anthropometric 
measurements taken. Oral glucose tolerance tests (OGTT) to ensure normal glucose tolerance 
and exercise stress tests (see previous chapter for method) were performed on all of the 
healthy controls to rule out undiagnosed hyperglycaemia or CVD Full clinical history and 
physical examination were performed on all study subjects. The study was approved by the 
Dublin City University Research Ethics and Beaumont Hospital Ethics Committee and 
conformed to the Declaration of Helsinki. Finally, each participant completed a health history 
questionnaire underwent a medical screening examination. 
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4.2.2 Assessment of Bone Mineral Density 
Bone mineral density (BMD) was measured using the GE Lunar Prodigy 2 DEXA scanner (GE 
Medical Systems, UK). Participants were positioned as per manufacturer instructions and bone 
mineral density was reported as grams of bone mineral content (BMC) per projected area (g.cm-
2) The mean of the lumber spine (L1 – L4) and the total BMD at the femur were used to classify 
patients according to WHO criteria (Brown & Josse, 2002). A sub-group of 66 participants (53% 
and 57% of those with and without diabetes respectively) underwent DEXA scanning. It was 
originally intended to conduct a DEXA scan on all participants in this experiment, however due 
to serious flooding in August 2008 the DEXA scanner was rendered unusable. A new DEXA 
scanner was acquired, but after initial quality control measures it was found that there were 
significant irregularities in the results being produced. It was felt at this time that the results 
measured on the two separate machines were not comparable and therefore only those scans 
taken on the original machine were used for analysis. 
 
4.2.3 Statistical Procedures  
SPSS 15.0 for Windows (SPSS Inc., USA) was used for statistical analysis. Data are reported 
as means ± SEM. Non-normally distributed variables including (fasting plasma glucose, IL-6, 
and hsCRP) were log-transformed for the purpose of analysis. Differences between groups 
were assessed using the unpaired Student t-test. The degree of relationship was calculated 
using Pearson’s product moment (r).  All data presented are adjusted for age and gender. 
Multiple linear regression analysis was performed with OPG as the dependent variable and age, 
gender, BMI, waist circumference, blood pressure, fasting glucose, total and LDL cholesterol, 
TRAIL, hsCRP, IL-6 as the independent variables.  A p<0.05 was taken as indicative of 
statistical significance.  Statistical analysis was carried out using SPSS statistical package 
(version 15.0; SPSS Inc., Chicago IL, USA). 
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4.2.4 Subject Characteristics 
Demographics for the type 2 diabetic patients and healthy controls are described in Table 4.1.  
Patients were matched for age, gender and BMI. 
 
Table 4.1 Subject Characteristics 
 Normal Type 2 Diabetes 
N 58 62 
Age (years) 55.6 ± 1.2 58.31.2 
Gender (M:F) 28:30 40:22 
BMI (kg/m2) 29.5 ± 0.4 30.0 ± 0.5 
Waist Circumference (cm) 101.3 ± 1.4 105.0 ± 1.3 ~ 
BMI (Body mass index), Values are mean ± SEM. ~ p = 0.06
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4.3 Results 
 
Subject Metabolic and Cardiovascular Characteristicsare presented in Table 4.2. Waist 
circumference, systolic blood pressure, medication use (anti-hypertensive, statin, ACE 
inhibitor/ARB, and aspirin use), fasting plasma glucose and triglycerides were all significantly 
higher in diabetics, while total HDL and LDL cholesterol were lower. Characteristics of the 
disease state, medication and complications of the type 2 diabetics are presented in Table 4.3.  
 
Table 4.2 Subject Metabolic and Cardiovascular Characteristics. 
 Normal Type 2 Diabetes 
N 58 62 
Waist Circumference (cm) 101.3 ± 1.4 105.0 ± 1.3 ~ 
Systolic BP (mmHg) 131.14 ± 2.53 142.3 ± 2.26 *** 
Diastolic BP (mmHg) 81.8 ± 1.4 80.26 ± 1.26 
Current smokers 4.7% 9.8% 
Anti-hypertensive use 13.2% 86.7% *** 
ACE/ARB use 8.6% 67.2% *** 
Statin use 15.1% 82.0% *** 
Aspirin use 5.7% 78.7% *** 
Fasting glucose (mmol.l-1) 5.2 ± 0.2 7.9 ± 0.2 *** 
Total Cholesterol (mmol.l-1) 5.4 ± 0.1 4.1 ± 0.1 *** 
LDL Cholesterol (mmol.l-1) 3.4 ± 0.1 2.0 ± 0.1 *** 
HDL Cholesterol (mmol.l-1) 1.4 ± 0.04 1.2 ± 0.04 *** 
Triglycerides (mmol.l-1) 1.4 ± 0.1 2.0 ± 0.1 *** 
TNF-α (pg/ml) 1.5 ± 0.3 1.4 ± 0.3 
BP (blood pressure), LDL (Low density lipoprotein), HDL (Hofbauer et al., 2002), TNF-α 
(Tumour necrosis factor alpha) Values are mean ± SEM, *p < 0.05, *p < 0.05, **p < 0.01, ***p < 
0.001 vs. Type 2 diabetes 
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Table 4.3 Characteristics of the Disease State in Patients with Type 2 Diabetes.  
 Median (range) or n (%) 
 
Duration of diabetes (years) 7 (1-20) 
HbA1c (%) 7 (5.1-10) 
Insulin treated 12 (19.67%) 
Metformin treated 37 (60.66%) 
Sulphonylurea treated 21 (34.43%) 
TZD treated 3 (5.92%) 
Diet alone 8 (13.12%) 
Microvascular complications 15 (24.19%) 
Macrovascular complications 20(32.26%) 
HbA1c (haemoglobin A1c), TZD (Thiazolidinediones) 
 
4.3.3 Effect of Glycaemic Status on Inflammatory Markers 
OPG (5.7 ± 0.2 vs. 4.9 ± 0.2 pmol.l-1; p < 0.05), IL-6 (3.0 ± 0.4 vs. 1.8 ± 0.4 pg.ml-1, p < 0.05) 
and hsCRP (2.2 ± 0.3 vs. 1.6 ± 0.3 mg.L-1, p < 0.05) were significantly higher in type 2 diabetic 
patients and adiponectin was significantly lower (4.8 ± 0.5 vs. 7.2 ± 0.5 μg.ml-1; p < 0.05) 
compared to the healthy non-diabetic controls and there were no differences in serum TRAIL or 
RANKL between those with or without diabetes (Figure 4.1). 
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Figure 4.1 Circuling concentrations of (A) Osteoprotegerin, (B) TRAIL, (C) sRANKL (D) hsCRP, (E) IL-6 
and (F) Adiponectin in Type 2 diabetics and in age and BMI matched normoglycemic healthy controls. 
Data are presented as mean ± SEM. *p < 0.05 vs. Type 2 diabetes. 
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4.3.4 Gender Breakdown 
In the entire group, OPG (5.77 ± 0.26 vs. 5.05 ± 0.18 pmol.l-1, p < 0.05) and adiponectin (7.80 ± 
0.66 vs. 4.23 ± 0.37 μg.ml-1, p < 0.0001) were higher in women than men. There were no 
significant gender differences for TRAIL, hsCRP, sRANKL or IL-6. OPG was correlated with age 
(r = 0.247, p < 0.05).  
 
4.3.5 Correlation Analysis 
TRAIL was correlated with LDL (r = 0.303, p < 0.01) and waist circumference (r = 0.202, p < 
0.05). In the healthy control group, controlling for gender there was a correlation between OPG 
and age (r = 0.364, p < 0.01). When both age and gender were controlled for, OPG was 
correlated with waist circumference (r = -0.262, p < 0.05), adiponectin (r = 0.366, p < 0.01), total 
cholesterol (r = 0.380, p < 0.01), LDL (r = -0.336, p < 0.05), fasting plasma glucose (r = -0.363, 
p < 0.05) and showed a strong tendency towards a significant inverse correlation with TRAIL (r 
= -0.294, p = 0.053), Left Hip BMD (r = -0.320, p = 0.079) and right hip BMD (r = -0.326, p = 
0.074). None of these relationships with OPG were evident in the type 2 diabetic cohort. TRAIL 
was however correlated with LDL (r = 0.325, p < 0.05) 
 
4.3.6 Subset Analysis on the Effect of Vascular Disease on Inflammatory Markers 
To investigate whether the elevated OPG, IL-6 and hsCRP observed in the diabetes group was 
due to the higher prevalence of vascular disease within this group, we compared mean values 
of these proteins, after exclusion of type 2 diabetes patients with either micro- or macro-
vascular disease (Table 4.4).  OPG was still significantly higher in those with diabetes (5.68 ± 
0.25 vs. 4.93 ± 0.2 pmol.l-1, p < 0.05) than normal controls, while the significant difference 
previously seen with IL-6 (2.29 ± 0.26 vs. 1.95 ± 0.23 pg.ml-1, p = 0.24) and hsCRP (1.93 ± 0.27 
vs. 1.59 ± 0.24 mg.L-1, p = 0.37) were now lost. In this group OPG correlated with IL-6 after 
correction for age and gender (r = 0.24, p < 0.05), but this association was lost after correction 
for glycaemic status.  There was no correlation between RANKL or TRAIL and IL-6, or hsCRP in 
either group. 
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Table 4.4 OPG, RANKL, TRAIL, IL-6 and hsCRP in Type 2 diabetics and Healthy Controls in 
subjects free from vascular disease. 
 Type 2 Diabetes  Normal 
 
N 38 58 
Age (years) 56.0 ± 1.6 55.6 ± 1.2 
Gender (M:F)  23:15 28:30 
BMI (kg.m-2) 30.61 ± 0.6 29.48 ± 0.42 
OPG (pmol.l-1) 5.68 ± 0.25 4.93 ± 0.20* 
TRAIL (ng.ml-1) 76.74 ± 4.33 82.19 ± 3.77 
RANKL (pmol.l-1) 2.25 ± 0.47 2.60 ± 0.43 
IL-6 (pg.ml-1) 2.29 ± 0.26 1.95 ± 0.23 
hsCRP (mg.l-1) 1.93 ± 0.27 1.59 ± 0.24 
TNF-α (pg.ml-1) 1.42 ± 0.28 1.43 ± 0.26 
BMI (Body mass index), TRAIL (TNF-related apoptosis inducing ligand), sRANKL (soluble 
receptor activator of NF-κβ ligand), Interleukin 6 (IL-6), hsCRP (high sensitivity c-reactive 
protein), TNF-α (Tumour necrosis factor alpha). Values are mean ± SEM. * p < 0.05 vs. Type 2 
Diabetes 
 
4.3.7 Bone Mineral Density and markers of inflammation 
In the subset of 66 participants (53% and 57% of those with and without diabetes respectively) 
that underwent DEXA scanning, there was no significant difference between OPG, adiponectin, 
sRANKL and TRAIL between those who were osteopaenic and those who had BMD in the 
normal range.  
 
4.4 Summary 
The main findings of Experiment II are that OPG but not RANKL or TRAIL is significantly 
increased in type 2 diabetes.  IL-6 and hsCRP is higher in individuals with diabetes and 
adiponectin is lower, but unlike OPG, they are no longer different when subjects with vascular 
disease are excluded. 
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Chapter V The effect of Obesity, 
Glycaemic Status and an acute 
glucose load on circulating 
concentrations of OPG 
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5.1 Introduction 
Rationale 
Type 2 diabetes, impaired glucose tolerance and obesity are characterized by fasting and 
postprandial hyperinsulinaemia (Reaven et al., 1993a), (Cavaghan & Polonsky, 2005) and 
insulin resistance. Unravelling the specific metabolic effects of elevated circulating insulin from 
failing insulin action remains challenging. However, several large, longitudinal studies have 
described a link between hyperinsulinaemia and the development of cardiovascular disease. 
(Pyorala et al., 1985), (Welborn & Wearne, 1979), (Eschwege et al., 1985). As well as its 
traditional glucose lowering role, insulin is a vasoactive peptide capable of exerting significant 
hemodynamic effects (Cersosimo & DeFronzo, 2006) including increased sympathetic activity, 
renal sodium retention, and vascular smooth muscle cell proliferation. (Goalstone et al., 1998), 
(Kawasaki et al., 2000). Indeed the activity of endothelial nitric oxide synthase, a potent 
vasodilator is increased several fold by insulin responsive cytokines such as IL-1β, IL-6, TNF-α, 
interferon-γ and adenosine (Landry & Oliver, 2001). The Framingham Offspring Study (Meigs et 
al., 2000) showed that there was a consistent relationship between hyperinsulinaemia and the 
procoagulant state, which was evaluated by measuring PAI-1, tissue plasminogen activator, von 
Willebrand factor, fibrinogen, plasma viscosity, and factor VII antigen (Uwaifo & Ratner, 2003). 
Nevertheless, other studies have found that that arterial infusion of insulin leads to an up 
regulation of both endothelin, a vasoconstrictor, and the vasodilator nitric oxide (Cardillo et al., 
1999). Recent studies have suggested an important role for insulin in the inhibition of OPG 
expression and secretion. Olesen et al. (2005) demonstrated in vitro that human vascular 
smooth muscle cells incubated with insulin exhibit markedly reduced OPG production when 
compared to controls (Olesen et al., 2005). One in vivo study which examined the effect of 6 
months of insulin therapy in young type 1 diabetics on OPG levels and endothelial function via 
flow-mediated endothelium-dependent arterial dilation found that OPG decreased significantly in 
these patients and that this decrease was strongly correlated with the change in flow-mediated 
endothelium-dependant arterial dilation (Xiang et al., 2007). Another very recent paper has also 
demonstrated an acute effect of insulin administration in reducing OPG secretion to the 
circulation in lean, type 2 diabetic and obese subjects during a euglycaemic-hyperinsulinaemic 
clamp. It was found that serum OPG was markedly reduced in all three groups and that the lean 
control group showed a significantly greater decrease than the type 2 diabetic and obese 
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subjects (Jorgensen et al., 2009). Interaction between insulin and the OPG / RANKL / RANK / 
TRAIL axis may be one mechanism by which elevated fasting and postprandial 
hyperinsulinaemia can independently affect the development of cardiovascular disease.  
 
Aims 
The purpose of this study was to examine changes in circulating OPG levels with varying 
degrees of glucose tolerance and to investigate the influence of adiposity and inflammatory 
processes on OPG concentrations. 
 
Hypothesis 
We hypothesized that the deteriorating inflammatory state coupled with the sharp rise in 
hyperinsulinaemia with decreasing glucose tolerance would uncouple the relationship between 
OPG and insulin sensitivity that we observed in our previous experiments. We also propose that 
acute hyperinsulinaemia associated with an oral glucose load may act to suppress OPG 
secretion and that this regulation would be differentially regulated dependant of glycaemic 
status.  
 
5.2 Materials and Methods 
 
5.2.1 Experimental Design Overview 
Sixty one male subjects were recruited to participate in this study. Twenty patients with type 2 
diabetes and twenty male patients with either impaired glucose tolerance or impaired fasting 
glucose were recruited from the diabetes clinic in Beaumont Hospital. An additional twenty one 
healthy obese male subjects free from CVD were recruited from Dublin City University. All three 
groups were age and BMI matched. In addition, data from twenty one lean age matched 
subjects who were part of the cohort used in the Experiment 1 were also included in the data 
set (Figures 5.1 and 5.4) for comparative purposes. Ethical approval was obtained from the 
Beaumont hospital and Dublin City University Research Ethics Committee. Volunteers were 
excluded if they had evidence of malignancy, renal impairment (serum creatinine >120 μmol.l-1), 
type 1 diabetes, pregnancy, any disorder of calcium metabolism (i.e. hyper- or hypo-calcaemia), 
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previous diagnosis of osteoporosis or use of medications affecting bone metabolism (i.e. 
calcium, vitamin D, bisphosphonates, oestrogen preparations, strontium, parathyroid hormone), 
recent (within previous 6 months) history of a macrovascular event (defined as an acute 
coronary syndrome, transient ischaemic attack, stroke, lower limb ischaemic event or any 
vascular interventional procedure), and osteoporosis on DEXA scan. Subjects reported to the 
laboratory in the morning following an overnight fast at which point fasting blood samples were 
collected. Oral glucose tolerance tests (OGTT) to assess glycaemic status were carried out on 
all subjects. Subjects were interviewed by a physician and had anthropometric measurements 
taken. A full clinical history and physical examination were performed by a medical doctor on all 
study subjects.  
 
5.2.2 Assessment of Glycaemic Status 
Subjects were assigned to a category of either normoglycaemia (NGT Obese), impaired 
glucose tolerance/impaired fasting glucose (IFG / IGT) or type 2 diabetes based on previous 
clinical history and WHO guidelines for an OGTT (Reinauer et al., 2002). In brief; subjects were 
classified with impaired fasting glucose if they had fasting blood glucose between 6.1 and 6.9 
mmol.l-1. They were considered to have impaired glucose tolerance if their fasting plasma 
glucose was ≤ 7.0 mmol.l-1 and their 2 hr plasma glucose was between 7.8 and 11.0 mmol.l-1. 
They were adjudged to be diabetic if either their fasting glucose was ≥ 7.0 mmol.l-1 and/or their 2 
hr plasma glucose was ≥ 11.0 mmol.l-1. Normal glucose tolerance (NGT) was considered to be a 
fasting plasma glucose < 6.1 mmol.l-1 and a 2 hr plasma glucose less than 7.8 mmol.l-1 in 
conjunction with a medical examination and interview which did not show any prior history of 
glycaemic dysfunction. All blood sampling and biochemical analysis were carried out as 
described previously in section 3.2.6 and 3.2.7. 
 
5.2.3 Statistical Procedures  
SPSS 15.0 for Windows (SPSS Inc., USA) was used for statistical analysis. Data are reported 
as means ± SEM. Normally distributed variables were explored using simple bivariate or partial 
regression. Non-normally distributed variables were log-transformed. A one-way analysis of 
covariance (ANCOVA) was used to examine differences between glycaemic categories with 
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age as a covariate. Bonferroni’s post hoc test was applied to determine differences among 
means. Statistical significance was set at p<0.05. 
 
5.2.4 Subject Characteristics 
Age and BMI for all subjects are presented in Table 5.1.There was no significant difference 
between groups for age or BMI. 
 
Table 5.1 Subject Characteristics 
 Type 2 Diabetes IGT / IFG NGT Obese 
 (20) (20) (21) 
Age (years) 56.2 ± 2.1 56.8 ± 2.3 53.8 ± 2.2 
BMI (kg.m-2) 30.5 ± 0.6 30.5 ± 0.8  30.2 ± 0.5  
BMI (Body mass index) 
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5.3 Results 
5.3.1 Markers of Insulin Sensitivity 
Indicators of metabolic function and insulin sensitivity are presented in Table 5.2 for the three 
subject groups. In order to assess the potential influence of adiposity and relative insulin 
resistance on circulating OPG levels in clinically normal glucose tolerant subjects, twenty one 
lean age matched males from experiment 1 were included later for further analysis (Figure 5.1)  
 
Table 5.2 Subject Characteristics and indicators of insulin sensitivity.  
 Type 2 Diabetes IGT / IFG NGT Obese 
 (20) (20) (21) 
Fasting Glucose (mmol.l-1) 7.4 ± 0.2 6.2 ± 0.1 * 5.2 ± 0.1 * † 
Fasting Insulin (pmol.l-1) 118.8 ± 15.6 127.7 ± 12.6 39.9 ± 4.3 * † 
2 hr Glucose (mmol.l-1) 12.6 ± 0.7 8.6 ± 0.3 * 5.1 ± 0.3 * † 
2 hr Insulin (pmol.l-1) 493.4 ± 74.5 526.8 ± 55.2 39.6 ± 24.6 * † 
HOMA-IR 6.4 ± 0.8 5.8 ± 0.6 * 1.6 ± 0.2 * † 
OGIS (ml.min.m-2) 289 ± 10 332 ± 10 424 ± 9 * † 
AUC Glucose (mmol.l.min) 1593 ± 62 1218 ± 30 * 816 ± 32 * † 
AUC Insulin (pmol.l.min) 64475 ± 9176 60693 ± 6032 29677 ± 3492 * † 
NGT (Normal Glucose Tolerance), HOMA-IR (Matthews et al., 1985), OGIS (Mari et al., 2001), 
AUC Glucose (area under the glucose curve), AUC Insulin (area under the insulin curve). 
Values are mean ± SEM. * p < 0.05 vs. Type 2 Diabetes, †   p < 0.05 vs. IGT / IFG.  
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Characteristics of the disease state and medication of the type 2 diabetics are presented in 
Table 5.3 
 
Table 5.3 Characteristics of the Disease State in Patients with Type 2 Diabetes.  
 Median (range) or n (%) 
 
Duration of diabetes (years) 5 (1-13) 
Insulin treated 3 (15%) 
Metformin treated 16 (80%) 
Sulphonylurea treated 5 (25%) 
TZD treated 1(5%) 
Diet alone 2 (10%) 
TZD (Thiazolidinediones) 
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Figure 5.1 Insulin (A) and Glucose (B) kinetics in response to a 75 g Oral Glucose Tolerance Test in Type 
2 diabetics ▲ , those with Impaired Glucose Tolerance or Impaired Fasting Glucose (Pomplun et al., 2007) 
♦ , age and BMI matched normoglycemic controls ● and a lean age matched control group ■. 
 
5.3.2 Insulin, Glucose, OPG and hsCRP Kinetics in Response to the OGTT 
The type 2 diabetics and the IGT/IFG group had significantly higher plasma insulin 
concentrations at all time points than both the age and BMI matched group or the lean age 
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matched group p < 0.01. There was no significant difference in plasma insulin levels at any time 
point between the type 2 diabetics and IGT/IFG group or between the two normoglycemic 
groups. Plasma glucose was significantly higher in the type 2 diabetic group at all time points (p 
< 0.01) and  IGT/IFG plasma glucose levels were significantly higher at all time points that the 
two normoglycaemic groups (p < 0.01). There was no significant difference in plasma glucose 
levels between the obese and lean normoglycaemic groups (Figure 5.1). However there were 
significant differences in fasting glucose, fasting insulin, HOMA-IR, OGIS as well other 
indicators of insulin sensitivity and glycaemic control between the groups (Table 5.1). There was 
no significant change in hsCRP in response to the OGTT in any of the glycaemic conditions. 
OPG was significantly reduced in response to the oral glucose load in the IFG / IGT but was 
unchanged in type 2 diabetics and normoglycemic obese subjects (Figure 5.2). 
 
5.3.3 hsCRP and Insulin Sensitivity 
OGIS (424 ± 9 vs. 332 ± 10, p < 0.05 and vs. 289 ± 10 ml.min.m-2, p < 0.05) and adiponectin 
(4.3 ± 0.3 vs. 3.1 ± 0.3, p < 0.05 and vs. 2.9 ± 0.2 μg.ml-1, p < 0.05) were significantly higher in 
healthy age and BMI controls than in either IGT / IFG subjects or type 2 diabetics. hsCRP was 
significantly lower in the healthy matched control group (1.2 ± 0.2 vs. 4.6 ±  0.9 mg.L-1 p < 0.05) 
and the IGT / IFG group (2.4 ± 0.7 vs. 4.6 ±  0.9 mg.L-1, p < 0.05). There was no significant 
difference in hsCRP levels between the healthy matched control group and the IGT / IFG 
subjects. OPG (4.7 ± 0.3 vs. 6.0 ± 0.5, p < 0.05 and vs. 6.3 ± 0.3 pmol.l-1, p < 0.05) was 
significantly lower in healthy controls than in either IGT / IFG subjects or type 2 diabetics. There 
was no significant difference in OPG levels between the type 2 diabetics and IGT/IFG groups 
(Figure 5.1). In order to assess the independent effect of obesity on circulating OPG levels, a 
fourth group of age matched lean controls from Experiment 1 were included for analysis. OPG 
levels in this group of age matched normoglycemic lean males were then compared to the other 
groups. The lean control group had significantly higher levels of OPG than the obese 
normoglycemic group, however there was no significant difference between this group (6.0 ± 0.3 
pmol.l-1) and either the type 2 diabetics (6.3 ± 0.3 pmol.l-1) or the IGT / IFG groups (6.0 ± 0.5 
pmol.l-1) (Figure 5.2). This finding which may be explained by the relative fasting and 
postprandial hyperinsulinaemia, that although not of clinical significance may still be sufficient to 
suppress OPG production and secretion and in the absence of a significant inflammatory state 
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to give impetus to increased OPG production as indicated by what would be considered normal 
hsCRP levels. 
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Figure 5.2 Circulating concentrations of Osteoprotegerin (A), (B), (C) and hsCRP (D), (E), (F) in Type 2 
diabetics, pre-diabetic (IFG/IGT) and normoglycemic obese controls at baseline and 2hrs after a 75 g oral 
glucose load (OGTT). 
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Figure 5.3 Differences in markers of insulin sensitivity and systemic inflammation in Type 2 diabetics, 
those with Impaired Glucose Tolerance (Pomplun et al., 2007) or Impaired Fasting Glucose (IFG) and age 
and BMI matched normoglycemic controls (A) Oral Glucose Insulin Sensitivity (OGIS), (B) high sensitivity 
C-reactive Proteins (hsCRP), (C) Osteprotegerin (D) Adiponectin. *p < 0.05 vs. Type 2 diabetes, † p < 0.05 
vs. IGT / IFG. 
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Figure 5.4 Osteprotegerin in Type 2 diabetics, those with Impaired Glucose Tolerance or Impaired Fasting 
Glucose (IGT/ IFG), age and BMI matched normoglycemic subjects (NGT Obese) and an age matched 
normoglycemic lean control group (Nissen & Sharp, 2003). 
 
 
5.4 Summary  
The main findings of Experiment III are that there is no difference in OPG between prediabetic 
and type 2 diabetic cohorts, but both have higher levels than matched obese controls. 
Interestingly, OPG in lean insulin-sensitive subjects is comparable to that of the pre-diabetic and 
type 2 diabetic patients but significantly higher than their matched lean counterparts. 
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Chapter VI General Discussion 
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The goal of this thesis was to investigate changes in Osteprotegerin concentrations in various 
stages of metabolic dysfunction, including obesity, insulin resistance and cardiovascular 
disease. The principle findings of the experimental studies presented here were as follows. 
 
Experiment I 
I. Obese subjects who have normal glucose tolerance and are free from cardiovascular 
disease have lower circulating levels of OPG than their lean age matched counterparts. 
II. Osteoprotegerin is inversely correlated with insulin sensitivity, adiponectin and 
indicators of total body and visceral adiposity and positively correlated with aerobic 
fitness. 
III. TRAIL is positively correlated with both fat mass and waist circumference, independent 
of age, gender and BMI. 
 
Experiment II 
IV. Osteprotegerin and IL-6 are significantly higher as and adiponectin significantly lower in 
type 2 diabetics than in age and gender matched normoglycemic controls, while there is 
no difference in TNF-α, TRAIL or sRANKL concentrations. 
V. Osteoprotegerin is higher in type 2 diabetics after excluding patients with previously 
diagnosed vascular disease, a distinction which could not be made using traditional 
inflammatory markers such as IL-6, hsCRP or TNF-α. 
 
Experiment III 
VI. There is no difference in OPG concentrations between those with prediabetes and overt 
type 2 diabetes, however both conditions appear to have significantly higher levels of 
OPG than age and BMI matched obese normoglycemic controls. 
VII. Interestingly, lean normoglycemic subjects have OPG concentrations which are similar 
to that of both pre-diabetic and type 2 diabetic patients but significantly higher than their 
matched obese counterparts.  
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The most significant finding from this series of experiments is the differential regulation of 
circulating OPG in obese and diabetic patients as presented in Figure 5.4. Circulating OPG has 
been reported to be significantly higher in patients with type 2 diabetes (Yaturu et al., 2008), 
(Secchiero et al., 2006), (Olesen et al., 2005), (Rasmussen et al., 2006), to correlate with the 
presence of coronary artery disease (Jono et al., 2002), (Schoppet et al., 2003), and to be an 
independent predictor of cardiovascular mortality (Browner et al., 2001), (Kiechl et al., 2004), 
(Ueland et al., 2004), (Omland et al., 2008). Indeed it has also been shown that OPG can 
independently predict silent coronary artery disease in type 2 diabetic patients (Avignon et al., 
2005). However, in the majority of studies the control groups are often age and BMI matched. 
Therefore, the assumption that circulating OPG progressively increases with increasing weight 
and insulin resistance may not be correct. There have been few published papers that have 
examined the relationship between adiposity, insulin sensitivity and OPG in a normal population 
free from overt cardio-metabolic disease. The findings from this thesis demonstrate an 
uncoupling of an insulin or insulin resistant mediated decrease in circulating OPG and suggest 
that elevated OPG in diabetic patients may be the result of inflammatory processes. 
 
In Experiment I we tested the hypothesis that in a healthy cohort, in the absence of a significant 
inflammatory promoter, that OPG may be differentially regulated in obesity and, that OPG may 
be chronically related to fasting and postprandial insulin excursions as assessed by an oral 
glucose tolerance test. Our findings from Experiment I indicate that obese subjects with normal 
glucose tolerance who are free from cardiovascular disease as confirmed by an exercise stress 
test and medical examination have lower circulating OPG compared with matched normal 
weight and overweight individuals. We also observed a positive relationship between OPG and 
adiponectin which was mirrored by concomitant inverse relationships with glucose stimulated 
insulin secretion in addition to similar significant negative relationships with both fasting insulin 
and glucose. These findings would at first seem to be at odds with previous studies that have 
found a positive relationship between circulating OPG levels and metabolic dysfunction (Anand 
et al., 2006), (Avignon et al., 2005), (Knudsen et al., 2003), (Terekeci et al., 2009), (Browner et 
al., 2001), (Jono et al., 2002), (Kiechl et al., 2004), (Schoppet et al., 2003), (Ziegler et al., 2005). 
A number of growth factors and inflammatory cytokines which are key players in the 
pathogenesis of atherosclerosis and coronary artery disease have also been implicated in the 
regulation of OPG in the vascular wall. Vascular endothelial cell-expression of OPG can be 
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induced by the addition of the inflammatory cytokines; TNF-α, IL-1α and IL-1β, (Secchiero et al., 
2006), (Ben-Tal et al., 2007). In vascular smooth muscle cells, a number of cytokines have been 
shown to augment OPG expression in vitro, including TNF-α, IL-1β, basic fibroblast growth 
factor (bFGF), platelet-derived growth factor (PDGF), and angiotensin II (Collin-Osdoby et al., 
2001), (Olesen et al., 2005), (Ben-Tal et al., 2007), (Zhang et al., 2002). A recent study by 
Olesen et al., (2005) also suggested an important role for insulin itself in the inhibition of OPG 
expression and secretion and demonstrated in vitro that human vascular smooth muscle cells 
incubated with insulin exhibit markedly reduced OPG production when compared to controls 
(Olesen et al., 2005). One in vivo study examined the effect of 6 months of insulin therapy in 
young type 1 diabetics on OPG levels and endothelial function and found that OPG decreased 
significantly (Xiang et al., 2007). Another very recent paper has also observed a negative effect 
of acute insulin administration on OPG secretion to the circulation of lean, type 2 diabetic and 
obese subjects during a hyperinsulinaemic-euglycaemic clamp (Jorgensen et al., 2009). By 
excluding subjects with metabolic or cardiovascular disease and therefore those with a 
significant underlying inflammatory process, we have demonstrated for the first time that subtle, 
sub-clinical, changes in fasting ambient insulin or insulin sensitivity coincide with a reduction in 
circulating OPG concentrations. Previously the role of obesity in the regulation of circulating 
osteoprotegerin has not been clear. Some studies report a decrease in OPG in obese subjects 
compared to lean controls (Ugur-Altun et al., 2005), (Holecki et al., 2007) but other studies have 
not found a relationship between OPG and BMI (Gannage-Yared et al., 2006), (Gannage-Yared 
et al., 2008), (Jorgensen et al., 2009). Weight gain is accompanied by a number of metabolic 
alterations including a decrease in insulin sensitivity. Ugur-Altan et al., (2005) divided a group of 
obese healthy subjects into tertiles based on insulin resistance as assessed using the HOMA-IR 
method and compared these groups to lean control subjects. When OPG was corrected for BMI 
it was significantly lower in all obese tertiles compared to lean controls. They also found that 
OPG was significantly lower in the least insulin sensitive obese tertile compared to the most 
sensitive. In Experiment I, insulin sensitivity was significantly lower in obese compared with 
overweight and normal weight groups and there was a positive relationship between OPG and 
insulin sensitivity for all subjects (Ugur-Altun et al., 2005). We found an inverse relationship 
between fasting OPG and the area under the curve for glucose and insulin during the OGTT in 
support of recent studies suggesting that elevated insulin may be an important effector exerting 
downward pressure on circulating OPG concentrations. When Jorgensen et al., (2009) reported 
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a decrease in OPG in response to hyperinsulinaemia, the magnitude of OPG-lowering effects of 
insulin was decreased by approximately 50 % in the obese and type 2 diabetic groups 
compared to lean controls (Jorgensen et al., 2009). A decrease in OPG has also been reported 
in lean and morbidly obese subjects following an oral glucose tolerance test (Hofso et al., 2009) 
and in lean males following a hyperglycaemic clamp (Knudsen et al., 2007). In this study, 
Knudsen et al., (2007) found that the decrease in OPG was related to the change in serum 
insulin and not glucose during the hyperglycaemic clamp. Therefore, subtle increases in fasting 
insulin secretion, as observed in Experiment I, may be adequate to decrease chronic OPG 
production in an obese normoglycemic cohort. If insulin sensitivity was a major regulator of 
serum OPG, exercise training or weight loss might be expected to induce a change in its 
circulating concentrations. We found a positive correlation between OPG and aerobic fitness 
which might suggest that exercise training may increase serum OPG in healthy subjects. 
However, other studies using a dietary restriction-induced weight loss intervention reported a 
further decrease in OPG (Holecki et al., 2007) or no change as a result of gastric banding 
(Gannage-Yared et al., 2008). No studies that we are aware of, have, as of yet examined the 
impact of exercise training on levels of circulating OPG. 
 
The positive relationship between OPG and adiponectin was robust and maintained after 
additional correction for BMI. Adiponectin is an adipocyte-specific endocrine protein with anti-
inflammatory and insulin sensitising actions. Circulating adiponectin is lower in obese subjects 
compared to lean controls and is also decreased with cardiovascular disease and type 2 
diabetes. It is not yet known if adiponectin secretion and OPG appearance are directly related 
physiological processes in vivo or if the positive correlation between OPG and adiponectin 
reported here, and in other studies (Gannage-Yared et al., 2006), (Gannage-Yared et al., 2008), 
is evident only in healthy cohorts. Interestingly receptors for adiponectin are present in both 
osteoblasts and osteoclasts, suggesting that adiponectin influences bone metabolism in an 
autocrine / paracrine as well as an endocrine manner (Berner et al., 2004), (Shinoda et al., 
2006). There is now also evidence of a similar role for OPG in adipose tissue. An et al., (2007) 
demonstrated that OPG and RANKL are expressed in differentiating 3T3L1 adipocytes and that 
OPG mRNA expression in this cell model could be attenuated in response to insulin and 
increased in response to TNF-α, much the same as in the VSMC model (Olesen et al., 2005). 
Interestingly, the treatment of these cells with the insulin-sensitizer, rosiglitazone, led to a dose-
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dependant decrease in OPG mRNA (An et al., 2007). Recombinant adiponectin increases bone 
resorption in vitro by reducing osteoblast formation through RANKL secretion and the inhibition 
of OPG production (Luo et al., 2006). The majority of published human studies on the subject 
also indicate that adiponectin is a negative regulator of BMD in both men and women (Misra et 
al., 2007), (Peng et al., 2008), (Lenchik et al., 2003), (Jurimae & Jurimae, 2007), (Richards et 
al., 2007). This negative effect may be mediated by the promotion of bone resorption (Peng et 
al., 2008). However, some studies have shown a positive effect of adiponectin on BMD (Tamura 
et al., 2007) or no effect (Oh et al., 2004). The relationship observed in Experiment I between 
OPG and adiponectin may be indicative of consistently elevated BMDs in obese relative to lean 
populations. 
 
Circulating TRAIL and RANKL are ligands for the soluble OPG receptor. We found a positive 
relationship between TRAIL, fat mass and waist circumference but did not observe a difference 
across BMI categories. TRAIL may exert an effect at the level of the vascular wall and in vitro 
evidence suggests that it can promote apoptosis in vascular smooth muscle cells, leading to 
increased plaque instability (Sato et al., 2006). On the other hand, OPG appears to promote 
endothelial cell survival (Cross et al., 2006), (Malyankar et al., 2000), possibly by inhibition of 
TRAIL-induced apoptosis (Pritzker et al., 2004). We did not find any significant changes or 
relationships for the other OPG ligand, sRANKL. This may be due to the fact that our subject 
cohort were healthy as other studies have reported elevated RANKL to be associated with 
increased (Kiechl et al., 2007) and decreased (Schoppet et al., 2003) cardiovascular disease 
risk. This inconsistency may also result from different assay methodologies. Several studies 
have used commercially available assays that measure unbound and uncomplexed forms of 
both RANKL or OPG (Xiang et al., 2006), (Knudsen et al., 2003), (Rasmussen et al., 2006), 
(Jorgensen et al., 2009). The RANKL assay used in these experiments measured soluble 
RANKL (sRANKL) i.e. bound to OPG in addition to the free component. The OPG assay used in 
this body of work measured both total OPG, including OPG bound to RANKL and TRAIL and 
has been used to measure OPG in many cohorts (Gannage-Yared et al., 2006), (Gannage-
Yared et al., 2008), (Anand et al., 2006), (Schoppet et al., 2003). It is problematic to compare 
the OPG concentrations from studies that have used different commercially available assays 
because of the difficulty in ascribing an exact molecular weight to the OPG-isoforms measured 
in different assays, thus making a conversion from non-SI to SI units problematic. Therefore, 
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previous studies that have exclusively measured uncomplexed OPG may have unintentionally 
excluded a large portion of the biologically active circulating OPG that has either bound to 
TRAIL or RANKL or indeed has undergone some other non-specific binding. Therefore changes 
in circulating free OPG observed in some previous studies in response to either insulin therapy 
or acute insulin infusion are as likely to reflect changes in the concentrations of known ligands, 
RANKL or TRAIL and thus their increased binding to OPG. 
 
Type 2 diabetes mellitus is associated with accelerated atherosclerosis and a threefold 
increased risk of cardiovascular disease (Kannel & McGee, 1979). Arterial calcification, a 
prominent feature of atherosclerosis, is prevalent and extensive in patients with diabetes (Chen 
& Moe, 2003) and is an independent predictor of cardiovascular mortality in both newly 
diagnosed (Niskanen et al., 1994) and established type 2 diabetes (Lehto et al., 1996). OPG-
knockout mice development osteoporosis and marked vascular calcification of the aorta and 
renal arteries (Bucay et al., 1998). Administration of recombinant OPG reverses arterial 
calcification (Min et al., 2000), (Price et al., 2001) and suggests that OPG plays an active role in 
the prevention of vascular calcification. The purpose of Experiment II was to measure serum 
OPG/RANKL/TRAIL in a cohort of well controlled type 2 diabetic patients with no evidence of 
underlying metabolic bone disease, comparing them to an equivalent age and BMI matched, 
normoglycemic, and healthy cohort and to determine whether any differences in OPG relate to 
the presence of underlying vascular disease or inflammation. We found that OPG, IL-6 and 
hsCRP (but not RANKL or TRAIL) were higher in patients with diabetes than in controls. OPG 
correlated with age and fasting glucose in healthy controls, but not in those with diabetes. After 
exclusion of diabetic subjects who had a previous history of vascular disease, OPG was still 
higher in those with diabetes, but IL-6 and hsCRP were no longer significantly different. Our 
findings from Experiment II indicate that OPG is significantly higher in diabetic patients, 
regardless of the presence or absence of diabetes related complications, when compared to an 
age and BMI matched control group with normal glucose tolerance. We did not find a significant 
difference between diabetics and healthy subjects for TNF-α irrespective of prior history of 
vascular dysfunction. Despite the fact that TNF-α is considered to be a potent promoter of OPG 
production, this result is perhaps not surprising as although increased TNF-α expression in 
obesity is evident in adipose tissue, muscle, and macrophages. Several studies, indicate that 
circulating TNF-α concentrations are not elevated in obese rodents and humans (Xu et al., 
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2002), (Cawthorn & Sethi, 2008). This finding has suggested that adipose tissue does not 
release TNF-α systemically in great quantities, which might imply that TNF-α exerts its effects 
locally rather than in an endocrine manner. Analysis and interpretation of the circulating 
concentrations of TNF-α in both obesity and type 2 diabetes have been somewhat complicated 
by the fact that even when using ELISA based assays from the same manufacturer some 
studies have reported values based on the use of assays that have measured high sensitivity 
TNF-α (Ng et al., 1999), (Plomgaard et al., 2007) and others have reported values using 
standard TNF-α assays (MacEneaney et al., 2009). It is likely that given the nature of the small 
changes in TNF-α observed in human studies that a high sensitivity assay such as that 
employed here would be more appropriate to assess circulating levels in healthy populations. 
For these reasons, after we found that there were no differences in TNF-α levels between the 
diabetic and normoglycaemic groups, we decided it would not be prudent to measure TNF-α 
prospectively in Experiment III or retrospectively in Experiment 1. 
 
No difference was observed in sRANKL or TRAIL between the two groups, suggesting that their 
role as a biomarker, specifically of metabolic dysfunction may be limited. To the best of our 
knowledge, this is the first study to investigate the triumvirate of OPG/RANKL/TRAIL in such 
detail in patients with type 2 diabetes. Our findings for OPG in this cohort are in agreement with 
those of Xiang et al., (2006) and Kim et al., (2005) who found higher serum OPG in patients 
with diet controlled diabetes and no history of vascular disease (Xiang et al., 2006), (Kim et al., 
2005). Both of these studies contained patients with newly-diagnosed diabetes, and it is not 
known the effect, if any, of glucose toxicity at diagnosis on serum OPG levels. Previous studies 
examining the relationship between OPG, RANKL, TRAIL and diabetes have had conflicting 
results. Some of the earlier studies investigating the role of OPG as a marker of cardiovascular 
disease did not include a homogeneous group of type 2 diabetics and no effort was made to 
exclude patients with underlying metabolic bone disease or who were on medications which 
could have interfered with bone metabolism (Schoppet et al., 2003), (Browner et al., 2001), 
(Kiechl et al., 2004), (Omland et al., 2008). This may be why an increase in circulating OPG has 
been consistently linked with the onset, progression and severity of cardiovascular disease 
(Jono et al., 2002), (Schoppet et al., 2003). OPG is an independent risk factor for incident 
cardiovascular disease (Kiechl et al., 2004), (Ueland et al., 2004), heart failure (Omland et al., 
2008), (Ueland et al., 2004), all cause (Browner et al., 2001) and vascular mortality (Kiechl et 
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al., 2004), (Omland et al., 2008), (Ueland et al., 2009). When the severity of vascular disease is 
assessed by coronary angiography, circulating OPG increases proportionally with the number of 
diseased vessels (Jono et al., 2002), (Schoppet et al., 2003). In patients with type 2 diabetes 
OPG is increased in some (Browner et al., 2001), (Xiang et al., 2006) but not all (Jorgensen et 
al., 2009) studies. The reason for this may be related to the presence or absence of micro and 
macrovascular complications in the studied groups. In studies that used a non-diabetic control 
group, circulating OPG was similar between controls and diabetic patients without vascular 
complications (Knudsen et al., 2003), (Terekeci et al., 2009), while other studies have shown 
significantly higher OPG in diabetes patients with asymptomatic silent coronary artery disease 
(Avignon et al., 2005), (Avignon et al., 2007) or microvascular complications including 
microalbuminuria (Xiang et al., 2006), retinopathy (Knudsen et al., 2003) and neuropathy 
(Terekeci et al., 2009). It is not known why circulating OPG is increased with type 2 diabetes 
and why this response is in contrast to obesity-related changes. It may be related to the 
increased presence of pro-inflammatory cytokines as the in vitro incubation of human vascular 
smooth muscle cells (Olesen et al., 2005) and human microvascular endothelial cells 
(Secchiero et al., 2006), (Collin-Osdoby et al., 2001) with TNF-α , but not glucose, increases 
OPG production. This would also support the suggestion that OPG protects against the 
development of vascular damage as OPG-deficient mice have increased arterial calcification 
(Bennett et al., 2006) that can be reversed following OPG replacement (Price et al., 2001). In 
Experiment II when the diabetic and normoglycemic groups were combined and analyzed 
together, OPG correlated positively with age and adiponectin and was inversely related to waist 
circumference, total cholesterol and fasting plasma glucose. However, none of these 
relationships were found when the diabetic group were analyzed in isolation. The finding of an 
inverse relationship between adiponectin and OPG in the grouped data is reminiscent of our 
finding in Experiment I. It appears that diabetes, possibly as a result of the inflammatory state or 
ambient hyperinsulinaemia, may ‘uncouple’ the positive relationship between OPG and insulin 
sensitivity observed in healthy groups. 
 
The role of insulin in this process is important but difficult to definitively prove in dynamic human 
experiments. The vasoactive role of insulin is mediated by the regulation of a number of 
important inflammatory cytokines that promote increase endothelial nitric oxide synthase activity 
(Landry & Oliver, 2001). Insulin may have an even wider role in the metabolic regulation of non 
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traditional tissues such as bone and the vascular endothelium. The relationship between 
glycaemic status and bone metabolism is complex and has been poorly understood. Despite 
higher BMD in diabetes, the risk of fractures in patients with type 2 diabetes is significantly 
increased (Carnevale et al., 2004). Indeed recent observations suggest that bone resorption is 
acutely reduced in the postprandial period (Clowes et al., 2002) and after an oral glucose load 
(Bjarnason et al., 2002). Clowes et al., (2002) demonstrated that a hyperinsulinaemic-
hypoglycaemic clamp led to a significant reduction in markers of bone turnover. The purpose of 
Experiment III was to investigate if and how OPG changes with progressive insulin resistance. 
In addition, we sought to examine if an acute differential effect of an oral glucose load and the 
resultant transient hyperinsulinaemia on circulating OPG could be identified. Our findings 
indicate that there was no significant change in hsCRP, a traditional marker of inflammation in 
response to a glucose load in the total cohort or in any of the specific groups. When the total 
group was analyzed in Experiment III we did not find a difference between OPG at baseline and 
120-min after the glucose challenge. Nevertheless OPG was positively correlated with AUC 
insulin and HOMA-IR which conflicts with our findings from Experiment 1. However, when 
glycaemic status was statistically controlled for using a partial correlation analysis, these 
relationships were lost.  
 
There was no significant change in OPG levels in either the normoglycemic-obese category or 
in the type 2 diabetics. Interestingly, circulating OPG levels did decrease 2 hrs after glucose 
consumption in the IFG / IGT group. At baseline OPG was lower in the normoglycemic obese 
group than the other categories and there were no significant differences between the lean, type 
2 diabetic, and IFG/IGT groups. We found that glucose intolerance was associated with lower 
adiponectin levels and higher hsCRP levels. The finding of increased adiponectin in obese-
normoglycaemic relative to pre-diabetic and type 2 diabetics is supported by Hofso et al., (2009) 
who also showed that adiponectin was lower in lean and morbidly obese normoglycemic 
subjects than pre-diabetic or new onset diabetes patients matched for age and BMI. Hofso et 
al., (2009) also saw that lean subjects had significantly lower CRP levels than their obese and 
pre-diabetic counterparts and that diabetics had significantly elevated CRP levels compared to 
the other groups, a finding which is consistent with our observations in Experiment III. 
Interestingly using an assay which measures unbound OPG, the authors did not find any 
significant difference between groups for circulating fasting OPG which again may indicate an 
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inherent problem for reports that have studied OPG dynamics in that there are two widely used 
assays which measure very different forms of the glycoprotein yet attempt to draw comparable 
conclusions. 
 
Taken together the results of this thesis would cast doubt on the generalized assumption of a 
progressive increase in circulating OPG with metabolic and cardiovascular disease. We suggest 
that the relationships observed in previous studies are specific and cogent only for the 
metabolic phenotype under investigation. Here we postulate one possible explanation for the 
often contradictory reports in the literature is that as an individual progresses from being lean 
and insulin sensitive to obese and relatively but NOT clinically insulin resistant, that fasting and 
postprandial hyperinsulinaemia suppress OPG production and secretion, as indicated by our 
findings in Experiment I and supported by others (Ugur-Altun et al., 2005). As the individual 
progresses to develop type 2 diabetes the appearance of an array of inflammatory cytokines 
which have been demonstrated to promote OPG secretion from several tissue types becomes 
the dominant regulator of OPG appearance. We therefore suggest that in place of the 
previously proposed observation of a linear relationship between OPG and disease progression 
that a V shaped function is more likely (Figure 6.1), with decreasing OPG as a result of 
hyperinsulinaemia in obesity and elevated OPG occurring in response to the onset and the 
worsening state of chronic inflammation, a characteristic of progressive dysglycaemia, and as 
evidenced by our findings in Experiment III.  
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Figure 6.1 Postulated model for the V-shaped regulation of OPG in response to hyperinsulinaemia and the 
inflammatory process. The progression from lean and insulin sensitive to obese and hyperinsulinemic with 
a significant inflammatory process leads to an insulin-mediated suppression of OPG production. The 
inflammatory process associated with the development of type 2 diabetes leads to an increase in OPG 
secretion. 
 
 
Increasingly it has been recognized that adipose tissue is an active metabolic tissue releasing 
cytokines such as adiponectin, TNF-α, IL-6, leptin and many others that have pleiotropic 
endocrine actions in the circulation, which can affect insulin sensitivity positively or negatively 
and contribute to vascular dysfunction. The vascular endothelium, like adipose tissue, can also 
produce and release glycoproteins yet little is known about the biological interaction of such 
factors. Although there have been significant advances in our understanding of these signalling 
mechanisms at the molecular and cellular level, we have not developed an integrated 
understanding of biological processes. 
 
It appears that insulin reliably suppresses OPG production under a wide variety of in vitro and in 
vivo conditions (An et al., 2007) and is also upregulated by a number of inflammatory mediators. 
Recombinant adiponectin reduces osteoblast formation via a mechanism whereby RANKL 
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mRNA production is increased and OPG decreased in cultured human osteoblasts (Luo et al., 
2006). There is also considerable epidemiological evidence that shows a consistent inverse 
relationship between adiponectin and BMD (Misra et al., 2007), (Peng et al., 2008), (Lenchik et 
al., 2003), (Jurimae & Jurimae, 2007), (Richards et al., 2007). When this is considered in 
conjunction with the fact that TNF-α appears to potently suppress adiponectin mRNA production 
in adipocytes (Ruan et al., 2002), one can begin to see that OPG may be an excellent example 
of a protein who’s regulation sits at the nexus of what were once considered to be disparate and 
insular metabolic tissues. Despite substantial advances in our comprehension of the integrative 
nature of metabolic homeostasis and dysfunction in health in disease in the last 20 years, we 
are still only beginning to understand the true extent of this integration. The findings in this 
thesis suggest that OPG production and secretion is subject to complex regulation by mediators 
produced from an array of tissue types, and that its perturbations in dysglycaemia, 
cardiovascular disease, arterial calcification as well as osteogenic disorders give evidence for a 
complex adipose-vascular-osteo-inusulinar axis.  
 
There are a number of limitations to the present series of experiments and generally to the field 
of in vivo research into OPG. As has previously been discussed OPG secretion can be 
attributed to a number of cellular sources and tissues. All of the literature to date describing 
OPG in human models of disease has measured circulating OPG, which may be too crude a 
measure. Currently there is no method to categorically attribute circulating levels to OPG to a 
particular cellular source or indeed pathology, a criticism which is equally valid for the data 
presented here. As mentioned earlier in this manuscript there is a discrepancy in the type of 
assays used in such studies, where some report unbound OPG and others including the work 
presented here report total OPG, making meta-analysis of the full body of literature on the 
subject difficult. It would be useful if future studies that examined the effect of either therapeutic 
intervention or in vitro manipulation on OPG production were to measure both total and 
unbound OPG in addition to TRAIL and RANKL to assess the true dynamic nature of this family 
of molecules in response to a variety of stimuli.  In conclusion, the results from this thesis 
suggest that an obesity-related decrease in insulin sensitivity or an increase in insulin secretion 
coincides with reduced circulating OPG in normoglycemic individuals. Furthermore, in this 
population OPG is positively correlated with insulin sensitivity and adiponectin. We also present 
evidence that these relationships are not maintained, possibly due to the systemic inflammation 
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found in pre-diabetes and type 2 diabetes, whereupon OPG is elevated relative to obese males 
with moderate hyperinsulinaemia but is not significantly different from lean males with low 
fasting insulin and negligible systemic inflammation. To What effect this fall in serum OPG, in 
association with increasing adiposity observed here, may have on vascular function in healthy 
subjects and why and how OPG increases in diabetic and non-diabetic patients with 
documented vascular disease appears to be complex and requires further study.  
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Appendix A Preparation Instructions for the OGTT 
 
 
 
 
 
 
Preparation for your Oral Glucose Tolerance Test 
 
1. You will be asked to attend room XB30 (Metabolic 
Research Unit) situated in the basement of the Science 
Block 
 
2. You should ensure that your diet in the 3 days prior to 
your visit is unrestricted and rich in carbohydrates 
 
3. You should not engage in any strenuous physical activity 
in the 24 hours prior to your visit to the lab 
 
4. You should ensure that you have fasted for 12 hrs prior 
to your visit to the lab, consuming only water in this time 
and during the test. 
 
5. You should ensure that you wear loose fitting 
comfortable clothes for the test 
 
6. You should not take any medication on the morning of 
or during the test 
 
7. You should refrain from smoking on the morning of or 
during the test 
 
Other notes: 
We have set up an email station that you can use for work 
purposes during your Oral Glucose Tolerance Test. There are 
also a number of live network points in the room which you 
are free to make use of should you require them. 
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Appendix B Data Collection Sheet 
 
 
 
 
 
Check List 
 
Consent signed       
OGTT         
Medical Screening      
Resting Blood Pressure     
Skin folds        
Circumferences       
Spirometry        
Resting ECG       
Aerobic fitness test      
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Start Time:  _______________   Blood Pressure ___  / ___    D.O.B.  ___ /____ /_____
 Sex: M   /   F 
 
Room Temp ______ Pressure ______ mmHg  Height:_______m Weight: 
_____kg 
 
Pre test check list 
 
Consent signed:   12 hr fast:   Dietary advice:   No smoking:   No medication:   
 
Resting Blood Samples 
 
Purple x 2:    Green x 1:     Blue x 2:    Red x 3:   
 
Check Time Time Comments Sample 1 Sample 2 mean Insulin 
   -10       
   0 75g CHO      
   30       
   60       
   90       
   120       
   180       
 
 
Finish Time: _______________ 
 
Circumferences      
 1 2 3 Ave.  1 2 3 Ave. 
Bicep     Hips     
Chest     Thigh     
Waist     Calf     
 
Skin Folds 
 Measurement 1 Measurement 2 Measurement 3 Ave. 
Triceps     
Pectoralis     
Subscapular     
Abdominal     
Midaxillary     
Suprailiac     
Thigh     
 
 
Signature of Tester:  __________________________ 
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Aerobic Fitness Assessment 
 
Temp: ______○C   Barometric Pressure: _____mmHg 
 
Date of Birth: ____ /____ /______   Sex M / F 
 
Height: ____ m      Weight: ______ kg 
 
RBP: Manual   1___ / ___ 2___ / ___ 3___ / ___ 4___ / ___ 
 
RBP: Automated  1___ / ___ 2___ / ___ 3___ / ___ 4___ / ___ 
 
 
Consent signed:    Medical history:    Resting ECG:   
 
Protocol used ______________ 
 
Stage RPE HR BP 
Warm up    
1    
2    
3    
4    
5    
6    
7    
8    
10    
11    
12    
13    
14    
15    
16    
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Appendix C Preparticpation Screening 
 
Department: School of Health and Human Performance, Dublin City University 
 
Principal investigators 
Dr. Donal O’Gorman   (01 7008060),  donal.ogorman@dcu.ie  
Mr David Ashley BSc.   (01 7008472),  david.ashley2@mail.dcu.ie,  
Prof. Niall Moyna   (01 7008802),  niall.moyna@dcu.ie,  
Dr. Noel McCaffrey MD   (01 7008187),  noel.mccaffrey@dcu.ie  
 
 
Pre-participation screening form 
First name       Surname 
_____________________     ______________________ 
 
Telephone Home  Telephone Work  Telephone Mobile 
________________  _______________  _______________ 
Email 
______________________________ 
Estimate your height    Estimate your weight 
_______ft   ____in    _____st  _____lbs 
Have you ever been told by a doctor that you have diabetes? Yes□  No□ 
Have you ever been told by a doctor you have a heart condition? Yes□  No□ 
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Appendix D Physician’s Medical Screening Form 
 
 
 
DATE            
CONTACT DETAILS) 
Last name: _____________________  First name: ______________ 
Date of birth:________________   Age _________   
Address: 
 _______________________________________________________ 
 
Mobile __________________  Work:_______________ 
Home:________________ 
Email Address:   _______________________________ 
 
Next of kin 
Name        Contact tel:    
 
Relationship to you       
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MEDICAL HISTORY (PHYSICIAN ADMINISTERED) 
 
 
2.  Have you ever had any of the following (tick box)? Yes  No 
 a) A heart attack     □  □ 
b) Heart surgery     □  □ 
c) An angiogram     □  □ 
d) Insertion of a stent     □  □ 
e) Treatment of an irregular heart beat  □  □ 
f) A blackout (loss of consciousness)  □  □ 
 
3. Please list any other medical conditions you suffer from  
at present or have suffered from in the past 
1.            
2.            
3.            
4.            
 
1.  Do you suffer from any of the following (tick box)?  Yes  No 
 a) High blood pressure (hypertension)   □  □ 
 b) Angina       □  □ 
  i.e  chest pain, neck pain, jaw pain, arm pain  
or undue breathless on exertion 
   (such as walking fast or walking up a hill) 
 c) Heart disease of any sort     □  □ 
  e.g.  heart attack 
blocked blood vessels to the heart 
abnormal heart rhythm 
 d) Peripheral vascular disease    □  □ 
e.g.  intermittent claudication (calf pain on walking) 
stroke 
 e) Elevated blood cholesterol or triglycerides  □  □ 
 f) Diabetes       □  □ 
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4.  List any medications which you are now taking 
             
             
             
 
 
5. Your family history 
 
Do any of your first degree relatives (parents, brothers, sisters) 
suffer from any of the following (tick box if yes)? 
        Yes  No 
a) heart disease   □  □  
   
b) high blood pressure   □  □ 
c) diabetes    □  □ 
 
Has any first degree relative of yours died from heart disease? Yes □ 
         No   □ 
 
 
6. Alcohol / Cigarettes 
 
Do you consume alcohol regularly? Yes  □    No  □  
 
If yes, how many units per week? ______________ 
 
 
Do you smoke?    Yes  □    No  □  
  
 
If yes, how many cigarettes a day? ______________ 
 
 
7.  Your Exercise Pattern 
 
Do you take part in regular exercise of physical activity ?   Yes  □   No  
□  
If yes, give details (how often per week, duration per session) 
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PHYSICAL EXAMINATION 
 
 
Blood Pressure ___  / ____  Pulse____ 
  
 
GENERAL APPEARANCE 
 
Subject looks:  Healthy____ Not healthy___ Very ill____ 
 
 
 
SUMMARY FINDINGS 
    Nothing    Details if Abnormal 
    Abnormal    
    Found   
 
HEAD AND NECK     □         
 
             
 
CHEST AND LUNGS    □         
 
             
 
HEART      □         
 
             
 
ABDOMEN      □          
 
             
 
EXTREMITIES     □         
        
             
 
NEUROMUSCULAR    □         
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RESTING ECG 
 
Descriptive Analysis: 
 
Rate:    ______bpm  
Rhythm:  __________________________ 
Arrhythmias  __________________________ 
   __________________________ 
   __________________________ 
 
Clinical Impression: 
_______________________________________________________________
_______________________________________________________________
_______________________________________________________________
______________________________ 
 
 
 
According to the medical history and physical exam, does subject qualify for this 
research study?  
 
Yes   
No   
 
Comments: 
_____________________________________________________    
_____________________________________________________    
 
 
     
 
 
   ___________________________ ____________ 
Physician's signature    (Date) 
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David Ashley
The Role of Serum Osteoprotegerin as a 
Biomarker of Metabolic Dysfunction in 
Obesity and Type 2 Diabetes
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Introduction
Pathophysiological features of Type 2 Diabetes
Impaired
insulin secretion
HYPERGLYCAEMIA
Adapted from: Stumvoll M, et al. Lancet. 2005;365:1333-46.
Decreased
incretin effect
Increased
hepatic glucose
production
Decreased glucose
uptake
Increased FA
Production
↓ insulin secretion
↑ insulin resistance
Increased
lipolysis
 
Resistin
TNF- α
IL-6
RBP-4
Pro-hyperglycaemic
Leptin
Adiponectin
Visfatin
Omentin
Anti-hyperglycaemic
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ADIPONECTIN
Lean    Obese
Female Male
Inflammation
Type II Diabetes
Cardiovascular
Disease
Insulin Sensitive
Insulin Resistant
PPARγ agonist
Treatment
Lipodystrophy
Adiponectin is unique in that its expression is 
suppressed with obesity and is associated with insulin 
sensitivity and protection against Type 2 diabetes and 
Cardiovascular Disease
 
Introduction
Adipose Tissue, Cardiovascular Disease and Bone
• Adipocytokines are involved in the regulation of glucose and 
lipid metabolism. 
• They exert anti‐ and pro‐inflammatory effects and are involved 
in blood pressure control, haemostasis and bone mass turnover
• Evidence suggests that CVD and osteoporosis often coexist
• Several proteins such as osteocalcin, osteopontin and bone 
morphogenic protein, which were once thought to be bone‐
specific in their biological action, have been identified in 
atherosclerotic lesions. 
• Such observations have given rise to the suggestion of the 
existence of an “Osteo‐adipose‐vascular” network 
• One such protein that has garnered considerable interest in 
recent years is the novel glycoprotein osteoprotegerin (OPG) 
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OPG knockout
Wild-type
Introduction
Osteoprotegerin (OPG)
• OPG knockout mice develop severe osteoporosis in addition to 
vascular calcification 
• This suggests a protective role for OPG in the vascular system,
• There is emerging evidence for its involvement in the vascular 
system, with its expression observed in vascular tissues 
• In vitro studies have demonstrated the ability of pro‐
inflammatory cytokines to upregulate OPG levels in both 
endothelial and vascular smooth muscle cells
• Suggesting a role for OPG in vascular disease, since 
inflammatory factors are thought to be key to the progression 
of CAD and atherosclerosis
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Vascular System
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To investigate the role of OPG in obesity and metabolic 
dysfunction and to further elucidate and explore the 
relationship between the OPG / RANK / TRAIL axis and 
established markers of inflammation and insulin sensitivity
Examine the impact of diabetes and vascular disease on 
their circulating concentrations while probing how these 
novel markers relate to other traditional inflammatory 
markers and adipocytokines. 
Study the influence of glycaemic status and adiposity 
together on serum levels of OPG and to interrogate if a 
worsening glycaemic status can influence its relationship 
with adiponectin and systemic inflammation.
Introduction
Thesis Aims & objectives
 
 
Experiment I
An investigation of serum OPG, TRAIL and 
sRANKL levels and their relationship with 
indicators of adiposity and insulin sensitivity 
in a healthy, representative Irish cohort.
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• Circulating OPG is significantly higher in patients with type 2 diabetes and is higher 
in the tunica media of type 2 diabetics than matched normal controls
• It has also been shown that circulating concentrations of OPG can independently 
predict silent CAD in type 2 diabetic patients
• Despite the higher circulating and tissue concentrations of OPG in patients with CVD 
there has been little research on high risk obese subjects
• Gannage‐Yared et al. (2006) examined the relationship between OPG and 
components of the metabolic syndrome in 151 healthy ageing men. 
• They found that OPG was inversely correlated with fasting plasma glucose and 
insulin sensitivity and positively correlated with adiponectin.
• Most of the research to date which has indicated that OPG is associated with a 
negative coronary outlook has been conducted in patients with underlying CVD 
• Few published papers have examined the relationship between insulin sensitivity, 
adiposity and OPG in a healthy population free from CVD
Experiment I – Healthy Cohort OPG / TRAIL / sRANKL  and Adiponectin
Introduction/rationale
 
 
Aims
The purpose of this study was to determine if BMI and 
insulin sensitivity influence the concentrations of serum 
OPG and TRAIL in subjects who do not have 
cardiovascular or metabolic disease.
Hypothesis
That in a healthy cohort, circulating OPG would be 
lower in obese subjects and inversely related to insulin 
resistance.
Experiment I – Healthy Cohort OPG / TRAIL / sRANKL  and Adiponectin
Introduction/rationale
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• 136 subjects
• 36 excluded because of undiagnosed hypertension,      
impaired glucose tolerance or abnormal ECG
12 hr overnight fast
No Smoking
or caffeine
No strenuous exercise
= 4 days between visits
Initial Briefing 
Meeting
VISIT 1
Anthropometrics
OGTT 2 hr
Fasting Blood Samples
Resting Blood Pressure
Medical Screening
Resting ECG
Risk Assessment
VISIT 2
Exercise Test
Experiment I – Healthy Cohort OPG / TRAIL / sRANKL  and Adiponectin
Experimental Design
 
 
Experiment I – Healthy Cohort OPG / TRAIL / sRANKL  and Adiponectin
Methods
• Glucose  Dual channel YSI 2300
• Insulin AutoDELFIA® Perkin Elmer FIA
• Adiponectin, 
IL‐6 and TRAIL ELISA, RnD
• CRP Immunonephelometry (Randox)
• Lipids Spectrophotometric analysis (Randox)
• OPG ELISA, Biomedica
• sRANKL ELISA, Biomedica
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Experiment I – Healthy Cohort OPG / TRAIL / sRANKL  and Adiponectin
Results
Table 3.1 Selected Anthropometric and Cardiovascular Characteristics of Subjects 
 
 Normal weight Overweight Obese 
 (36) (41) (23) 
Gender (male/female) 19/17 19/22 11/12 
Age (years) 44.4 ± 1.5 46.7 ± 2.0 47.2 ± 2.8 
BMI (kg.m-2) 22.8 ± 0.2 26.7 ± 0.2 * 31.4 ± 0.3 * † 
Waist Circumference (cm) 78.5 ± 1.2 89.8 ± 1.2 * 102.2 ± 2.0 * † 
Waist to Hip Ratio 0.82 ± 0.01 0.87 ± 0.01 * 0.93 ± 0.02 * † 
Body fat (%) 19.6 ± 1.15 27 ± 1.16 * 31.9 ± 1.5 * † 
VO2 max (ml.kg.min-1) 41.5 ± 1.9 37.5 ± 1.5 29.6 ± 1.7 * † 
Systolic BP (mmHg) 117.1 ± 2.2 120.4 ± 1.6 130.3 ± 2.2 * † 
Diastolic BP (mmHg) 74.0 ± 1.5 76.5 ± 1.4 80.6  ± 2.1 * 
Subject Characteristics
 
 
Metabolic data
Experiment I – Healthy Cohort OPG / TRAIL / sRANKL  and Adiponectin
Results
Table 3.2 Metabolic Markers and Indicators of Insulin Sensitivity.  
  Normal weight Overweight Obese 
Fasting Glucose (mmol.l-1) 4.8 ± 0.1 5.0 ± 0.1 5.3 ± 0.1 * † 
Fasting Insulin (ρmol.l-1) 26.4 ± 3.5 38.2 ± 4.2 * 51.3 ± 5.6 * 
Triglycerides (mmol.l-1) 0.97 ± 0.05 1.32 ± 0.10 * 1.55 ± 0.15 * 
HOMA-IR 0.83 ± 0.12 1.25 ± 0.14 * 1.8 ± 0.2 * † 
OGIS (ml.min.m-2) 533 ± 11 512 ± 9 451 ± 11 * † 
AUC Glucose (mmol.l.min) 671 ± 18 738 ± 19 * 831 ± 36 * † 
AUC Insulin (pmol.l.min) 20487 ± 2444 29585 ± 4285 42336 ± 4979 * † 
hs-CRP (mg.L-1) 0.92 ± 0.18 0.92 ± 0.08 1.16 ± 0.15 
Adiponectin (μg.ml-1) 9.9 ± 0.9 6.6 ± 0.5 * 4.8 ± 0.5 * 
TRAIL (ρg.ml-1) 72.2 ± 5.4 81.6 ± 3.9 82.4 ± 6.9 
sRANKL (ρg.ml-1) 3.4 ± 0.6 3.0 ± 0.4 2.9 ± 0.7 
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TRAIL
Experiment I – Healthy Cohort OPG / TRAIL / sRANKL  and Adiponectin
Results
• TRAIL was significantly related to
• Fat mass (r = 0.255, p < 0.05)
• Waist circumference (r = 0.207, p < 0.05)
 
 
Experiment I – Healthy Cohort OPG / TRAIL / sRANKL  and Adiponectin
Results
3
4
5
6
7
Normal weight Overweight Obese
O
st
eo
pr
ot
eg
er
in
 (p
m
ol
. l-1
) *  †
Osteoprotegerin and Obesity
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Experiment I – Healthy Cohort OPG / TRAIL / sRANKL  and Adiponectin
Results
Osteoprotegerin‐ Correlation Analysis
Table 3.3 Age and Gender Adjusted Correlations Between OPG and Anthropometric 
and Metabolic Indices. 
 r p  
BMI (kg.m-2) -0.331 ***   
Waist Circumference (cm) -0.268 **   
VO2 max (ml.kg.min-1)  0.237 *   
Fasting Glucose (mmol.l-1) -0.248 *   
Fasting Insulin (ρmol.l-1) -0.202 **   
AUC Glucose (mmol.l.min) -0.279 **   
AUC Insulin (pmol.l.min) -0.271 **   
HOMA-IR -0.222 *   
OGIS (ml.min.m-2)   0.221 *   
Adiponectin (μg.ml-1)   0.391 ***   
 
 
Experiment I – Healthy Cohort OPG / TRAIL / sRANKL  and Adiponectin
Results
Osteoprotegerin and Adiposity
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r = -0.348, p< 0.001, controlling for 
age and gender, r = -0.268, p =0.008
r = -0.348, p< 0.001, controlling for 
age and gender, r = -0.331, p =0.001
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The main findings of Experiment I are that obese 
subjects who are normal glucose tolerant and free 
from CVD, have lower circulating OPG when 
compared with normal weight and overweight 
individuals. In this cohort OPG is positively 
correlated with adiponectin and insulin sensitivity.
Experiment I – Healthy Cohort OPG / TRAIL / sRANKL  and Adiponectin
Summary
 
 
Experiment II
The relationship between OPG, TRAIL, 
sRANKL and markers of inflammation in Type 
2 Diabetes and Vascular Disease.
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? 110 subjects volunteered to participate in this study. 
? 58 normoglycemic, healthy subjects free from CVD were recruited from DCU
? 62 patients with type 2 diabetes were recruited from the diabetes clinic in 
Beaumont Hospital. 
? OGTT to ensure normal glucose tolerance and exercise stress tests were 
performed on all of the healthy controls to rule out undiagnosed
hyperglycaemia or CVD
Experiment II – OPG inflammatory markers and type 2 diabetes
Experimental design
58 NGT
62 T2DMs
Age and 
BMI 
Matched Medical screening including OGTT and 
GXT to rule out CVD or undiagnosed 
IGT or T2DM
Subset
Exclusion of Hx of 
Micro/macro VD Age and 
BMI 
Matched
Fasting bloods 
and detailed 
screening
 
 
• Arterial calcification is a prominent feature of atherosclerosis and common in 
patients with type 2 diabetes. 
• Our understanding of this process has further developed in recent times with the 
identification of a possible role for the OPG/RANKL/TRAIL axis in the process
• Studies of serum RANKL have been inconclusive, with both increased and reduced 
risk of CVD disease being reported with elevated concentrations
• Only one paper has measured RANKL levels in individuals with type 2 diabetes, 
finding no difference from healthy individual (Secchiero et al., 2006). 
• Studies to date suggest higher serum OPG levels in type 2 diabetes
• However many of these studies have had poorly defined control groups 
• IL‐6 and hsCRP are frequently used to gain a measure of the degree of underlying 
inflammation
• Whether OPG, RANKL or TRAIL could reflect low‐grade vascular inflammation in 
individuals with diabetes is not yet known
Experiment II – OPG inflammatory markers and type 2 diabetes
Introduction/rationale
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Subject 
Characteristics
Experiment II – OPG inflammatory markers and type 2 diabetes
Results Table 4.1 Subject Metabolic and Cardiovascular Characteristics. 
 Normal Type 2 Diabetes 
N 58 62 
Age (years) 55.6 ± 1.2 58.31.2 
Gender (M:F) 28:30 40:22 
BMI (kg/m2) 29.5 ± 0.4 30.0 ± 0.5 
Waist Circumference (cm) 101.3 ± 1.4 105.0 ± 1.3 ~ 
Systolic BP (mmHg) 131.14 ± 2.53 142.3 ± 2.26 *** 
Diastolic BP (mmHg) 81.8 ± 1.4 80.26 ± 1.26 
Current smokers 4.7% 9.8% 
Anti-hypertensive use 13.2% 86.7% *** 
ACE/ARB use 8.6% 67.2% *** 
Statin use 15.1% 82.0% *** 
Aspirin use 5.7% 78.7% *** 
Fasting glucose (mmol.l-1) 5.2 ± 0.2 7.9 ± 0.2 *** 
Total Cholesterol (mmol.l-1) 5.4 ± 0.1 4.1 ± 0.1 *** 
LDL Cholesterol (mmol.l-1) 3.4 ± 0.1 2.0 ± 0.1 *** 
HDL Cholesterol (mmol.l-1) 1.4 ± 0.04 1.2 ± 0.04 *** 
Triglycerides (mmol.l-1) 1.4 ± 0.1 2.0 ± 0.1 *** 
TNF-α (pg/ml) 1.5 ± 0.3 1.4 ± 0.3 
  
 
Experiment II – OPG inflammatory markers and type 2 diabetes
Experimental design
• TRAIL was correlated with LDL (r = 0.303, p < 0.01) and waist circumference 
(r = 0.202, p < 0.05). . 
• In the healthy control group, controlling for gender there was a correlation 
between OPG and age (r = 0.364, p < 0.01)
• When both age and gender were controlled for, OPG was correlated with 
– waist circumference (r = ‐0.262, p < 0.05), 
– adiponectin (r = 0.366, p < 0.01), 
– total cholesterol (r = 0.380, p < 0.01), 
– LDL (r = ‐0.336, p < 0.05), 
– fasting plasma glucose (r = ‐0.363, p < 0.05)
– TRAIL strong trend (r = ‐0.294, p = 0.053)
• None of these relationships with OPG were evident in the type 2 diabetic 
cohort 
Correlation Analysis
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Metabolic data
Experiment II – OPG inflammatory markers and type 2 diabetes
Results
Table 4.2 Characteristics of the Disease State in Patients with Type 2 Diabetes. 
 Median (range) or n (%) 
 
Duration of diabetes (years) 7 (1-20) 
HbA1c (%) 7 (5.1-10) 
Insulin treated 12 (19.67%) 
Metformin treated 37 (60.66%) 
Sulphonylurea treated 21 (34.43%) 
TZD treated 3 (5.92%) 
Diet alone 8 (13.12%) 
Microvascular complications 15 (24.19%) 
Macrovascular complications 20(32.26%) 
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Experiment II – OPG inflammatory markers and type 2 diabetes
Results – OPG / TRAIL / sRANKL and hsCRP
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Experiment II – OPG inflammatory markers and type 2 diabetes
Results – Adipocytokines
1
1.5
2
2.5
3
3.5
4
Type 2 Diabetes Healthy Control
IL
-6
 (p
g.
m
l-1
)
4
5
6
7
8
Type 2 Diabetes Healthy Control
A
di
po
ne
ct
in
 (u
g.
m
l-1
)
E F
* *
  
 
Experiment II – OPG inflammatory markers and type 2 diabetes
Vascular Disease and inflammatory markers
Subset Analysis on the Effect of Vascular Disease on Inflammatory Markers
To investigate whether the elevated OPG, IL‐6 and hsCRP observed in the 
diabetes group was due to the higher prevalence of vascular disease within this 
group, we compared mean values of these proteins, after exclusion of type 2 
diabetes patients with either documented micro‐ or macro‐vascular disease.
• OPG was still significantly higher in type 2 diabetics than 
normal controls 
• The significant difference previously seen with IL‐6 and 
hsCRP was no longer present
• In this group OPG correlated with IL‐6 after correction for 
age and gender (r = 0.24, p < 0.05), but this association was 
lost after correction for glycaemic status.  
• There was no correlation between RANKL or TRAIL and IL‐6, 
or hsCRP in either group.
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Experiment II – OPG, inflammatory markers and type 2 diabetes
Summary
The main findings of Experiment II are that OPG but not 
RANKL or TRAIL is significantly increased in type 2 
diabetes.  IL-6 and hsCRP is higher in individuals with 
diabetes and adiponectin is lower, but unlike OPG, they are 
no longer different when subjects with vascular disease are 
excluded.
  
 
Experiment III
The effect of Obesity, Glycaemic Status and 
an acute glucose load on circulating 
concentrations of OPG
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Experiment III –Glycaemic Status, glucose loading and OPG 
Introduction/rationale
Aims
To examine changes in OPG levels with varying degrees 
of glucose tolerance and to investigate the influence of 
adiposity and inflammatory processes on OPG 
concentrations.
Hypothesis
The deteriorating inflammatory state coupled with the 
sharp rise in hyperinsulinaemia with decreasing 
glucose tolerance uncouples the relationship between 
OPG and insulin sensitivity that was observed in 
Experiment I and II
 
 
• As well as its role in maintaining normoglycemia, insulin is a vasoactive peptide 
capable of exerting pleiotropic hemodynamic effects
• Recent studies have suggested an important role for insulin in the inhibition of OPG 
expression and secretion.
• Olesen et al. (2005) showed that vascular smooth muscle cells incubated with 
insulin exhibit markedly reduced OPG production compared to controls 
• Xiang et al. (2007) found that OPG was decreased in response to 6 months of insulin 
therapy in young type 1 diabetics and that this decrease was strongly correlated 
with changes in endothelial function.
• Jorgensen et al. (2009) examined the effect of insulin infusion (hyperinsulinaemic 
clamp) on OPG production in lean, type 2 diabetic and obese subjects
• OPG was markedly reduced in all groups and but the lean control group showed a 
significantly greater decrease than the type 2 diabetic and obese subjects.
• Interaction between insulin and the OPG / RANKL / RANK / TRAIL axis may be one 
mechanism by which elevated fasting and postprandial hyperinsulinaemia can 
independently affect the development of cardiovascular disease.
Experiment III –Glycaemic Status, glucose loading and OPG
Introduction/rationale
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Subject Characteristics
Experiment III –Glycaemic Status, glucose loading and OPG 
Results
Table 5.1 Subject Characteristics and indicators of insulin sensitivity.  
 Type 2 Diabetes IGT / IFG NGT Obese 
 (20) (20) (21) 
Age (years) 56.2 ± 2.1 56.8 ± 2.3 53.8 ± 2.2 
BMI (kg.m-2) 30.5 ± 0.6 30.5 ± 0.8  30.2 ± 0.5  
Fasting Glucose (mmol.l-1) 7.4 ± 0.2 6.2 ± 0.1 * 5.2 ± 0.1 * † 
Fasting Insulin (pmol.l-1) 118.8 ± 15.6 127.7 ± 12.6 39.9 ± 4.3 * † 
2 hr Glucose (mmol.l-1) 12.6 ± 0.7 8.6 ± 0.3 * 5.1 ± 0.3 * † 
2 hr Insulin (pmol.l-1) 493.4 ± 74.5 526.8 ± 55.2 39.6 ± 24.6 * † 
HOMA-IR 6.4 ± 0.8 5.8 ± 0.6 * 1.6 ± 0.2 * † 
OGIS (ml.min.m-2) 289 ± 10 332 ± 10 424 ± 9 * † 
AUC Glucose (mmol.l.min) 1593 ± 62 1218 ± 30 * 816 ± 32 * † 
AUC Insulin (pmol.l.min) 64475 ± 9176 60693 ± 6032 29677 ± 3492 * † 
  
 
? 61 male subjects were recruited to participate in this study
? 20 patients with type 2 diabetes
? 20 patients with either IGT/IFG
? 21 healthy obese male subjects free from CVD were recruited from DCU 
? All three groups were age and BMI matched. 
? Data from 21 lean age matched subjects from experiment I were also included 
in the later analysis 
Experiment II – OPG inflammatory markers and type 2 diabetes
Experimental design
21 NGT Obese
20 IGT/IFG
Age and 
BMI 
Matched
Medical screening 
including OGTT and GXT 
to rule out CVD or 
undiagnosed IGT or T2DM
20 T2DMs
21 NGT Lean from Experiment I
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Experiment III –Glycaemic Status, glucose loading and OPG 
Results – OPG
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OGIS and adiponectin were 
significantly higher in healthy 
age and BMI matched controls 
than in either IGT / IFG subjects 
or type 2 diabetics 
hsCRP was significantly lower in 
the healthy matched control 
group and the IGT / IFG group
OPG was significantly lower in 
the NGT Obese group
 
 
• There was no 
significant change in 
hsCRP in response to 
the OGTT in any of the 
glycaemic conditions. 
Experiment III –Glycaemic Status, glucose loading and OPG 
Results – OPG
• OPG was significantly 
reduced in response to the 
oral glucose load in the IFG / 
IGT group but was 
unchanged in type 2 
diabetics and normoglycemic 
obese subjects
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Experiment III –Glycaemic Status, glucose loading and OPG 
Results – OPG 
 
 
Experiment III – Glycaemic Status, glucose loading and OPG
Summary
The main findings of Experiment III are that there is no 
difference in OPG between prediabetic and type 2 diabetic 
cohorts, but both have higher levels than matched obese 
controls. Interestingly, OPG in lean insulin-sensitive 
subjects is comparable to that of the pre-diabetic and type 2 
diabetic patients but significantly higher than their matched 
lean counterparts.
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General Discussion and Conclusion
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General discussion
Future directions
Future studies that examine the effect of either 
therapeutic intervention or in vitromanipulation on OPG 
production should measure both total and unbound OPG 
in addition to TRAIL and RANKL an order to assess the 
true dynamic nature of this family of molecules in 
response to a variety of stimuli.  
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